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Abstract 
Proteins are essential parts of living organisms and protein-protein interactions (PPIs) 
interactions mediate many essential regulatory pathways. As such, PPIs have been 
implicated in a number of diseased states, however, it is currently unclear how to effectively 
target them due to the relatively poorly defined surface at the protein interface. When PPIs 
are mediated by the binding of an α-helix, key interactions usually occur on non-adjacent 
residues, appearing on the same face of the α-helix, resulting in close interactions. The 
abundance of this secondary structure in proteins and its relative rigidity provide an ideal 
basis for the design of synthetic mimics.
 
In
 
this thesis, an account of the design strategies 
developed to address this problem is provided, and sets the work described herein in context. 
Previously, the Wilson group developed 3-O-alkylated oligobenzamide (3HABA) scaffolds 
as potential α-helix mimetics and suitably functionalised trimers were identified as 
micromolar inhibitors of the p53/hDM2 interaction. To understand more how to develop 
potent inhibitors of this interaction, a larger library was necessary. This was achieved by 
generating a library of 3HABA building blocks encompassing a range of natural and 
unnatural functionalities. Parallel to building the monomer library, development of a general 
solid phase methodology for deactivated anilines was essential. The course taken was to 
provide a solution for this challenging technical problem, and to identify the scope of the 
SPS methodology. Using the developed methodology, libraries of compounds targeting the 
p53/hDM2 and Mcl-1/NOXA B interactions were synthesised and their biophysical 
properties evaluated resulting in directions for future library development. To extend the 
approach to helix mediated PPIs involving more than one face, bifacial scaffolds designed at 
target the ER/coactivator complex are also described. This works discusses how molecular 
modelling, initial biophysical testing and docking studies led to second generation ligands 
with better in silico properties. 
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Chapter One 
Protein-Protein Interactions and                                 
Strategies for their Inhibition 
Section 1.4.1 of this chapter contributed to a review article published in Nature Chemistry.
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1.1 Relevance of Protein-Protein Interactions 
Proteins are essential parts of living organisms and participate in every process within 
the cell. They are responsible for a plethora of functions including catalysis, transportation, 
signalling and the transmission of information from DNA to RNA.  Furthermore, proteins 
are central to the immune system, acting as vehicles for the immune response but also 
facilitating viral entry into cells. Due to the extensive involvement of proteins in cellular 
processes, continuous effort has been made to predict their functions from amino acid 
sequences and where possible their tertiary structure.  Many of these biological functions 
involve protein-protein interactions (PPIs) so identification, characterisation and inhibition 
of PPIs is crucial for drug discovery.
2-4
  
 
Figure 1.1 (a) Binding in an enzyme-substrate complex containing few strong interactions.                         
(b) Binding in protein-protein complex containing many small, additive interactions. 
Designing small molecule inhibitors to fit enzyme active sites has been relatively 
successful.
5
 The catalytic area is found within a well-defined cavity or cleft within the 
enzyme and contains multiple recognition sites (Fig. 1.1a) allowing inhibitors to be designed 
with appropriate functionality (e.g. hydrogen bonds, π-π interactions, electrostatic forces and 
salt bridges). Native substrates may also present effective templates for inhibitor design 
making it possible to synthesise small compounds with many interactions. PPIs on the other 
hand were once considered “undruggable” and have not been a focus of drug development 
until recently. The extensive, relatively featureless surface of proteins (800-1100Å
2
) with 
distant and varied interactions creates a daunting task for inhibitor development (Fig. 1.1b)
6
; 
designing inhibitors to complement the poorly defined hydrophobic, charged or polar 
domains in order to show competitive inhibition is difficult. There has been considerable 
interest in PPIs and a major goal is to gain a better understanding and quantification of the 
key features controlling these interactions. This will hopefully lead to greater success in the 
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prediction of protein associations and assist with the elucidation of cellular pathways and 
drug design.
3
                                                             
1.1.1 Structural and Thermodynamic Features of Protein-Protein Interaction 
 Many studies have been made to formulate a system allowing for reliable 
predictions about PPIs to be made. These have been hampered by many different factors 
including protein flexibility, the presence of even partial disorder, the existence of 
ensembles with distinct conformations separated by energy barriers, and the cooperativity in 
protein-protein association.
3
 Wells and co-workers exploited a technique (alanine scanning) 
which involved the interfacial residues being mutated to alanine systematically to determine 
the change in binding free energy. Alanine scanning presented evidence that there are 
regions on a protein surface that distinguish it from the rest of the protein surface; the 
functional epitope also known as a ‘hot spot’.7 A hot spot is defined as a residue whose 
substitution by alanine leads to a significant drop in the binding free energy (∆G ≥ 2 
kcal/mol) to its protein partner.
8
 Hot spots are usually found within densely packed areas in 
which clusters of amino acids are in contact with each other forming a network of 
interactions. These can be described as ‘hot regions’ and explain why those residues have a 
dominant contribution to the stability of the complex.
2,9
 Figure 1.2 demonstrates how close 
key binding residues can be in a hot spot and shows how a small molecule is able to interact 
with the protein over these regions.  
Figure 1.2 Ligand bound to hot region on the interleukin receptor, IL-2. Hot spot residues for 
binding to IL-2 are shown in green (PDB ID: 1PW6).
10
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1.1.2 α-Helix Mediated Protein-Protein Interactions 
Over 30% of protein secondary structure is helical making it the most abundant 
secondary structural unit in proteins. The helix contains important shape and sequence-
selective recognition motifs. The importance is highlighted by the number of proteins that 
bind their partner through an α-helix and it is anticipated that this interaction may be general. 
With 3.6 residues and a 0.54 nm rise per turn and average dihedral angles Φ and Ψ of -60° 
and -45° (Fig. 1.3a), side-chains are placed above one another every 3-4 turns. Thus helices 
can be considered to have three distinct faces (Fig. 1.3b).  
 
Figure 1.3 (a) Backbone dihedral angles in a polypeptide chain (b) View down the centre of a 
helix highlighting the three faces (left) with a cartoon representation (middle) and an 
alternative view of the helix (right); α-carbons represented by CPKs, with each colour 
corresponding to one of the three helical faces. (c) p53/hDM2 – regulates cellular stress (PDB 
ID: 1YCR). (d) Bcl-xL-Bak regulates apoptosis (PDB ID: 1BXL). (e) ER/coreceptor – 
regulates growth and function of different tissues (PDB ID: 2QZO). (f) gp41 hexameric coiled-
coil leads to Viral fusion (PDB ID: 1AIK).   
 In a number of α-helix mediated PPIs, the binding interactions occur through 
non-adjacent residues displayed on the same face of the α-helix; normally the i, i+3/i+4, 
i+7/i+8 (and i+11) residues are involved in binding resulting in close interactions. The 
p53/hDM2
11
 and Bcl-2 family
12
 of PPIs have such a binding motif, with primarily 
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hydrophobic residues making key interactions within a hydrophobic helix binding cleft (Fig 
1.3c-d). The interaction between estrogen receptor and its coactivator proteins however, 
involves two faces of the helix and a charge clamp on the receptor surface helps to further 
stabilise the complex (Fig. 1.3e).
13
 Other interactions may involve three faces of the helix or 
binding in a much shallower groove. The gp41 hexameric coiled coil assembly demonstrates 
even greater diversity of PPIs through the packing of three, much longer, 40 residue 
N-terminal helices with a trimeric coiled coil core consisting of C-terminal helices (Fig. 
1.3f).
14
 The Arora group used computational alanine scanning mutagenesis of the Protein 
Data Bank to identify and assess helical interfaces in PPIs. They identified a list of target 
PPIs amenable to disruption by helix mimetics and grouped them according to the number of 
helical faces involved in binding. The most common motif was identified to involve 
hydrophobic residues displayed on a single face of the helix at the i, i + 4 and i + 7 
positions.
15
 
1.2 PPI Targets and their biological importance 
Mutation in a cell’s DNA is the fundamental cause of cancer, although many 
mutations may occur in cells which are harmless. Mutations of DNA can be inherited or can 
be caused by external factors such as sunlight, viruses and certain lifestyle choices (i.e. 
smoking, drinking and diet). In healthy cells, a defence mechanism called apoptosis is 
initiated which is a highly conserved, specific and selective means of controlling tissue mass 
and shape. It prevents mutations from spreading by controlling cell death within 
multicellular organisms.
16
 Some cancers, however, are caused by mutations in the DNA of 
genes such as oncogenes or tumour suppressors. These genes control when a cell is required 
to grow and importantly, when to stop growing. The process of apoptosis does not take place 
in cells in which these mutations occur and so the cancer cell survives. The cells then begin 
to grow uncontrollably and processes such as mitosis take place allowing the mutation to 
spread. The result of such mutations can lead to tumours.
17 
1.2.1 Protein 53 / Human Double Minute Two Interaction 
Tumour protein 53 (TP53 or p53) plays a central role in cell cycle regulation and as 
such is a major tumour suppressor in humans. 
18
 It has been found that over 50% of human 
tumours contain a mutated or absent gene that codes for p53.
19
 In healthy cells, the 
production and degradation of the p53 protein is regulated by the binding of hDM2 (Fig. 
1.4), which in turn is induced by p53 in a negative feedback loop. Regulation is controlled 
by hDM2 via multiple mechanisms: it physically blocks the interaction between p53 and 
DNA thereby inhibiting its transcriptional activity, it induces nuclear export of p53, and on 
binding acts as a “tag” stimulating p53 degradation through its E3 ubiquitin ligase activity.  
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Over expression of hDM2 in cancer cells is shown to inactivate p53 by preventing it from 
exerting its apoptotic activity and allowing for cell proliferation. In about 30% of soft tissue 
and human osteogenic sarcomas, hDM2 is over expressed due to gene amplification. This 
indicates that hDM2 has an important role in the development of these tumours and so this 
PPI has become a major target for cancer chemotherapy.
20
   
        
Figure 1.4 hDM2 and the helical binding epitope of p53 showing the key interacting residues 
(PDB ID: 1YCR). 
The hypothesis is that by inhibiting binding interactions in the p53/hDM2 complex, 
p53 protein will be freed and this will allow it to exert its apoptotic properties. Crystal 
structures of the complex have revealed a hydrophobic binding pocket on hDM2 in which an 
α-helical region of p53 makes hydrophobic interactions. These contacts are made through 
Phe19, Trp23 and Leu26, corresponding to the i, i+4 and i+7 residues of the helix 
respectively (Fig. 1.4). Attaching these or similar functionalised residues to a rigid scaffold 
occupying the same orientation should result in an effective hDM2 inhibitor.
11, 20 
1.2.2 Nuclear Hormone Receptors  
 Steroid hormones occur naturally in the body and are essential in controlling the 
growth and activity of normal cells in many different tissues. The estrogen receptors (ER) 
and androgen receptor (AR) are ligand-activated transcription factors that belong to the 
nuclear hormone receptor superfamily and are responsible for mediating the physiological 
effects of the steroid hormone ligands. Estrogens and testosterones bind to the receptors with 
a high specificity and affinity and the resulting ligand/receptor dimer is able to exert its 
effects at both nuclear and cell membrane sites. Transcriptional control by the nuclear 
receptors requires interaction with coregulator complexes, either coactivators for stimulation 
or corepressors for inhibition of target gene expression. Interaction with the coregulator 
occurs after the ligand is bound, concomitant with structural changes which occur on 
binding of the ligand, exposing the surface required for coregulator binding. Along with the 
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desired regulation of normal cells, hormones have also been found to control the growth of 
several forms of cancer tumours. Drugs or treatments that block the effects of hormones, or 
lower the levels can therefore be used to treat some types of cancer.
21-23
 
1.2.2.1 Estrogen Receptors 
Estrogen receptors can be split up into two main groups, estrogen receptor alpha 
(ERα) and estrogen receptor beta (ERβ).22 ERα and ERβ are coded by separate genes which 
are found on different chromosomes accordingly. Both genes can be split into six structural 
domains (termed domains A-F) and within these, well defined functional domains are 
contained. Within ERα and ERβ, homology between the domains vary: 96 % homology in 
the DNA binding domain (C), 53% homology between E/F domains and A, B and hinge (D) 
domains are not well conserved. It is within the E and F domains that the coregulatory 
domains are found, such as the ligand binding domain (LBD) and the ligand-dependent 
activation function 2 (AF-2) surface. The LBD contains sequence specific features essential 
for interaction with ER coactivators and corepressors.
21 
Complexation between ERs and 
other cellular factors is required to modulate ER-mediated transcriptional activity and so 
selectivity between the two ERs can be achieved due to the lack of homology within the 
nucleotide sequence.
24
 This thesis however, will focus on the ERα. 
1.2.2.1.1 Estrogen Receptor α 
ERα regulates the growth and function of tissues found in the female reproductive 
system such as breast, uterus and ovaries. It has also been identified as playing an important 
role in many pathological processes with 70% of breast tumours developing due to the 
stimulatory effect of estrogens. In gene transcription, ERα forms complexes with 
coactivators enabling transcriptional activation to occur. The p160 protein family is a group 
of ERα coactivators and consists of three members; SRC-1, Tif-2/GRIP1 and SRC-3/AIB1. 
Knockout studies showed that in ERα-positive breast cancer, the p160 gene is amplified 
indicating that these coactivators are important in ERα signalling.24 These coactivators 
interact with the ERα via small amphipathic α-helical peptide sequences containing a 
common recognition motif; LXXLL (L = leucine, X = any amino acid) also known as the 
nuclear receptor box (NR box) (Fig. 1.5)
25
.
 
The amino acids at position X vary, helping to 
facilitate specific NR box recognition for a particular nuclear receptor. The NR box binds to 
a hydrophobic cleft on the ERα AF-2 surface on the LBD controlled by the specificities of 
the activating ligand, 17-β-oestradiol (E2).24  Studies using X-ray crystallography showed 
that the leucine side-chains in positions i and i+4 are projected into a hydrophobic groove 
whilst the side chain at the i+3 position projects into a hydrophobic pocket (Fig. 1.5).
7
 The 
crystal structure also suggests that the peptide backbone interacts with the charged residues 
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that flank the binding groove on the ER further stabilising the complex. It has been proposed 
that these features may allow the ERα-coactivator interaction to be targeted by LXXLL 
motif-like inhibitors, preventing transactivation from occurring.
24
 
 
Figure 1.5 The LBD on ERα and the binding helical epitope of a nuclear receptor coactivator. 
The leucine residues in the LXXLL recognition motif are shown in grey (PDB ID:2QZO).  
1.3 Approaches for Inhibition of α-Helix Mediated Protein-Protein 
Interactions 
The need to modulate PPIs is increasing, and the challenges this presents have been 
discussed in addition to the critical features on the protein which can be exploited to 
overcome these challenges. The rest of this chapter will highlight major advances in 
developing generic approaches for PPI modulation. Several strategies for PPI inhibition have 
been developed and these can be grouped into three major categories. Type I (constrained 
peptides and β-peptides) and Type III (proteomimetics) mimetics use the native helix motif 
as a basis for inhibitor design and these strategies will be discussed in depth. Type II 
mimetics on the other hand are typically small molecule inhibitors, identified using 
conventional drug discovery methods such as high throughput screening (Nutlin-3a:                 
Fig. 1.6a)
26
 and fragment-based design (ABT-737 and ultimately ABT-263: Fig. 1.6b)
27
. 
Despite these important breakthroughs, identifying small molecule inhibitors of PPIs has 
proven challenging and since they are designed to selectively target one specific PPI, they 
have less relevance within the context of designing inhibitors and developing a general rule 
for PPI inhibition is much less likely; these types of inhibitors will therefore not be 
discussed. 
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Figure 1.6 Chemical structures of (a) Nutlin-3a identified via HTS and (b) ABT-737 and 
ABT-263 idenified via a fragment based approach. 
1.4 Type I Mimetics 
Peptides are often considered therapeutically undesirable due to poor transport 
properties and their sensitivity to proteolytic degradation.
28
 However, peptides have the 
advantage of providing a highly conserved and complex set of functions that cannot be com-
pletely mimicked by a small molecule, and which potentially results in diminished 
interference with normal biological processes.
29 
The development of therapeutics composed 
of the helical domain central to the PPI of interest has therefore attracted due attention. Type 
I mimetics are short fragments of peptide which strive to replicate the local topography of 
the α-helical structural motif. Once removed from the stabilising environment of a protein, 
synthetic peptides become far less organised in solution, adopting only random 
conformations and the ability to bind to the partner protein is consequently retarded.
30
 
Several approaches are being explored to improve helicity whilst also addressing problems 
of proteolytic stability and other pharmacokinetic factors. These approaches can be grouped 
into two general categories: constrained peptides and helical foldamers. 
Figure 1.7 Schematics illustrating different approaches for covalent helix stabilisation (helix 
faces are coloured red, blue and green, with white faces indicating that the covalent 
stabilisation interferes with molecular recognition of that face).  
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1.4.1 Constrained Peptides 
This class of peptide can also be categorised within helix stabilisation methods. 
These are methods which restrict the peptide backbone, assisting with pre-organisation of 
the amino acid residues and initiating helix formation. Early strategies for helix stabilisation 
include helix nucleating templates and metal-mediated bridges, however, covalent 
cyclisation affords the most successful bioactive conformations for inhibiting the desired 
target.
31
  On a single face of the α-helix structure, lie residues at the i, i+4, i+7 and i+11 
positions. A number of methods employ pairs of residues at these positions covalently 
linking side-chains, whilst other cyclisation strategies use main chain-main chain 
connections such as the hydrogen bond surrogate (HBS) method (Fig. 1.7).  
1.4.1.1 Disulfide Bridges 
One of the first examples of helix stabilisation via disulfides was reported by 
Wemmer et al. who synthesised hybrid peptides containing a disulfide linkage which formed 
the same basic 3D structure as Apamin. The hybrid peptide was effective in inducing a 
biological response which necessitates a helical conformation.
32
 Following this, Schultz and 
co-workers studied the effect of stereoisomers of cysteine positioned at the i and i+7 
positions. When D-Cys and L-Cys were incorporated at the i and i+7 positions respectively, 
intramolecular disulfide formation was achieved with little perturbation on helical 
conformation. L,L analogues showed a marginal increase in helicity from the unconstrained 
peptide and L,D analogues resembled random coils or β-sheet conformations.33 Later studies 
from the Mierke and Spatola groups concurred that the D,L configuration of oxidised 
cysteines at the i and i+3 positions was also the best combination for targeting their desired 
receptors.
34,35
 Schultz also demonstrated the structure temperature dependence of a peptide 
containing a single disulfide bridge. Unlike typical α-helices, the ends of the peptide relaxed 
to a random-coil conformation on heating whilst the residues within the bridge preserved 
partial helicity.
33
  
An alternative method for constraining peptides is to use side chain-side chain 
lactam bridges. Spatola and co-workers compared the efficiency of disulfide and lactam 
constraints in stabilising peptides containing the conserved NR box LXXLL pentapeptide, 
with the aim of designing potent and selective inhibitors of steroid receptor-coactivator 
interactions.
36
 A disulfide bridged nonapeptide inhibited the ERα/coactivator interaction 
with an inhibition constant an order of magnitude higher than the lactam bridged analogue 
(Ki = 25 nM vs 220 nM); confirming molecular modelling predictions. It was also 
considerably more potent than a comparable linear peptide with 13 residues and 
approximately 15 times more selective for ERα than ERβ. CD spectra of the peptide 
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indicated minimal helical character in an aqueous environment, however, an X-ray crystal 
structure (PDB ID: 1PCG) confirmed that the disulfide linked peptide does bind in the 
expected conformation implying receptor-induced conformational changes of the 
constrained coactivator peptide on binding.
36
  
Following this, Spatola and co-workers carried out an extensive SAR study on 
disulfide bridged Selective Estrogen Receptor Modulators (SERMS) to determine what 
factors affect the binding affinity and selectivity. The study probed the effects of changing 
configuration, disulfide ring size and peptide chain flexibility via homocysteine and 
penicillamine incorporation (Fig. 1.8). They also manipulated the LXXLL NR box to 
contain a range of unnatural leucine surrogates. Several important concepts came out of the 
SAR study allowing them to design potent and selective inhibitors,
35
 alongside replacement 
of the disulfide with a thioether link to produce a potent inhibitor of the ERα/co-activator 
interaction with an inhibition constant of 6.9 nM. The cystathionine linked peptide also 
demonstrated over 9 fold selectivity for ERα than ERβ.37 
 
Figure 1.8 Chemical Structure of unnatural amino acids; homocysteine and penicillamine. 
1.4.1.2 Lactam Bridges 
The aforementioned lactam link is another approach for constraining peptides and is 
probably the most investigated. Early designs of lactam bridges produced biologically active 
cyclic peptides and since then much work has focused on side chain-side chain lactam 
bridges incorporated into longer peptides. The earliest demonstration following this rationale 
was reported by Rosenblatt et al.
38
 A parathoid hormone related protein (PTHrP) analogue 
was stabilised via a lactam link between Lys and Asp in the i and i+4 positions respectively. 
The constrained peptide was 5-10 times more potent than the parent linear peptide and 
incorporation of the corresponding D-amino acids at either position considerably reduced 
potency. The authors speculated that configuration dependence may reflect steric 
requirements imposed by the receptor or by steric hindrance imposed on Lys and Asp by 
neighbouring residues. Subsequently, Geistlinger and Guy applied a similar approach for 
stabilisation of estrogen-binding coactivator peptides.
39
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McDowell and co-workers explored the use of constrained peptides to inhibit HIV 
type 1 fusion events.
40
  HIV infection requires membrane fusion mediated by the C-terminal 
heptad region (CHR) of the gp41 peptide binding in an antiparallel fashion in a groove on 
the N-terminal heptad region (NHR) of gp41. Comparison of the relative activities of a linear 
peptide with various constrained peptides demonstrated a correlation between helicity and 
inhibitory potency, whilst activity of the peptide containing a restraint on the binding face 
was reduced entirely. All truncated peptides, however, were found to be less potent than the 
full length analogues.
40
 The study was taken further by Kim and co-workers; they aimed to 
stabilise a 14 residue C-terminal peptide targeting the hydrophobic pocket of  HIV-1 gp41 
by incorporating unnatural helix favouring amino acids and chemical cross-links.
41
 They 
found that cross-linking two Glu residues at the i and i+7 positions with an α,ω 
diaminoalkane group resulted in the most potent inhibitor (IC50 = 35 μM, Kd = 1.2 μM). An 
X-ray crystal structure of the cross-linked peptide bound to the HIV-1 gp41 hydrophobic 
pocket demonstrated that it binds with virtually the same helical conformation as the native 
C-terminal peptide (Fig. 1.9a,b).
41
 
 
Fig. 1.9 (a) Crystal structure showing the binding of a cross-linked peptide bound to the 
hydrophobic pocket on HIV-1 gp41 (PDB ID: 1GZL) (b) Crystal structure showing the 
binding of the C-terminal peptide in the hydrophobic pocket HIV-1 gp41 (PDB ID: 1AIK). 
Fairlie and co-workers reported an approach for stabilisation of short α-helical 
peptides which relies upon a Lys1→Asp5 linkage. They used a pentapeptide module to 
create cyclic peptides with different arrangements of linkers. This provided versatility in 
designing helix mimics to expose different side chains appropriate for different helix faces 
(Fig. 1.10). Biological activities of the water-soluble helices, derived from proteins with 
diverse functions and different receptors, were shown to be superior to linear analogues and 
even surpass the native ligand.
42
  With this approach the group successfully mimicked the 
helical epitopes of (i) a quorum sensing pheromone which abolished growth of the bacteria 
S. pneumonia at sub micromolar concentrations,  (ii) the F fusion protein of Respiratory 
Syncytial Virus showing picomolar inhibition of viral fusion, (iii) the RNA-binding viral 
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protein HIV-1 Rev showing nanomolar affinity for the RNA segment Rev Responsive 
Element and (iv) the human hormone nociceptin and induced intracellular ERK 
phosphorylation at picomolar concentrations (the most potent agonist identified to date). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 Cyclic pentapeptide modules having different distributions of interacting side 
chains (grey CPK = ‘x’ amino acids) and linking bridges (red or blue = K→D linkage) 
1.4.1.3 Hydrocarbon Stapling 
Whilst disulfide and lactam bridges are successful at stabilising α-helices, these 
naturally occurring functionalities are accordingly somewhat susceptible to degradation in 
cells. Grubbs and Blackwell first introduced a non-native carbon-carbon bond constraint via 
a ring-closing metathesis (RCM) reaction with O-allyl serine residues in an effort for 
enhanced biostability.
43
 Verdine and co-workers elaborated on this approach and 
incorporated unnatural α,α-disubstituted amino acids with olefin tethers into a C-terminal 
peptide sequence of RNAse A; multiple configurations, linker lengths and positions were 
explored to identify ideal combinations to maximise helix content.
44
 This new hydrocarbon-
stapled backbone approach provided a platform for a number of significant studies in this 
field over the last decade. By incorporating analogous olefin bearing tethers into a 23 residue 
Bid BH3 peptide at the i, i+4 positions, Korsmeyer and co-workers generated peptides with 
a noticeable improvement in peptide α-helicity, protease resistance and in vitro and in vivo 
biological activity.
45
 In vivo studies found a stabilised peptide penetrated a wide panel of 
leukaemia cells and selectively triggered the apoptotic pathway (IC50 values ranging from 
1.6.- 10.2 μM). Tumour suppression and often tumour regression was also displayed in mice 
bearing established human leukaemia xenografts when treated with the stabilised peptide 
and this approach has ultimately been commercialised.
45
 
Apoptosis is widely agreed to be mediated by the competitive interactions between 
pro- and anti-apoptotic members of the Bcl-2 family, however, how the pro-apoptotic Bax 
and Bak proteins trigger apoptosis remains a matter of debate.
46
 The Walensky group 
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developed a series of ligands based on the Bid BH3 domain (referred to as “death domain” 
because of its ability to promote apoptosis). These ligands were stabilised by the 
hydrocarbon cross-linker and recapitulated the α-helical character of native death domains, 
directly binding to Bax and initiating Bax mediated mitochondrial apoptosis. 
47
 In addition, 
the Walensky group described an inhibitor of the Mcl-1 protein; in this instance, the most 
potent stapled peptide was not one derived from a known BH3 effector protein with a high 
affinity for Mcl-1 but rather a stapled peptide derived from Mcl-1 itself .
48
 
Further targets that have been addressed using this approach included p53/hDM2 
and ER/coactivator interactions.
49, 50 
 Crystal structures of stapled peptides bound to these 
targets have been described (Fig. 1.11), and in the case of ER, highlight that caution must be 
exercised in interpreting structure–property relationships for these ligands: the hydrocarbon 
linker itself can bind in the cleft of the target protein.  Transcription factors have proven to 
be among the most difficult targets for therapeutic intervention owing to a much larger 
interface and the absence of a hydrophobic pocket. Bradner and co-workers successfully 
developed a direct-acting agonist of the oncogenic transcription factor NOTCH1 by 
evaluating a series of stapled peptides based on the coactivator peptide MAML1.
51
 An 
extensive in vitro analysis of a 15-residue peptide stapled at the i and i + 4 positions, 
conclusively demonstrated binding to a NOTCH1-transcription factor complex, directly 
antagonising recruitment of MAML1. This stapled peptide was shown to suppress NOTCH1 
signalling whilst a bioluminescent murine model exhibited a direct link between inhibition 
of the NOTCH pathway and anti-leukaemic activity in vivo.
51
  
 
Figure 1.11 Crystal structures of stapled peptides bound to (a) hDM2, mimicking the 
p53/hDM2 interaction (PDB ID: 3B3V) and (b) ERα, mimicking the interaction between ERα 
and it’s coactivators (PDB ID: 2YJA). Staples are shown in green and key binding residues 
shown in grey. 
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Finally, Walensky and co-workers recently demonstrated that hydrocarbon double-
stapling structurally fortifies longer bioactive peptides, conferring protease resistance in 
vitro and in vivo and that oral absorption of such peptides is achievable. These peptides also 
displayed enhanced antiviral activity against neutralisation-resistant HIV-1 virus through 
inhibition of gp41 assembly when compared to singly stapled or unmodified peptides.
52
 The 
hydrocarbon stapling approach can thus be considered as one of the main success stories in 
the development of designed inhibitors of PPIs thus far: Aileron Therapeutics was founded 
in 2005, and acquired exclusive rights from numerous institutions such as Harvard, Dana-
Farber Cancer Institute, Materia and NYU to develop and commercialise a drug discovery 
pipeline based on stapled peptides. The company have recently completed the first-ever 
stapled peptide clinical trial for treating endocrine disorders, are due to start clinical trials in 
2014 with Roche using an optimised p53 pathway reactivator and have recently secured              
$30 M in new financing to advace the pipeline of clinical candidates. 
53
 
1.4.1.4 Hydrogen Bonding Surrogate 
The HBS motif presents a covalent linkage in lieu of a native main-chain hydrogen 
bond.
54, 55
 The method established by Arora and co-workers employs ring-closing metathesis 
on olefin-bearing residues at the i and i + 4 positions. This method is attractive as 
recognition features on the helix surface are not encumbered by the constraining element; 
the cross-link is positioned on the inside of the helix, whereas side chain tethers block at 
least one face of the putative helix.
56 
In addition to this, incorporation of the crucial residues 
(for lactam bridges, disulfides etc.) may remove important side chain functionalities.
56
 A 
highly helical HBS-peptide of the BAK BH3 α-helix was shown to bind to Bcl-xL with a Kd 
value of 69 nM and was 60-fold more resistant to trypsin-mediated proteolysis than the 
linear analogue,
39
 whilst a HBS-helix derived from the C-peptide from gp41 was shown to 
bind to the N-terminal hydrophobic pocket and inhibit gp41-mediated cell fusion (IC50 = 43 
μM) by inhibiting formation of the six-helix bundle.57 In further work, a HBS-helix of p53 
(Kd = 160 nM for p53/mDM2 interaction) was shown to target the complex with similar 
selectivity to that of Nutlin-3 when screened against other proteins which are known to bind 
helical peptides (including hDMX and Bcl-2 family proteins).
58
 In vitro studies of a HBS-
helix of the C-terminal transactivation domain of HIF-1α exhibited a Kd value of 420 nM for 
binding to p300 CH1 domain and down-regulated VEGF transcription.
59
 Finally, the Arora 
group used this approach to target the Ras/SOS interaction. Based on the guanine nucleotide 
exchange factor SOS, they reported a cell-permeable synthetic α-helix that interferes with 
the Ras/SOS interaction and down-regulates Ras signalling in response to receptor tyrosine 
kinase activation.
60
 The Arora group has more recently explored the use of a thioether 
linkage (teHBS; Fig. 1.12)) as an alternative to the all hydrocarbon tether and demonstrated 
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this modification is appropriate by comparison with a conventional HBS helix for inhibition 
of p53/mDM2 (Kd = 224 nM for teHBS and 232 nM for HBS).
61
 
Figure 1.12 Schematics illustrating the different HBS and teHBS approaches. 
1.4.1.5 Photocontrolled α-Helices 
The above strategies have developed some potent peptide based inhibitors of PPIs, 
however, the activity of these constrained peptides cannot be controlled. Alleman and co-
workers have developed a system in which protein-binding activity can be controlled by an 
external stimulus in a reversible manner. The approach utilises an azobenzene cross-linker 
which is introduced via cysteine residues at the i, i+4, i+7 or i+11 positions. The cross-linker 
undergoes cis/trans isomerisation on irradiation which switches the peptides between 
random coil-like and α-helical conformations.62 This strategy has previously been used to 
control binding of α-helices to DNA but has since been pursued for photocontrollable 
peptides for PPI inhibition.
63
 
Using this azobenzene system, Alleman and co-workers synthesised 
photocontrollable helices based on the BH3 domain peptides of Bak and Bid to target the 
anti-apoptotic Bcl-xL.
64
 Cross-links were located at the i, i + 7 and i, i + 11 positions in a Bak 
peptide and i, i + 4 positions in a Bid peptide. Significant helix stabilisation was observed in 
peptides when the cross-link was in the cis configuration with i, i + 4 and i, i + 7 Cys 
linkages (Fig. 1.13a), whilst linkers at i, i + 11 positions found the trans configuration to be 
helix-stabilising (Fig. 1.13b). Peptides in their helix-stabilised configurations displayed high 
affinities for Bcl-xL with dissociation constants of 55 nM  (Bid), 49 nM (Bak
i+7
) and 21 nM 
(Bak
i+11
), and in some cases cross-linked peptides showed 200-fold selectivity for binding to 
Bcl-xL over helix-binding hDM2. Helix destabilised forms of Bak
 
(Kd = 825 nM) and Bid (Kd 
= 1275 nM) peptides were found to bind more weakly to Bcl-xL. The data demonstrates a 
unique ability to control activity of constrained peptides and holds potential for studying and 
modulating cellular function by selectively interfering with PPIs.
64
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Figure 1.13 Photocontrol of peptide conformational preference with azobenzene cross-linker 
(green). (a) Helical conformation stabilised in the cis configuration with i, i + 4 and i, i + 7 Cys 
linkages. (b) Helical conformation stabilised in the trans configuration with i, i + 11 Cys 
linkages. (c) Chemical structure of the photocontrollable cross-linker (trans configuration). 
A range of alternative cross-linkers are now being developed that confer enhanced 
properties and/or ease of synthesis. Two recent examples exploit biphenyl- and meta-xylene-
derived cross-links.
65, 66
 The former furnished optimised inhibitors of the Mcl-1 protein, 
whereas the latter provided novel inhibitors of calpain through mimicry of its proteinogenic 
enzyme inhibitor. Studying the literature, there are contradicting theories as to what factors 
will increase the inhibitory activity of short constrained peptides other than the linker itself. 
This includes which amino acids to cross-link and their relative positions, where in the 
sequence should they be and the length and flexibility of the linkers. Some groups aim to 
maximise helical content of short peptides for a smaller entropic penalty on binding whilst 
others assert that this may distort the helical conformation into an inactive form.  A less 
defined conformation is thus considered adequate and a linker is necessary merely to reduce 
the number of degrees of freedom of the peptide in the unbound state. As such, there is 
currently not a truly generic technology for mimicking short protein helices with constrained 
peptides. 
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1.4.2 Helical Foldamers 
The alternative approach for Type I mimetics are foldamers, whose conformation is 
designed to mimic that of the canonical α-helix. In this generic structure, it is known that 
intramolecular hydrogen bonding can confer stability or instability; complementary 
hydrogen bonding donors (amide N-H) and hydrogen bond acceptors (amide C=O) located 
on non-consecutive residues along the peptide (Fig. 1.14) confer conformational specificity 
and add stability to the secondary structure. In a series of modelling experiments, the 
Gellman group studied the ability of unnatural β- and γ-amino acids to confer such 
stabilisation in modified peptides.
67
 From this, they postulated that absent nearest neighbour 
backbone hydrogen bonding, observed in β-peptide derivatives, would induce 
conformational specificity.  This identified β-peptides as promising candidates for helical 
foldamers. 
 Figure 1.14 (a) Schematic of a polyamide backbone displaying favourable (black) and 
unfavourable (green) hydrogen bonding. (b) Intramolecular hydrogen bonding network within 
the α-helix. 
β-peptides are generated from a simple backbone alteration to α-amino acids: 
addition of a methylene unit. Initially, it was thought that the extra carbon would introduce 
additional flexibility, reducing its tendency to adopt well defined folded states in solution. 
Subsequent structural studies illustrated that conformational constraints and substitutions, 
furnished β-peptides with an increased tendency to fold over α-peptides.68 Furthermore, 
Seebach et al showed that this ‘simple’ backbone modification could impart enhanced 
resistance to proteolysis and more favourable pharmacokinetics to β-peptides.69  As 
previously mentioned, long range backbone hydrogen bonding is inherent to helical stability 
and β-peptides are named after the number of backbone atoms per hydrogen bond ring; 14-
helix and 12-helix being the best characterised. When designing mixed α/β-peptides 
systems, one has to consider a number of features: the constitutional (β2, β3, β2,3 etc) and 
configurational ((R), (S)) variety of the building blocks, the position of a single β-amino acid 
in the peptide sequence and the spacing between β-amino acids. This substitution pattern has 
been shown to affect the peptide folding preferences (helices, β-sheets, hairpins etc) and has 
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been extensively reviewed.
70
  More recently, such systems have been employed in the 
mimicry of biological relevant peptides and this section will focus of the success of helical 
foldamers in this respect. 
1.4.2.1 β-peptides    
The question of biological relevance of these hybrid peptides was first addressed by 
Seebach et al, who demonstrated that small seven-nine residue amphiphathic β-peptides 
could mimic alipoproteins by mildly inhibiting small-intestinal cholesterol absorption 
(compared to no activity with α-peptides).71 They also proved more resistant to proteolysis,71 
demonstrating these ‘first-generation’ ligands had potential for designing biologically active 
β-peptides, despite having several inherent differences.72  
The Schepartz group subsequently designed a β3 decapeptide which had significant 
14-helical stability in aqueous solution due to side chain-side chain salt bridges on one 
helical face and internal macrodipole stabilisation. Targeting the p53/hDM2 interaction, key 
residues from the activation domain of p53 (p53AD: Phe19, Trp23, Leu26) were 
strategically positioned within the peptide to align on a single face upon folding. The most 
potent inhibitor targeted the interaction with an affinity close to that of the native peptide 
(IC50 = 80.0 ± 3.2 μM for the β
3 
peptide vs IC50 = 2.47 μM for p53AD).
73 
 Parallel SAR 
studies found introduction of a 6-chlorotryptophan analogue in place of the Trp side chain 
improved potency by 10 fold.
74-76
 The Schepartz group also applied this approach to inhibit 
gp41 mediated cell-cell fusion with a β3-decapeptide.  Although less potent than a prescribed 
HIV fusion inhibitor (IC50 = 5.3 μM vs IC50 = 0.11 nM), the β
3
 peptides are one third of the 
size, metabolically stable and available for combinatorial optimisation, showing potential for 
inhibitors of other systems that employ common fusion mechanisms with extended helices.
77
 
1.4.2.2 Mixed α/β peptides 
In addition to β-peptides, which exclusively contain β-amino acids, another canonical 
foldamer class is one which contains α- and β-amino acids (initially in a 1:1 alteration) and 
as such are termed α/β peptides. α/β peptides have been extensively characterised, displaying 
4 distinct helices, each having a unique spatial arrangement of side chains (with a given 
sequence separation) analogous to side chain arrangement found in α-helices.78-81  
Preliminary studies from the Gellman group were made to identify foldameric ligands for 
the BH3-recognition cleft of Bcl-xL. Assessing the affinity of over 200 α/β- and β-peptides 
with different helical conformations towards Bcl-xL, only α/β-peptides thought to adopt a 
14/15-helical secondary structure displayed significant binding.
82
 Sequence-affinity 
relationship profiling ultimately led to the identification of a potent chimeric inhibitor (Ki = 
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2.2 nM). These were made up of an N-terminal α/β-peptide segment of Bak, fused to a C-
terminal α-peptide segment ((α/β+α)-peptides): only 60% of the Bak peptide could be 
successfully mimicked by a ‘continual’ α/β- or β- scaffold.83 The success of a chimeric 
approach suggested that mimicry of large binding epitopes may be accomplished by 
replacement of short segments of the epitope with distinct foldameric scaffolds, decreasing 
the proportion of α-amino acid residues, with the ultimate goal of metabolic stability without 
compromising affinity. Subsequent studies produced a crystal structure of the most potent 
peptide mimicking the Bim-BH3 peptide bound to Bcl-xL (Fig. 1.15). This provided much 
insight into results from previous binding studies, highlighting the importance of subtle 
changes in side chain positioning.
84
  
Figure 1.15 (a) X-ray crystal structure of pro-apoptotic Bim bound to Bcl-xL (PDB ID: 3FDL) 
(b) X-ray crystal structure of a chimeric Bim mimetic bound to Bcl-xL : comparison with a 
shows the foldamer to bind in the same hydrophobic cleft  (PDB ID: 3FDM) (c) Top view of 
the α/β foldamer highlighting the interacting α- (green) and  β-residues (dark blue) and the 
solvent exposed β-residues (light blue). 
Traditionally, a structure-based approach was the method of choice which involved 
changing the native helix by incorporating constraints and various side chains to maximise 
helicity, whilst projecting the key side-chains in the correct orientation. Building on previous 
studies, the Gellman group adapted their approach by applying a ‘sequence-based’ design 
which involved replacing subsets of regularly spaced α-residues with the corresponding β3-
residues. Each replacement introduces an extra methylene unit at regular occurrences, 
keeping the fundamental sequence of the native helix the same. This was applied to the 
design of α/β-peptides of Puma (another pro-apoptotic member of the Bcl-2 family), 
incorporating an ααβαααβ sequence repeat along the peptide, and starting at varying 
positions along the peptide;
85
 peptides with this repeat pattern have been previously shown 
to adopt a helix-like conformation by crystal structures.
86
 From evaluation of seven peptides, 
a potent inhibitor of Bcl-xL was identified (Ki = 1 nM) which was also found to bind to Mcl-
1(Ki = 150 nM).85 Co-crystal structures of these sequenced-based designed inhibitors show 
that the β-residues align on a single face of the helix producing a slight curvature to the 
peptide. The study revealed how subtle changes in key geometrical features (helix radii, 
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helix bowing etc) can greatly affect the binding affinity.
87
 Subsequent studies were made to 
evaluate different sequences, including ααβ and αααβ repeat units. The αααβ pattern 
produced four low-nanomolar inhibitors of the Bcl-2 anti-apoptotic proteins based on the 
Bim-BH3 pro-apoptotic peptide, inducing cytochrome c release in wild-type mouse 
embryonic fibroblast (MEF) extracts.
88
 
 Figure 1.16 (a) Top view of the native gp41 six helix bundle, (b) Top and (c) lateral views of 
the six helix bundle formed by α/β-CHR foldamers and native α-NHR peptides. β-residues are 
represented in green c highlighting the single face positioning of the residues. 
  The basics of the sequence-based approach were applied to design α/β-peptide 
mimics of the long HIV membrane protein gp41.
89
 This involved a two-step process: β3-
residue insertion into the α-sequence of the CHR domain of gp41 forming ααβαααβ repeats 
and then systematically changing selected β3-residues with cyclically constrained β-residues 
to rigidify the backbone.  As the α/β-peptide has to be considerably longer than those 
previously designed, the second step was necessary to overcome the entropic penalty 
associated with pre-organising longer oligomers. Crystallographic data showed the α/β-CHR 
peptides form a near identical six helix bundle with the NHR domain as the native CHR 
sequence (Fig. 1.16a,b), and cell fusion and virus-infectivity assays indicate the α/β-peptides 
effectively block HIV cell-fusion (Ki = 9 nM, ~380-fold improvement on the analogous 
acyclic α/β-peptide). Furthermore, antiviral activity was demonstrated to be comparable to 
that of the native α-peptide with ~280 fold enhanced resistance to proteolysis.89 As 
demonstrated in Figure 1.16c, the β-residues in an ααβαααβ based peptide are found along a 
single face of the helix. Gellman et al exploited this feature to impart stability to the gp41 
α/β-peptide mimics. Inserting β- analogues of acid/base residue pairs in appropriate positions 
so as not to remove key functionality, stabilisation was achieved via side chain ion pairing at 
the i and i + 3 and/or i and i + 4 positions, replacing cyclic constraints.
90
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1.5 Type III Mimetics  
 Although a number of amino acids are involved in constructing the highly ordered, 
helical motif, it is only certain residues which are responsible for the interaction with its 
target protein. Proteomimetics strive to replicate the topography of the native helix by 
mimicking the spatial projection of key binding residues, rather than recapitulating the entire 
helical motif. In doing so, molecular weight is reduced and biostability is enhanced whilst 
retaining the important binding features of the α-helix: or the helix pharmacophore.91 
Currently, there are numerous proteomimetics designed with a sufficiently rigid scaffold to 
help project side chains, analogous to those of the α-helix, with the correct spatial 
orientation.
 
This is important for two reasons (i) mimicking the 3D orientation of the α-helix 
side chains provides correct binding conformation; residues have the correct orientation and 
distances required for efficient binding
92 
and (ii) less entropy is paid on binding due to the 
rigidity of the scaffold allowing for higher affinity binding to the protein. Ideally, however, 
the scaffold must have some flexibility to be able to bind to the target protein and adopt the 
best conformation for binding.  
1.5.1 Proof-of-Concept and Early Design Strategies 
The template selected for one of the first attempted α-helix mimetics was a                      
1,1,6-trisubstituted indane.
92
 It is a relatively rigid template allowing the spatial orientation 
of the substituents to be predicted. Molecular modelling of the indane template showed a 
good overlay exists between the 1- and 6- position to the Cα and Cβ bonds of the i, i+1 
residues of the α-helix. The second substituent on the 1-position of the indane also 
corresponds to the i-1 residue. Willems and co-workers reported that derivatives with large 
hydrophobic side chains (Phe-Phe and Trp-Phe at the 1 and 6 positions) showed micromolar 
affinities similar to the parent dipeptides in binding to the tachykinin receptors NK1, NK2 
and NK3.
92
 Further work found that 1,1,6-trisubstituted indanes showed similar affinities to 
tachykinin receptors and other neuropeptide targets. 
93
 Due to the small size of indanes (Fig. 
1.17a), they are limited to mimicking two successive amino acids. As a result, they did not 
prove effective at inhibiting α-helix mediated PPI’s, however, they demonstrated that small 
molecules were able to project functionality in suitable spatial orientations for binding to a 
target protein and many larger scaffolds have since been designed.
4
  
Development of the terphenyl α-helix originated from a biphenyl molecule. Similar 
to several other molecules such as allenes, alkylidenes cycloalkanes and spiranes, these 
structures contain a helical twist. However, when these compounds are superimposed onto a 
polyalanine helix, only the biphenyl skeleton complies with the requirements of an α-helical 
conformation - for example the disposition of the amino acid side chain and twist angle.
94
 In 
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addition to this, the biphenyl unit is contained within 2.1 % of all reference drug molecules 
indicating that this structure has favourable bioactive properties. This is attributed to the 
flexibility, size and shape of the unit allowing it to bind to a wide variety of protein pockets. 
Figure 1.17 (a) The indane scaffold: proof-of-concept for peptide mimetics. (b) The terphenyl 
scaffold: terphenyl derivative inhibitors of the CaM/smMLCK 1a and Bak/Bcl-xL 1b 
interactions. 
Hamilton and co-workers were the first to report the use of the terphenyl backbone 
as an α-helix mimetic.95 The tris-functionalised 3,2’,2’’-terphenyl scaffold (Fig. 1.17b) was 
an attractive template for the initial design due to the simplicity of the structure; it was also 
an entirely non-peptidic scaffold which could be synthesised in an iterative fashion. The aryl 
core assumes a staggered conformation enabling functional side chains to be projected with 
similar distances and angular relationships to those located in α-helices. The 
tris-ortho-substituted terphenyl was found to mimic the i, i+4, and i+7 residues by adopting 
a staggered conformation, representing two turns of an α-helix. Libraries of compounds, 
incorporating various functionalised side chains, were subsequently synthesised. 
Initial tests using terphenyl derivatives showed them to be antagonists for the 
interaction between CaM and an α-helical domain on smMLCK.  Derivative 1a competes 
with smMLCK with an IC50 of 9 nM.
95
 In subsequent studies, CD was used to determine the 
ability of terphenyl derivative 1b to target the HIV-1 transmembrane envelope glycoprotein, 
gp41, and disrupt the assembly of a fusion-competent hexameric core. A dye-transfer cell 
fusion assay confirmed inhibition of the HIV-1 mediated fusion exhibiting an IC50 of 15.70 ± 
1.30 µM.
96
 Further studies involving fluorescence polarisation assays have shown terpheny1 
derivatives to be capable of inhibiting the p53/hDM2
97
 and Bcl-xL-Bak
98
 PPIs. Bcl-xL-Bak 
selectivity over p53/hDM2 was achieved by a subtle exchange of a methyl-1-naphthyl for 
methyl-2-naphthyl side chain, demonstrating the ability to selectively modulate different 
complexes.
98
  Terphenyls were also shown to be active in intact cells (HEK293): inducing 
apoptosis by the intended mechanism by disrupting BH3-mediated interactions with Bcl-
xL.
99
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1.5.2 Second Generation Design Strategies 
Difficulties in the synthesis and solubility of terphenyl due to the hydrophobic 
template inspired Hamilton and co-workers to develop a new scaffold based on a 
trispyridylamide foldamer (Fig. 1.18a).
100
 The polyamide backbone adopts a planar 
conformation with all alkoxy side chains projected on the same face of the molecule (syn) 
and tilted at 45°
 
to maximise interactions of the lone pair on the oxygen atom with the amide 
NH group. The observed geometry results from a bifurcated hydrogen bonding network 
between the amide proton and the pyridyl nitrogen and ether oxygen. Electrostatic clashes 
between the amide carbonyl and the pyridine nitrogen in the anti conformation further 
favours the observed syn geometry. Overlaying the scaffold with a polyalanine α-helix 
reveals a close resemblance between side chains and the i, i+4 and i+7 residues and a 
modular synthesis facilitated the generation of a small library of compounds. Fluorescence 
anisotropy assays demonstrated derivative 2 to inhibit the Bcl-xL-Bak complex (Ki = 1.6 
µM). 
100
  
Figure 1.18 (a) The trispyridylamide scaffold: trispyridylamide derivative inhibitor of the Bcl-
xL-Bak complex 2. (b) The benzoylurea scaffold. (c) Benzoylurea 3 and terphenyl 4 isosteric 
inhibitors of the Bcl-xL-Bak interaction. 
To date, most reports on synthetic inhibitors of PPIs have focused on mimicking 
small structural domains, most commonly up to two or three turns of the helix.  Longer 
α-helices, however, are frequently found in higher-ordered structures such as helix bundles, 
coiled coils and transmembrane domains of proteins and play a critical structural and 
functional role. The Hamilton group designed a benzoylurea scaffold (Fig. 1.18b) to mimic 
extended regions of an α-helix.101 The central aromatic ring on the terphenyl scaffold is 
replaced with an acylurea motif: a foldameric, aromatic ring isostere. A modular synthesis 
provides easy incorporation of natural and unnatural amino acid side chains, installing 
desired recognition properties with reasonable synthetic effort. This strategy achieved 
significantly elongated helix mimetics with four to five benzoylurea subunits spanning 
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lengths of up to 37.1 Å, corresponding to helices of approximately seven turns (30 amino 
acids). To test the validity of the benzoylurea scaffold against α-helix mediated PPIs, 
derivative 3 was synthesised, an isostere of the most potent terphenyl inhibitor 4
98
 of the 
Bcl-xL-Bak interaction (Fig. 1.18c). The benzoylurea 3 exhibited comparable inhibition to 
that of terphenyl 4 (Ki = 2.4 M and Ki = 114 nM respectively) demonstrating the potential 
for this scaffold as an α-helical mimetic.98 
Further work reported by the Hamilton group focused on novel terephthalamide and 
4,4-dicarboxamide scaffolds (Fig. 1.19a,b).
102, 103
 This was in search for compounds with 
more versatile syntheses and better physical properties than those possessed by terphenyl 
compounds. In the terephthalamide design, two carboxamide groups have been inserted in 
place of flanking phenyl rings on the terphenyl helix. This restricts rotation through 
intramolecular hydrogen bonds between the amide NHs and the alkoxy oxygen atom, 
thereby influencing the position of the amino acid side chain. The dicarboxamide scaffold 
combines the hydrophobic core of the oligophenyl scaffold with the accessible carboxamide 
groups of the terephthalamides. Inhibitory activities of derivatives of both scaffolds were 
tested against the Bcl-xL/Bak interaction (Ki = 0.78 μM 5a; 1.8 μM 6). Further studies 
demonstrated that treatment of human HEK 293 cells with terephthalamide derivative 5b 
resulted in disruption of the same interaction in whole cells with an IC50 of 35 µM.
102
 
Despite 4,4-dicarboxamides displaying the ‘required’ 4 key residues, improved potency over 
terephthalamides was not always seen. This raises the fundamental question of what is 
actually required to effectively target PPIs. 
 
Figure 1.19 (a) The terephthalamide scaffold: terephthalamide derivative inhibitors of the Bcl-
xL/Bak interaction 5a and 5b. (b) The 4,4-dicarboxamide scaffold: 4,4-dicarboxamide 
derivative inhibitors of the Bcl-xL/Bak interaction 6.
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1.5.3 Amphiphilic α-Helix Mimetics 
 Rebek and co-workers developed amphiphilic α-helix mimetics based on a 
pyridazine scaffold (Fig 1.20a).
104
 Inspired by Hamilton’s success with the terphenyl 
scaffold, they set out to develop a structurally similar compound, featuring more hydrophilic 
components with a synthetically easier route. The scaffold consists of a series of oxazole-
pyridazine-piperazine rings, that present both a hydrophobic surface for recognition onto the 
protein surface and a “wet edge” which is rich in hydrogen bonding motives. The 
hydrophilic backbone ensures that during complexation with its target, the “wet edge” 
remains directed towards the solvent, and it was anticipated to exhibit increased water 
solubility through protonation of the basic piperazine ring at physiological pH. The binding 
affinity of the scaffold and similar derivatives for Bcl-xL was determined by a fluorescence 
anisotropy assay. Results suggest that the presence of the cationic ammonium group may 
cause unfavourable interactions on binding to the receptor. A wide range of compounds 
based on the pyridazine scaffold were analysed, however, they do not approach the affinity 
demonstrated by the terphenyl compounds.
105
 
 
With a similar objective, the 5-6-5-imidazole–phenyl–thiazole scaffold (Fig 1.20b) 
was designed by Hamilton and co-workers in which the terminal positions of the original 
terphenyl are replaced with more hydrophilic five-membered heterocycles.
106
 The interaction 
between Dbs and Cdc42 regulates the resistance of cancer cells to cytotoxic therapies. 
Derivative 7 was designed to mimic the key binding region on Dbs, and a fluorescence assay 
demonstrated it to disrupt the interaction with IC50 of 67.0 μM.  
Figure 1.20 Amphiphilic helix mimetics: (a) the pyridazine scaffold and (b) a 5-6-5-
imidazole–phenyl–thiazole scaffold 7 based on key binding region on Dbs. 
1.5.4 Backbones with Chirality 
 
König and co-workers reported on the synthesis of an inherently chiral 1,4-
dipiperazino benzene scaffold (Fig. 1.21a).
107
 This scaffold is another development on the 
terphenyl scaffold in which the relative orientation of the key side chain functionalities 
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remain the same as those in terphenyl-type helix mimetics, substituting the two outer phenyl 
rings for piperazine rings (also improving their water solubility). X-ray crystallography 
revealed 1,4-dipiperazino to display side chains in a similar geometrical arrangement (i, i+3 
and i+7 residues) to an idealised α-helical structure. The subject of chirality was also 
addressed by the Arora group. They developed a chiral oligooxopiperizine scaffold (Fig 
1.21b) after postulating that scaffolds containing chiral backbones may be more effective in 
discriminating between chiral protein pockets. Molecular modelling of the scaffold revealed 
it to have an inherent helical structure, confirmed by CD studies, and predicted the side 
chains to mimic residues at the i, i+4 and i+7 positions.
108
 The chiral nature of these 
compounds will allow investigation into stereochemical aspects of protein - α-helix mimetic 
recognition. However, no reports on inhibition of PPIs have been described for any of these 
scaffolds.  
 
Figure 1.21 Inherently chiral scaffolds: (a) the 1,4-dipiperazino benzene scaffold,                                         
(b) the oligooxopiperizine scaffold.
 
1.5.5 Multi-facial Inhibitors 
The design of many mimetics described thus far, have focused on displaying key 
functionality on a single face. However, approximately 40% of all multiprotein complexes 
that occur through a helix, have key residues displayed on two or more faces.
15
 Such 
interactions are found in the ER/coregulator complexes. Careful analysis of a coactivator 
protein by Katzenellenbogen et al revealed that the three leucine residues in the LXXLL 
motif are on the edge of an equilateral triangle, and so one design criteria for ER inhibitors, 
was to have a central core with appropriate substituents attached.
109
 Several scaffolds 
(triazene, pyrimidine, trithiane and cyclohexane) targetting this interaction were synthesised 
based on molecular modelling and docking studies. A series of fluorescence anisotropy 
competition assays found compounds from the pyrimidine (Fig. 1.22a) series to be the most 
successful: pyrimidine 8a showed the highest affinity with a Ki of 29 μM. 
109
 Similar design 
criterion can be applied to AR/coregulator complexes. AR coactivators also bind through the 
consensus LXXLL sequence in addition to sequences containing multiple phenylalanine or 
tryptophan residues (WXXLF, FXXLF etc.).
110
 Further studies from the Katzenellenbogen 
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group reflect the size differences in ER and AR binding pockets. Selective pyrimidine-core 
inhibitors were achieved by varying the size / length of hydrophobic side chains: 
ER/coactivator inhibition IC50 = 7.9 μM 8b; no binding 8c, AR/coactivator inhibition IC50 = 
no binding 8b; 1.5 μM 8c.111 
Figure 1.22 (a) The pyrimidine scaffold: pyrimidine derivative inhibitors of steroid 
hormone/coactivator interactions (8a-c). (b) The pyridylpyridone scaffold: pyridylpyridone 
derivative inhibitor of the ER/coactivator interaction 9.
 
Designing an inhibitor of the LXXLL motif requires a molecule which mimics the 
distances and angular projections of the i, i+3 and i+4 residues on the helix (i.e. consecutive 
residues). Both the Willems
93 
and Hamilton groups
112
 have demonstrated that placing a 
second ortho substituent on a bis-heteroarly scaffold can achieve this. With this is mind, the 
Hamilton group designed an α-helix mimetic for inhibition of the ER/coregulator complex - 
the pyridylpyridone scaffold (Fig. 1.22b).
113
 The indane-based scaffold was chosen as it has 
improved water solubility and bioavailability as well as a synthesis which allowed for easy 
introduction of substituents into the 2-pyridyl and 1,5-pyridone positions. An X-ray crystal 
structure of a pyridylpyridone derivative showed that it adopts a conformation that should 
effectively mimic the required residues (i, i+3 and i+4) of the GRIP1 coactivator peptide 
whilst in the solid state. Further investigation via fluorescence anisotropy found that these 
molecules inhibit the interaction with low micromolar inhibition constants. Pyridylpyridone 
9 exhibited the best binding (Ki = 4.2 μM) which is comparable to that of the control SRC-1 
NRII peptide.
113
 
1.5.6 Oligobenzamide Based Inhibitors 
Library generation of designed helix mimetics would allow for thorough 
investigation into the binding region on any given PPI. Oligobenzamides are attracting due 
attention as proteomimetic scaffolds due to a synthetic accessibility via amide bond 
formation, an ability to incorporate a variety of functionalities mimicking natural and 
unnatural moieties and a predictable conformation. After initial molecular modelling studies 
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on a 3-O-alkylated oligoamide scaffold (Fig. 1.23) to mimic residues on an idealised helix (i, 
i+4 and i+7 positions),
114, 115
 the Wilson group demonstrated derivatives of the scaffold act 
as inhibitors of the p53/hDM2 interaction: 10 (IC50 = 1.0 μM) was comparable in potency to 
the native peptide (IC50 = 1.2 μM).
116
 Boger and co-workers constructed a large library 
(>8000) of helix mimetics containing tris-, bis- and monobenzamide scaffolds: the ‘missing’ 
benzoic acid building blocks being replaced with natural amino acids. Variations of the 
mimetics contained aniline, nitro or boc groups at the N-terminus and acid or methyl ester 
groups at the C-terminus. Compounds in this study failed to exhibit notable affinity for the 
p53/hDM2,
117
  however, later studies with monobenzamide derivatives (Fig. 1.23e) report 
the inhibition of gp41 assembly with micromolar affinity (Ki = 0.6-1.3 μM) and effective 
activity in a cell-cell assay (IC50 = 5-8 μM).
118
 The Wilson group later modified the original 
scaffold, producing a 2-O-alkylated oligoamide scaffold. Stronger intramolecular hydrogen 
bonding resulted in a backbone with reduced curvature; derivatives of this series, however, 
exhibited comparable affinity to the regiosomeric 3-O-alkylated analogues.
119
   
 
Figure 1.23 The 3-O-alkylated oligobenzamide scaffold: (a) chemical structure of the scaffold 
(b) low energy conformation of the scaffold containing suitable side chains to target the 
p53/hDM2 interaction, (c) p53 helix displaying the key binding residues, (d) overlay of 
scaffold with p53 demonstrating a good geometrical match, (e) derivative monomer scaffold 
targeting gp41 assembly. 
After a structure-based computational design to identify p53/hDM2 inhibitors, the 
Guy group reported on a similar scaffold in which side chains are attached directly onto the 
ring and lacking terminal aniline / acid moities (Fig. 1.24a). A library of 173 compounds 
was synthesised (including dimer intermediates) (Fig. 1.24b) using solution phase parallel 
chemistry and a series of fluorescence polarisation assays identified several low micromolar 
inhibitors: most potent inhibitor 11 achieving a Ki of 12 μM.
120
 A library of hybrid dimers of 
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this scaffold, with a pyridyl building block (Fig 1.24c) was constructucted by Craik and co-
workers to target the dimerisation interaction of Kaposi’s sarcoma-associated herpesvirus 
protease. A fluoregenic activity assay screening >180 compounds identified low micromolar 
inhibitors: 12 displaying the most potent inhibition with an IC50 of 3.1 µM. The Wilson 
group also applied an N-alkylated oligobenzamide scaffold (Fig. 1.24d) in the mimicry of α-
helices based on observations made from the Rebek group. Rebek et al demonstrated that the 
intrinsic preference for the cis geometry can be inverted in self-assembled capsules through 
non-covalent interactions in the trans conformation and so it was hypothesised that the                   
N-alkylated scaffold may adopt a similar extended conformation.
121
 The initial report by 
Wilson and co-workers represented the first solid-phase synthesis of α-helix mimetics and 
showed them to inhibit the p53/hDM2 interaction with low micromolar affinity (IC50 = 2.8 -
4.1 µM).
122
 Subsequent studies adapted the synthesis for a microwave assisted solid phase 
procedure, incorporating a range of natural and unnatural functionalities / side chains.
123
  
Figure 1.24 Oligobenzamide based scaffolds: (a-c) scaffolds alkylated directly onto the 
benzene ring, (d) N-alkylated oligobenzamide scaffold, (e) 3-O-alklated oligobenzamide 
derivative containing a wed edge.  
A novel bis-benzamide scaffold was designed by Ahn and co-workers to address the 
amphiphilic nature of many native α-helices. The scaffold places side chains mimicking the i 
and i+7 residues on one face, and side chains mimicking the i+2 and i+5 residues on a 
second face: producing either amphiphlic or a potential bifacial mimic.
124
 The Wilson group 
elaborated on this approach to improve the solubility of the 3-O-alkylated scaffold: 
synthesising 3,6-O-dialkylated building blocks displaying a hydrophobic side chain from the 
3- position and a hydrophilic glycol chain from the 6- position (Fig. 1.24e).
125
 13 showed 
comparable efficiency in a fluorescence anisotropy assay, targeting the p53/hDM2 
interaction, to the original non-functionalised analogue 10, with an IC50 = 7.54 µM but with 
greatly improved solubility. The solubilising group was therefore shown to have little impact 
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on binding affinity, indicating improvements in helix mimetic properties could be achieved 
with this type of orthogonal functionalisation.
125
 
1.6 Project Aims 
Several strategies have evolved over the last 10-15 years in the field of PPI mediation. 
Although some of the most potent inhibitors so far have been ‘small molecules’, these are 
specifically tailored for a given PPI and are therefore considered to lack versatility. Several 
general features of the α-helix, however, provide a template for inhibitor design from which 
generic approaches might be devised to target a wide range of PPIs. Constrained peptides, 
foldamers and proteomimetics are classed as designed inhibitors, and although a true generic 
approach is still sought, each strategy displays many unique features and offers valuable 
knowledge into the important features of the protein-protein interface.   
Previously in the Wilson group, the 3-O-alkylated oligobenzamide scaffold has been 
synthesised using a solution phase synthesis employing monomers with a variety of O-alkyl 
substituents, namely a variety of hydrophobic side chains to target the p53/hDM2 
interaction:
114
 fluorescence anisotropy assays have shown some of these to act as 
micromolar inhibitors.
116
 The work described herein will build on this work, reporting on the 
development of a methodology which will allow for an efficient solid-phase synthesis of 
libraries of compounds based on the aforementioned scaffold. A variety of natural and 
unnatural amino acid side chains will be incorporated through Fmoc protected monomer 
building blocks to screen in fluorescence competition assays against multiple PPI targets. 
Further work will discuss the development of potential ER/coactivator inhibitors via 
molecular modelling and docking studies, structural characterisation and biophysical 
experiments on a bisbenzamide scaffold containing modified 3-O-alkylated building blocks.   
1.7 Oligoamide Naming Protocol 
The following chapters contain several scaffolds based on an O-alkylated benzamide 
structure. In order to differentiate between them with ease, including intermediate building 
blocks, a generic naming protocol has been devised. The following list describes the naming 
patterns adopted throughout and scaffolds a-h can be found in Figure 1.25: 
 The 3-O-alkylated oligobenzamide scaffold a can be thought as having a ‘3HABA’ 
scaffold derived from 3-hydroxyaminobenzoic acid 
 The isomeric 2-O-alkylated oligobenzamide scaffold b can be thought of as having a 
‘2HABA’ scaffold derived from 2-hydroxyaminobenzoic acid 
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 The synthesis of the scaffolds can be illustrated as using ‘3HABA based’ building 
blocks or can be more specifically referred to as:  
o ‘3HNBA’ building blocks (c) for 3-hydroxynitrobenzoic acid  
o ‘3AHB’ building blocks (d) for methyl-3-aminohydroxybenzoate  
o Analogous naming is applied to 2HABA based building blocks 
 Dimer e can be thought as having a ‘DHABA’ scaffold derived from 3,6-
dihydroxyaminobenzoic acid 
  Dimer f is a hybrid containing both ‘3HABA’ and ‘DHABA’ based building blocks 
 The synthesis of the scaffolds can be illustrated as using ‘DHABA based’ building 
blocks or can be more specifically referred to as:  
o ‘DHNBA’ building blocks (g) for 3-dihydroxynitrobenzoic acid  
o ‘DAHB’ building blocks (f) for methyl-3-aminodihydroxybenzoate  
o Hybrid oligomers can be expressed such as  DHABA:3HABA (e)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.25 Structures of scaffolds and building blocks referred to in the naming protocol: (a) 
3HABA based scaffold, (b) 2HABA based scaffold, (c) 3HNBA building block (3HABA 
based), (d) 3AHB building block (3HABA based), (e) DHABA based scaffold, (f) hybrid 
DHABA:3HABA dimer scaffold, (g) DHNBA building block (DHABA based), (h) DAHB 
building block (DHABA based): n.b. some acronyms are not highlighted in this thesis but 
should be applied in future work 
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1.7.1 Numbering System 
To simplify the numbering and NMR assignment of our trimers, a sequential 
nomenclature numbering system has been devised, where each of the monomer building 
blocks is considered separately (Fig. 1.26). Assignment of the compounds is as follows; 
naming proceeds from N to C terminus where each 3HABA residue is assigned a number 
with respect to its position on the chain and each individual residue numbered using the 
standard system. Side chain assignment follows a peptide nomenclature pattern in which the 
carbon attached to the alkoxy oxygen is assigned as Cα, and numbering of further aliphatic 
parts continue with Cβ, etc. In the case of aromatic side chains, the aromatic carbons are 
numbered CAr1, CAr2, etc. The numbering of the protons is based on the carbon numbering 
system. The monomer number is added as a prefix to the individual carbon / proton number 
for differentiation.  Examples of oligomers are given below however monomer intermediates 
follow the same assignment. Protons in the Fmoc structure are differentiated by the prefix F; 
protons from the CH2 group are numbered FHα, the neighbouring CH will be FHβ, and the 
aromatic protons are FH2 to FH5. 
Figure 1.26 Oligomer numbering system: a) Shows proton numbering of oligomers, b) shows 
carbon numbering of oligomers, c) shows proton numbering of monomer building blocks. 
 Naming of compounds in the experimental, using a (Fig. 1.25) as an example, will 
be found as follows: NH2-[O-CH2-CO2H-(3-HABA)]-[O-Bn-(3-HABA)]-[O-iPr-
(3-HABA)]-Gly-CO2H 
o Each square bracket represents a single building block and provides 
information on the type of building block (3HABA) and its corresponding 
side chain 
o A nitro derivative will have a NO2- prefix 
o A ester derivative will have a -CO2Me suffix
  
 
 
 
 
 
 
 
2 Chapter 2 
Solid Phase Methodology for Synthesis of 
O-Alkylated Aromatic Oligoamide Inhibitors of 
α-helix Mediated Protein-Protein Interactions    
This chapter is adapted from the research article published in Chem. Eur. J.
126
 and 
contributed to work in a research article published in Org. Biomol. Chem.
119
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2: Solid Phase Methodology  
 
37 
 
2.1 Introduction  
  A major effort in modern bio-organic chemistry focuses on the design, synthesis and 
structural characterisation of foldamers:
68
 non-natural oligomers that adopt well-defined 
secondary, tertiary and quaternary structures.
127-130
 One ultimate objective of such studies is 
to recapitulate the functional behaviour of biomacromolecules.
131
 Particular emphasis has 
been placed on inhibitors
60, 82, 88, 89, 132, 133
 of -helix mediated15 protein-protein interactions134 
– an endeavour which in its own right represents a major challenge.135, 136 The development 
of synthetic methodology that allows access to small-to-medium sized libraries of foldamers 
incorporating diverse side chains represents the cornerstone upon which such studies are 
pursued. In this regard, it is noteworthy that the most robust methodology exists for 
peptoids,
137
 -peptides138 and more recently oligoureas;139 templates that have seen the most 
significant use in a biological context.
82, 140
 The Wilson group
114, 116, 119, 122, 123
 and others
117, 
124, 141-143
 have recently reported on the use of aromatic oligoamides
130
 as potential -helix 
mimetics.
144, 145
 Rather than topographical mimicry of the -helix (as is the case for ,75  
/82, 88, 89 and other foldamers132), these compounds mimic an -helix by presenting key 
side chains from a rod-like template in a spatial orientation that matches that of the -helix 
(Figure 2.1).
146
   
Figure 2.1 (a) Idealised α-helix (taken from PDB ID: 1YCR) with i, i + 4 and i + 7 side chains 
highlighted. (b) Chemical structure of 3HABA helix mimetic. (c) Minimised structure of a 
helix mimetic with R
1
 = R
2
 = R
3
 = iPr. (d) Idealised α-helix superimposed onto minimised 
aromatic oligoamide. 
The 3-O-alkylated oligoamide (3HABA) scaffold (Fig. 2.1b,c) was evaluated for 
helix mimicry by comparison with the p53 transactivation domain (PDB ID: 1YCR) in 
which three side chains – Phe19, Trp23 and Leu26 – are shown to play a key role at the 
p53/hDM2 interface.
119
 Of the structures within 1.5 kJ mol
-1
 of the lowest energy 
conformation, all were observed to position side chains on one face, indicating the desired 
conformation should be accessible. The RMSD was calculated on the agreement between the 
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carbon of the peptide and the alkoxy oxygen of the scaffold. The scaffold aligns well in 
parallel to the dipole moment of the peptide and in an anti-parallel orientation which further 
validates the hypothesis of a rod like -helix mimetic. RMSD values averaged at 0.4951 and 
0.4953 for the parallel (Fig. 2.1d) and anti-parallel orientations respectively. 
Although solution methods for assembly of very large
147 
 and long aromatic 
oligoamides
148
 have been described, a significant advance in this area would be the ready 
availability of solid phase methods tolerant to a diverse array of side chains; this would 
facilitate library generation and ease of purification. Other than the Wilson groups’ reports 
on N-alklyated aromatic oligoamides,
122, 123
 only a limited number of reports have been 
described on the synthesis of benzanilides
149, 150
 and related aromatic oligoamides
151, 152
 that 
meet the criteria outlined above. During development of the methodology, the Ahn group 
published an alternative strategy to synthesise 3-O-alkylated trisbenzamides.
150
 This 
followed an N→C chain elongation to address the reduced reactivity of the aniline and each 
cycle followed a sequence of four iterative reactions.  This method is not compatible with 
other methods for solid phase peptide synthesis (SPPS), therefore addition of amino acids or 
incorporation of oligobenzamides into peptides may be problematic. In addition to this, the 
linear nature of the synthesis (a total of 9 reactions once resin bound) affords relatively poor 
yielding trimers: averaging at approximately 30 % yield. For these reasons, continuing with 
development of the methodology was deemed synthetically vital; this chapter describes the 
development of such a method that can be used for synthesis of 3-O-alkylated aromatic 
oligobenzamides using standard Fmoc solid phase strategies and iterative coupling and 
deprotection steps. Using microwave irradiation, trimers can be assembled on a solid-
support in 2.5-4 hr in sufficient purity for screening purposes – a significant improvement on 
any previously published method. The methodology is tolerant to a large and diverse 
collection of monomers and amenable to synthesis of longer oligomers. The approach and 
observations in developing it should have wide applicability for the synthesis of aromatic 
oligoamide foldamers in general.  
2.2 Results and Discussion 
In developing the approach it was desirable to avoid use of novel protecting group 
chemistries and so fundamental features were sought that are compatible with standard 
Fmoc solid phase strategies such as the use of Fmoc as a semi-permanent protecting group 
and permanent acid labile protecting groups on the side chains. On this basis, a four step 
synthesis of a broad array of monomers 14a-r was developed (Scheme 2.1) exploiting either 
alkylation of the intermediate phenol at the diversification point using alkyl halides or 
alcohols under Mitsunobu conditions. As is shown, a full array of peptide based side chains 
Chapter 2: Solid Phase Methodology  
 
39 
 
covering the entirety of functionality found in native peptide side chains is accessible (with 
the exception of Cys, Arg and His) whilst several non-natural side chains and chiral side 
chains can also be incorporated. An Fmoc protected monomer mimicking Gly was also 
synthesised; the standard monomer design positions the phenolic oxygen as the atom 
mimicking the -position of the amino acid within the helix and therefore this represents a 
poor mimic of Gly and would require protection during synthesis. Commercially available 3-
methyl-4-aminobenzoic acid 19 was thus protected with Fmoc to furnish the Gly mimic 14s. 
Scheme 2.1 Synthesis of Fmoc protected monomers for SPPS. 
There are several noteworthy points as follows: (i) for benzylic side chains it was 
necessary to use tin (II) chloride for nitro group reduction as opposed to palladium on 
charcoal, so as to avoid cleavage of the side chain,
114
 (ii) for the hydrolysis step, care may be 
required to avoid cleavage of the side chain, requiring use of lithium hydroxide and mild 
conditions (e.g. room temperature). Cleavage of the side chain by elimination of the phenol 
can occur under forcing conditions – a feature which prevented us from obtaining a 
monomer mimicking histidine. Additionally, for side chains possessing an electron 
withdrawing group  to the phenol, elimination is promoted during monomer synthesis, 
hydrolysis and coupling (see below) (Fig. 2.2a). Finally, for the tert-butyl ester side chain, 
deprotection of the tert-butyl group using sodium hydroxide was observed presumably via a 
ketene intermediate (Fig. 2.2b).  
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Figure 2.2 Examples of (a) Elimination in a side chain containing an electron withdrawing 
group  to the phenol (b) deprotection of tert-butyl group. 
 
 
Scheme 2.2 Solid phase synthesis protocol. 
A general outline of the solid phase synthesis method is illustrated in Scheme 2.2. In 
terms of developing this methodology, the amide bond forming reaction is challenging as the 
substrate is a deactivated aniline. Acid labile Wang resin was selected for these studies and 
resin loading was achieved using thionyl chloride or Ghosez’s reagent, however, standard 
coupling reagents such as HCTU and EDCI do suffice, either directly to the resin or to Gly 
loaded resin. A series of screening experiments for anilide formation was then attempted 
using the isopropyl monomer 14a, chloroform as solvent and microwave assistance (using a 
CEM™ peptide synthesiser) to identify suitable coupling reagents. Of these, only those 
forming acid chlorides proved successful (i.e. thinoyl chloride, 
dichlorotriphenylphosphorane and Ghosez’s reagent). This was not entirely surprising given 
that prior studies,
114, 116, 122
 in the absence of microwave, indicated that strongly activated 
acids (e.g. acid chlorides) would be necessary to mediate formation of the amide bond. Due 
to the acidic nature of these reagents and the acid sensitive nature of the resin and possible 
protecting groups, several strategies to make activated monomers such as activation with a 
pentafluorophenol or an N-hydroxysuccinimide group on the carboxylic acid were also 
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investigated, however, both failed to induce coupling. Another method inspired by work 
from the Danishefsky group involved converting the acid to a thioester
153
 (Scheme. 2.3). 
Addition of an isocyanate should form a very strong bimolecular acylating agent 
(formimidate carboxylate mixed anhydride (FCMA) intermediate) facilitating anilide 
formation. Treatment of monomers 14a + 14e with Lawesson’s reagent resulted in highly 
unstable thioacids and were poor yielding for subsequent amide hydrolysis. 
Scheme 2.3 Scheme showing reaction of a thioacid with an isocyanate. 
 Using the successful acylating agents, optimisation of the method then proceeded 
by attempting oligomer synthesis and broadening the monomer set. Unfortunately, the 
majority of monomers in the set were found to be poorly soluble in chloroform and so 
testing was carried out in DMF. Using in situ formation of the acid chloride from Ghosez’s 
reagent and microwave irradiation no anilide formation was observed. Similarly, pre-
activation or isolation of the acid chloride followed by microwave assistance was unable to 
effect the anilide formation. An explanation for these results was obtained from LC-MS 
analysis of the reaction mixture which revealed capping of the immobilised aniline by both 
DMF and Ghosez’s reagent to give a stable amidine. This capping reaction which is 
observed even where the acid chloride is used directly, indicates that the solvent reversibly 
reacts with the acid chloride to generate the Vilsmeier intermediate which can then cap the 
aniline. This behaviour is not observed for synthesis of N-alkylated aromatic oligoamides
123
 
– one explanation is that capping of an N-alklyated aniline results in an unstable 
intermediate which cannot lose a proton to form the amidine (Fig. 2.3).  With these results in 
hand, a solvent screen was performed to identify polar aprotic solvents which would not lead 
to such side-reactions. 
Figure 2.3 Mechanism for capping of anilines during SPS via Vilsmeier intermediates. 
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Table 2.1 Table of synthesised oligomers. R
1
, R
2
 and
 
R
3 
(lower-case letters) are compound 14 
analogues and R
4
 (upper-case letters) are amino acids: Trimer 20 is made up from                                
14a–14a–14a–Gly. ' synthesised using in situ activation of monomer with thionyl chloride                
'' synthesised using in situ activation of monomer with Ghosez’s reagent.  
 
Figure 2.4 Chemical structure of side chains incorporated into trimers using the SPS 
procedure. 
The solvent screen identified NMP as a suitable solvent with which to perform 
solid-phase coupling to give the aromatic benzamides. After further screening and 
optimisation, it was established that direct use of the acid chlorides obtained from thionyl 
chloride or pre-activation using Ghosez’s reagent prior to coupling in the microwave 
Trimer R
1 
R
2 
R
3 
R
4 Final 
Purity (%) 
Yield (%) 
Precipitate HPLC 
20 a a a G 95 73 - 
21 e e e G 95 92 - 
22 e h a G 90 71 - 
23 a h e G 90 82 - 
24 e g a G 95 78 - 
25 g j a G 99 99 - 
26 e i a G 99 86 - 
27' a d a G 99 73 35 
28' a n a G 99 - 19 
29 a s a G 99 64 32 
30' a f a G 99 79 21 
31  a k a G - - - 
32 a l a G - - - 
33'  a m a G 99 69 22 
34'' a o a G 99 - 22 
35 a p a G 90 69 32 
36' a q a G 99 - 28 
37' a r a G 99 - 17 
38 a a a - - - - 
Oligomer Sequence 
Final 
Purity (%) 
Yield 
Precipitate HPLC 
39 a b d (I) 99 - 35 
40 G a a a (G) - - - 
41 a c b b (G) 95 91 - 
42 a c c a(G) 95 93 - 
43 a a a a a a (G) 95 87 - 
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synthesiser could affect coupling in high yield. It is important to note that the highest 
coupling conversion obtained using dichlorotriphenylphosphorane was 20% and a 
significant impurity of mass 557 was obtained in both DMF and NMP and so work using 
this reagent was discontinued. The use of acid chlorides was preferable for the majority of 
alkyl/ aryl Fmoc protected monomers 14 as these could be precipitated and stored for at least 
one month with no decomposition. For the more highly functionalised monomers which 
tended not to precipitate upon reaction with thionyl chloride, it was preferable to use the in 
situ method (these highly functionalised monomers also tended to be less stable as acid 
chlorides). For direct addition of acid chlorides, a single cycle of coupling at 50°C for 30 
minutes in the absence of base was sufficient to achieve high conversion, however, for 
longer oligomers, double couplings were used. For Fmoc removal, no special optimisations 
were required and 20% piperidine in NMP was sufficient. Care was required with the global 
deprotection reaction which was performed off-line from the synthesiser; certain side chains 
(see below) were found to be susceptible to cleavage via elimination with the indole side 
chain a notable example, thus this stage of the procedure requires careful monitoring.  
With these observations and optimisations established, the versatility of the method 
was demonstrated by synthesising a sufficient number of trimers 20-37 (Table 1) so as to 
demonstrate that each monomer in the set could couple and be coupled to. In addition, it was 
also illustrated that it is possible to couple directly to the resin 38 and amino acids other than 
Gly could be appended to the C-terminus 39 (through use of different amino acid loaded 
Wang resins) and to the N-terminus 40. The only problematic monomer was 14k with the 
resulting oligomer undergoing cleavage of the benzylic phenol under the standard 
deprotection conditions required to cleave the phenolic tert-butyl protecting group. In 
addition, whilst reasonable coupling was observed with monomer 14l, isolation and 
characterisation of the resulting trimer was not possible.  Finally, the versatility and power 
of the method was also illustrated though synthesis of longer oligomers 41-43 (up to a 
hexamer). This foldamer was obtained in 10 hr using double couplings and the NMR 
spectrum is shown in Figure 2.5 for the product obtained direct from the resin. This 
spectrum is typical of the spectral data that is obtained direct from resin cleavage and 
indicates that the oligomers are obtained in sufficient purity for preliminary screening. In a 
number of cases, this was not the case, however, cleaner material can be obtained by 
preparative HPLC. 
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Figure 2.5 
1
H NMR spectrum (500 MHz, DMSO-d6, 60 
o
C) of hexamer 43. 
2.2.1 Conformational Studies 
2.2.1.1 Molecular Modelling 
As previously discussed in Chapter 1, some PPIs involve much longer helices: for 
example the gp41 hexameric coiled coil interaction. To illustrate the potential for longer 
oligomers to act as mimics of extended helices, molecular modelling was performed on the 
hexamer 43 as is illustrated in Figure 2.6. To do this a conformational search was carried 
out on hexamer 43 and the structure was minimised by employing a full Monte Carlo search 
in the software Macromodel® using the MMFFs (Merk Molecular Force Fields) method. 
Water was chosen as implicit solvent and free rotation around the amide bonds was allowed 
in order to increase the accuracy of the conformational search. The results revealed the 
lowest energy conformation was the extended structure with all six side chains lying on the 
same face; a conformation displaying an alternative arrangement of side chains, however, 
has a relative potential energy of +3.2 kJ mol
-1
 demonstrating a variety of rotamers are 
accessible. Using a crystal structure of gp41
14
 (PDB ID: 1AIK), a series of superpositions 
was taken from the hexamer using different combinations of side chains (eg side chains R
1
, 
R
2
 + R
3
 or R
5
, R
4
 + R
3
) and the extended helix using different combinations of residues (e.g. 
i, i + 3 and i + 7 or i, i + 4 and i + 8) and at varying positions on the helix (e.g. towards the N 
or C terminus). From the relatively small set sampled in comparison to the available 
combinations, RMSD values ranging from 0.421-0.788 Å was achieved when superimposing 
3 atom pairs consisting of the oxygen of the alkoxy group and the carbon of the amino 
acids.  
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The superposition of the lowest energy conformation of the hexamer using the 
alkoxy oxygen from rings 2, 3, and 4 with residues at i, i + 3 and i + 7 positions respectively 
(residues Thr569, Leu566 and Gln562) is shown in Figure 2.6a. This demonstrates side 
chains from rings 1, 2, 3, 4 and 5 are orientated in a very similar fashion to residues at the i - 
4, i,  i + 3, i + 7 and i + 10 positions. Molecular modelling studies infer having different 
arrangements of side chains is thermodynamically viable. With this in mind, the Ar-CO 
bond on ring 5 has been rotated and the overlays in Figure 2.6b-d show side chain 6 is 
found to occupy the same space as residues in the i + 14, i + 15, and i + 16 positions. This 
demonstrates that such oligomers could find use in the inhibition of more extended -helix 
mediated PPIs.  
 
Figure 2.6 Figure showing superposition of hexamer 43 with gp41extended helix (PDB ID: 
1AIK). (a) Low energy conformation of hexamer. (b-d) Demonstrating how rotation of side 
chain from ring 6 allows mimicry of residues at the i + 14, i + 15, and i + 16 positions. 
2.2.1.2 X-Ray Crystal Studies 
Finally several crystal structures of a representative trimer 44 (described 
previously)
114, 116
 were obtained (Dr. P. Prabhakaran synthesised and obtained the crystals of 
44, Prof. M. Hardie and C. Kilner acquired and solved the crystal structures) comprising 
isopropyl monomers and with a C-terminal methyl ester and N-terminal nitro group (Fig 
2.7a-c). These correlate with previously published analysis of the conformational preference 
of these oligomers
114, 154, 155
 i.e. that they adopt a rod-like conformation with free rotation 
around the Ar-CO axes and rotation around the Ar-NH axes restricted through S(5) 
intramolecular hydrogen-bonding. These crystal structures are extremely significant for the 
project as they demonstrate that side chains can adopt both syn and anti orientations with 
respect to one another, whilst variations along the backbone permit the side chains to project 
in subtly different orientations. As most key binding residues occur on the same face of the 
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helix, this ability for the oligomers to rotate and project functionality in the correct 
orientation is a vital feature of these compounds to maximise interactions for inhibition.  
 
Figure 2.7 Solid-state structures of trimer 44 (left) Structure I (middle) Structure II and              
(right) structure III. 
2.3 Conclusion 
A robust method for synthesis of aromatic oligoamides containing a diverse array of 
natural and non-natural amino acids side chains using a microwave assisted automated 
peptide synthesiser has been developed. A four step monomer synthesis allows generation of 
Fmoc protected building blocks for SPS with trimers accessible in 2.5-4 hr in sufficient 
purity for screening after precipitation (alkyl or aromatic side chains) or after HPLC (side 
chains with acid labile protecting groups). These foldamers represent excellent templates to 
act as mimetics of the -helix and hence as inhibitors of protein-protein interactions. The 
method represents a powerful tool with which to obtain PPI inhibitors by sequence based 
design and for library generation to screen against unknown targets.   
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3.1 Addressing the Hypothesis 
As demonstrated in Chapter 1, the modulation of PPIs represents a current and 
challenging area for drug discovery: the use of designed molecules (Type I and Type III 
mimetics) to target helix mediated PPIs was discussed. Small molecule modulators 
identified via traditional drug discovery routes (HTS and fragment based approach) were 
omitted since many PPIs share similar topographical features,
15
 and a generic approach to 
target such complexes is an ultimate goal. The conclusion of this would be a common 
scaffold that contains intrinsic diversification points such that minor changes result in 
selective inhibitors for a number of PPI targets.  
Discussed in Chapter 2 was the 3-O-alkylated oligobenzamide scaffold (3HABA) 
developed in the Wilson group. The supposition behind the scaffold was that if a rigid rod is 
formed and suitable functionality is presented with a comparable spatial orientation to side 
chains of an α-helix114, selective inhibitors of helix mediated PPIs could be generated.116 
Adapting the original solution phase synthesis, Chapter 2 reports the rapid generation of a 
small library of oligobenzamides using a modular solid phase synthesis developed on a 
microwave assisted peptide synthesiser. The library focused on identifying the scope of the 
methodology in terms of functionality and chain length, whilst also designing potential 
inhibitors of the p53/hDM2 interaction. 
 Scheme 3.1 SPS protocol for synthesis of 3-O-alkylated oligobenzamides. ‘X’ can be ‘O’ or 
‘any amino acid’. 
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Using the SPS method described in Chapter 2, a small library of 16 oligomers (Fig. 
3.1) was successfully synthesised: designed with potentially good and bad inhibitors of the 
p53/hDM2 interaction to further test the validity of the approach. This built on previous 
work targeting this interaction and initiated new studies to assess the potential of the 
3HABA scaffold to disrupt the Mcl-1/NOXA B interaction. Accordingly, the majority 
contained aromatic and aliphatic functionality; however, other functionality was included in 
several trimers. The iterative procedure is outlined in Scheme 3.1 and trimers were obtained 
with >90% purity after precipitation (by UV chromatography and NMR spectra). After 
HPLC purification of trimers obtained using the in situ method (Method C) in Chapter 2, 
insufficient material was recovered to characterise the oligomers and also carry out 
screening studies, therefore no binding data was obtained for this larger set of oligomers 
containing a wider range of functionality. The following work will discuss how fluorescence 
anisotropy data is collected and processed in order to determine inhibition constants, and 
will examine the initial screening results from each interaction and the development of the 
library in response to these results. 
Figure 3.1 3HABA based oligomer library for screening against the p53/hDM2 and                       
Mcl-1/NOXA B interaction. Set 1 (20-25, 27) and 2 (41, 42) from Chapter 2 and Set 1 (45-47) 
and 3 (48-51) are newly synthesised.  
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3.1.1 SAR of oligomers targeting p53/hDM2 
p53 binds with its negative regulator via key hydrophobic residues on the p53 
activation domain, into a hydrophobic cleft on the hDM2 LBD. More specifically the Phe19, 
Trp23 and Leu26 residues at the i, i+4 and i+7 positions (Fig. 3.2a) .
11 
In a previous study 
from the group,
116
 trimer 10 (Fig 3.2b) containing similar substituents to the key residues on 
the p53 helix, was identified as the most potent 3HABA proteomimetic in a fluorescence 
anisotropy competition assay targeting p53/hDM2. Using the same side chains, an 
equivalent trimer 22 (with a C-terminal Gly) was synthesised to use as a reference to carry 
out an SAR study for targeting the p53/hDM2 interaction.  In this context, oligomers were 
screened to determine the following:  
22, 23 Obtain a direct comparison with previously tested oligomers to study the 
effect of Gly and to determine if position of the aniline / acid effects the 
binding mode 
24, 25, 45, 46 To determine how halogenated aromatic groups effect binding 
20, 27, 47 To determine how substituting aromatic groups for alkyl groups effects 
binding  
41, 42  To determine if larger oligomers are tolerated by the protein 
28, 48, 49 To determine how hydrophilic functionality effects binding 
50, 51 To determine if addition of functionalised amino acids affects solubility / 
binding 
 
Figure 3.2 (a) p53/hDM2– regulates cellular stress (PDB ID: 1YCR): p53 binds with Phe19, 
Trp23 and Leu26 hydrophobic residues. (b) Most potent 3HABA inhibitor 10 identified from 
previous studies containing hydrophobic residues: R
1 
= Bn, R
2
 = 2Nap and R
3
 = iPr. (c) New 
C-terminal Gly analogue 22 as reference for SAR study. 
3.1.2 SAR of oligomers targeting Mcl-1/NOXA B 
Mcl-1 is one of the many anti-apoptotic members of the Bcl-2 family and binds to 
NOXA B (BH3-only pro-apoptotic member). The involvement of this interaction in 
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oncogenesis is still under investigation; however, it has been identified as an important 
therapeutic target in studies involving ABT-737 (Fig. 1.6b).
156
 The helical binding motif is 
shown in Figure 3.3a and involves key interactions from the Glu74, Leu78, Ile81 and Val85 
residues. Oligomer 48 (Fig. 3.3b) was synthesised as an intended inhibitor of Mcl-1/NOXA 
B, containing similar substituents to the key residues on NOXA B: R
1
 = Asp, R
2
 = iBu, R
3
 = 
iLeu and R
4
 = Val. An additional 5 proteomimetics were selected for a preliminary SAR 
study, targeting Mcl-1/NOXA B, on the following rationale: 
48, 49    Oligomers containing similar functionality NOXA B: potential good mimics 
47 Has similar functionality to the BID peptide which also binds to Mcl-1: 
potential good mimic 
24 Contains large aromatic groups which may be too large for the binding cleft: 
potential poor mimic 
27, 41  Oligomers lacking a Glu mimic but containing other similar functionality to 
NOXA B: potential good mimics 
 Figure 3.3 (a) Binding of NOXA B to its partner protein Mcl-1. Key binding residues on 
NOXA B positioned at the i, i+4, i+7 and i+11 residues: Glu74, Leu78, Ile81 and Val85 
respectively (PDB ID: 2JM6). (b) Designed potential inhibitor of Mcl-1/NOXA B interaction 
containing appropriately functionalised side chains: 48 R
1
 = Asp, R
2
 = iBu, R
3
 = iLeu and R
4
 = 
Val.  
3.2 Fluorescence Anisotropy Assays 
3.2.1 Fluorescence Anisotropy 
Anisotropy can be defined as a property that has directional dependence, and in this 
context, the directional dependence of the fluorescence property of a fluorophore will be 
exploited. When a fluorophore is irradiated, a photon of a specific energy is absorbed and 
the fluorophore gets excited to a higher energy state. After the fluorescence lifetime, a lower 
energy photon is released (with heat), returning the fluorophore back to its original energy 
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state. This excitation and relaxation involves redistribution of electrons and requires 
excitation by a photon having a specific polarisation with respect to the axis of the molecule. 
In a mixure of randomly oriented molecules, only molecules oriented within a particular 
range of angles to the applied polarisation are excited. These molecules will, accordingly, 
emit with a specific polarisation relating to the orientation of the molecule. The size of a 
fluorophore determines the rate at which the molecule rotates: smaller entities rotate faster 
than larger entities. Therefore, if the fluorophore can freely rotate, changing the orientation 
of the molecule before relaxation and hence emission of a photon, the degree of polarisation 
of the emitted light will be reduced and the anisotropy will be low.  Conversely, if the 
fluorophore is large and does not rotate before emission, the degree of polarisation of the 
emitted light will be much higher and, hence, the anisotropy will be high.  
Figure 3.4 Schematic showing the mechanics of the plate reader to collect fluorescence 
readings. 
3.2.2 Collecting and Processing Fluorescence Data 
To collect fluorescence data for any given interaction, data was collected using an 
EnVision plate reader. Figure 3.4 gives a schematic of this process: Broadband light is 
passed through a polarised excitation filter, resulting in plane polarised light with an 
appropriate wavelength band to the fluorophore. As the excitation light hits the dichroic 
mirror, it is reflected onto the sample and absorbed by correctly orientated fluorophores. The 
same mirror forms part of the emission channel by allowing lower energy emission 
wavelengths to pass through whilst blocking the excitation light, reducing saturation at the 
detector. The emission light then hits the dual emission beam splitter, directing half through 
a parallel (S-) polarising emission filter and directing half through a perpendicular (P-) 
polarising emission filter (S- and P- with respect to the polarised excitation filter). The few 
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photons which pass through the instrument are passed through a photomultiplier (PM) tube 
which amplifies the light signal into a voltage, which is read by the computer. Readings 
from S- and P- channels can be taken simultaneously, minimising artifacts such as 
photobleaching and sample movement, therefore G (instrument and assay dependent factor) 
is normalised to 1. The data is then used to calculate the average anisotropy or fraction of 
ligand bound, plotted against [protein] or [proteomimetic] and fitted to a logistic model to 
extract Kd, IC50 or EC50 values (See Appendix I). 
3.2.3 Idealistic Binding Measurements  
The fundamentals of the assay rely on the change in rotation time of the fluorophore 
to provide binding constants such as Kd, Ki (or IC50s to be explained later). Figure 3.5a gives 
a graphical representation of the assay and is explained further in sections 3.2.3.1 and 
3.2.3.2. 
Figure 3.5 (a) A graphical representation of the fluorescence anisotropy assay. Left 
equilibrium (protein titration) allows for calculation of the Kd and right equilibrium 
(competition assay) allows for calculation of the Ki  (or IC50). (b) Example of a sigmoidal 
curve obtained after a protein titration. (c) Example of a sigmoidal curve obtained after a 
competition assay. 
3.2.3.1 Protein Titration: Dissociation Constant 
 On the left of the first equilibrium (Fig. 3.5a), there is a peptide tracer (the 
fluorophore) and the much larger protein.  When the tracer is in an unbound state, the 
molecule has a fast rotation due to its small size: this will therefore exhibit low anisotropy. 
However, when the tracer binds to the protein (right of the first equilibrium), a larger 
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complex is formed displaying much slower rotation: this will therefore exhibit high 
anisotropy. This first equilibrium provides the rate of dissociation (Kd) of the complex and is 
determined by carrying out a serial dilution of the protein, whilst keeping the concentration 
of the tracer constant. If tested over the correct range, a sigmoidal curve should be observed 
(Fig. 3.5b) displaying low anisotropy at low protein concentrations and high anisotropy at 
high protein concentrations. 
3.2.3.2 The Competition Assay: Inhibition Constant 
On the left of the second equilibrium (Fig. 3.5a), there is a large fluorophore complex 
exhibiting high anisotropy. On addition of a ligand, the tracer may be displaced becoming 
free to rotate: resulting in a decrease in anisotropy. This second equilibrium provides the Ki 
(IC50) of a potential inhibitor ligand, and is determined by carrying out a serial dilution of the 
ligand, whilst keeping the concentration of protein and tracer constant. If tested over the 
correct range, a sigmoidal curve should be observed (Fig. 3.5c) displaying low anisotropy at 
higher ligand concentrations and high anisotropy at lower ligand concentrations.  
Figure 3.6 The multiple equilibria involved in the p53/hDM2 competition assay preventing Ki 
determination: Aggregation of the tracer contributes to the anisotropy during protein titration 
(r1) and interaction of the tracer with the proteomimetic contributes to the anisotropy during 
the competition assay (r2). 
3.2.3.3 Assay Equilibria 
Previous studies from the group revealed a complex set of equilibria that prevent the 
calculation of the inhibition constant, Ki.
116
 They proposed that instead of a simple two step 
competition (Fig. 3.5a), it is more likely that the fluorophore self aggregates and also 
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interacts with competitor ligands. The anticipated equilibria can be explained through 
analysis of assay data and are shown in Figure 3.6  
The minimum anisotropy, rmin, should correspond to a solution where the tracer is 
completely free to tumble, hence it should be equivalent to the theoretical value, r0. Rmin was 
determined during the protein titration and was actually found to be greater than r0: caused 
by aggregation of the tracer, r1. On displacement of the tracer molecule by the competitor, 
the tracer can interact with the competitor as [competitor] > [tracer]. The tracer:competitor 
complex  (r2) may be much smaller than the tracer:tracer complex and would therefore have 
a smaller contribution to the anisotropy r2 < r1. This can be seen from the does-response 
curves which have lower anisotropy values than the observed rmin at the beginning of the 
protein titration: hence why calculation of the IC50 (or EC50) is necessary.  
3.3 Biophysical Data for p53/hDM2 Assays 
The use of fluorescence anisotropy to determine binding constants has been well 
established within the Wilson group with respect to the p53/hDM2 interaction (Fig.3.3a)
116, 
119, 122, 125
 and as such, this was the first interaction the library was tested against. Although 
extensively employed, it was important to repeat certain standard experiments to ensure the 
assay was reproducible in my hands. Following previous studies, a fluorescein tag was used 
as the fluorophore on the p53 activation domain (Flu-p5315-31 purchased: Peptide Science 
Research Ltd.) tracer molecule and a His-tag construct of hDM2 was used for the protein 
(His-hDM217-126 L33E molecular cloning and expression: Dr. K. Long).  
Figure 3.7 Protein titration curve of the p53/hDM2 interaction (Kd = 129.67 nM). 
3.3.1 hDM2 Protein Titration 
The Kd of the interaction was determined having a [hDM2] of 10 µM - 0.15 nM and 
a constant [p53*] of 54.5 nM. The plate was allowed to incubate for 1 hour and results from 
this experiment can be found in Figure 3.7: a Kd value of 129.67 ± 2.9 nM (see Appendix II) 
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was obtained which is comparable to data previously obtained in the group (Kd = 75.38 ± 
4.2
116
 and 164.4 ± 10.8 nM).  
3.3.2 Competition Assays  
3.3.2.1 p53 Displacement Assay 
The first control experiment required was the competition assay involving 
displacement of labelled p53 (p53*) by unlabelled p53. In addition to understanding if the 
assay was reproducible in my hands, three parallel assays were made with varying DMSO 
concentrations (0%, 5% and 10% in the first well) to determine whether DMSO had a 
significant effect on the results. High DMSO concentrations were likely to be necessary due 
to solubility of the 3HABA oligomers in the aqueous buffer. The [p53] ranged from 50 µM 
– 34 nM and the [p53*] was constant at 54.5 nM across the plate. The plates were allowed to 
incubate for 1 hour each and results from this set of experiments are shown in Figure 3.5: 
consistent IC50 values were obtained across the three DMSO concentrations and were 
comparable with values obtained previously in the group (1.49-2.15 μM vs 1.2 μM116). 
Figure 3.8 p53 displacement curves at 0%, 5% and 10% DMSO concentrations: IC50  = 2.04 ± 
0.15 μM, 2.15 ± 0.16 μM and 1.49 ± 0.07 μM respectively. 
3.3.2.2 Nutlin Competition Assay 
Nutlin-3a (Fig. 1.6a) is known to bind to hDM2 and is one of the most potent 
inhibitors of the p53/hDM2 interaction identified to date.
26
  A second positive control test 
using this inhibitor in the competition assay was accordingly carried out to ensure 
comparable results. The [Nutlin-3a] in the first well was at 10 µM in 10% DMSO and the 
[p53*] was constant at 54.5 nM across the plate.  The plates were allowed to incubate and 
time course studies, taking readings at 30 min intervals for 3 hours, were made. IC50 values 
were consistent within this incubation period and the does-response curve for Nutlin-3a is 
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shown in Figure 3.9. In my hands, Nutlin-3a demonstrated an IC50 value of 24.00 ± 01.0 nM 
which is comparable to the literature value (90 nM).
26
 
Figure 3.9 Nutlin-3a dose-response curve against the p53/hDM2 interaction: IC50 = 24.00 ± 
01.0 nM. 
Figure 3.10 (a) Oligomers 22, 23, 10 and 52 mimicking the Phe19, Trp23 and Leu26 residues 
of p53. (b) Dose-response curves for oligomers 22 and 23: IC50 = 21.43 ± 1.22 µM and 23.65 ± 
4.51 µM respectively. 
3.3.3 3HABA Library Screening 
In previous studies, the 3HABA oligomers were synthesised in a solution-phase 
iterative process and oligomers were comprised solely of 3HABA based building blocks. In 
the SPS procedure, synthesis on a Gly loaded Wang resin achieved the best loading and so 
oligomers have a C-terminal Gly residue. To determine the effect this had on binding, 22 
and 23 were synthesised as analogues of potent inhibitors from previous studies (10 and 
52).
119
 Binding curves for 22 and 23 are shown in Figure 3.10 and exhibit comparable IC50 
values of 21.43 ± 1.22 and 23.65 ± 4.51 respectively: suggesting the position of the aniline / 
acid moieties on the scaffold may not influence the orientation the inhibitor binds with. 
However, the shape or steepness of the curves are quite different and this feature is 
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expressed as the Hill coefficient which describes the cooperativity of a ligand binding to a 
larger protein. In this instance it gives an indication if other non-specific interactions are 
occurring between the proteomimetic and tracer, thereby having an effect on binding.  The 
Hill coefficients for 22 and 23 are 1.27 ± 0.28 and 3.00 ± 0.46 respectively, suggesting that 
22 binds noncooperatively and oligomer 23 has more negative cooperative binding via 
interference of the tracer:protein complex by formation of a proteomimetic:tracer complex. 
The previous binding studies determined 10 and 52 to display IC50 values of 6.35 ± 0.30 μM 
and 4.15 ± 0.20 μM respectively,119 indicating the glycine may have a negative effect on the 
potency of the 3HABA scaffold which may be attributed to the poorer solubility of the Gly 
analogues.  
 
 Figure 3.11 (a) Reference oligomer 22 and trimers 24, 45, 46 and 25 varying aromatic groups 
at the R
1
 and R
2 
positions. (b) Comparison of dose-response curves between 22 and oligomers 
24, 45, 46 and 25: IC50 = 16.51 ± 0.71 μM 25; 14.93 ± 2.30 µM 45; 80.71 ± 6.91 μM 46. (c) 
Competition assay data for oligomer 25: Data points unable to fit to a logistic model. 
Oligomers 24, 45, 46 and 25 were synthesised to see how halogenated aromatic 
groups as Phe19 and Trp23 substitutes may influence binding. Dose-response curves from 
competition assays from this set are shown in Figure 3.11b-c. Using trimer 22 as the 
reference molecule (R
1 
= Bn, R
2
 = 2Nap, R
3
 = iPr), the following results and conclusions 
were made.  A pCl-Bn side chain replaced R
2 
in trimer 24 and the R
1 
in trimer 45. In both of 
these trimers, a slight improvement in binding is observed (IC50 = 16.51 ± 0.71 μM 24, IC50 
= 14.93 ± 2.30 45) suggesting that insertion of a pCl-Bn group could be beneficial. A mCF3-
Bn side chain replaced R
2 
in trimer 46 and a dramatically higher IC50 is observed (80.71 ± 
Chapter 3: Biophysical Evaluation of 3-O-Alkylated Oligobenzamides  
 
60 
 
6.91 μM).  R1 and R2 were replaced with pCl-Bn and mCF3-Bn respectively in trimer 25 and 
a reproducible does-reponse curve is shown in Figure 3.12c (see Appendix II for additional 
data). The data obtained is not reasonable to fit and provided no evidence for binding of this 
compound. In light of these results, it may be reasoned that the mCF3-Bn group may not be 
favourable for binding.  
Figure 3.12 (a) Reference oligomer 22 and trimers 47, 20 and 27 with aromatics substituted 
for alkyl groups at the R
1 
and/or R
2 
positions. (b) Comparison of the dose-response curve of 22 
against those for oligomers 47, 20 and 27: IC50 = 5.19 ± 0.17 μM 47, 14.61 ± 0.97 µM 20, 6.56 
± 0.20 μM 27.  
Figure 3.13 (a) Reference oligomer 22 and tetramers 41 and 42. (b) Comparison of the dose-
response curve of 22 against those for tetramers 41 and 42: IC50 = 25.27 ± 4.81 µM 41, 63.93 ± 
4.94 µM 42 
Trimers 47, 20 and 27 (Fig. 3.12a) were modified to assess how inserting alkyl 
groups at the R
1
 and R
2
 positions might affect binding. Dose-response curves from 
competitions assays for this set are shown in Figure 3.12b. With respect to 22, trimer 47 has 
an iBu group replacing the bulky naphthyl group at the R
2
 position. Surprisingly, removal of 
one aromatic group dramatically improves the IC50 value (5.19 ± 0.17 µM 47). Trimer 20 has 
both aromatic side chains replaced with iPr groups and again, an increase in binding affinity 
was observed and found to be reproducible (IC50 = 14.61 ± 0.97 µM and 10.03 ± 1.19 µM). 
A second trimer with all alkyl side chains (27) obtained a surprising low IC50 (6.56 ± 0.20 
µM). Although it is not clear why improved binding is observed, suggestions for this could 
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include increased self aggregation of dimers containing aromatic side chains from 
hydrophobic interactions (such as π-π stacking) resulting in fewer molecules available for 
binding, or simply the 2Nap side chain could be a poor Trp mimic. 
Tetramers 41 and 42 (Fig. 3.13a), containing only alkyl side chains, were also tested 
against this interaction. Dose-response curves for these oligomers are found in Figure 3.13b 
and IC50 values were determined to be 25.27 ± 4.81 µM and 63.93 ± 4.94 µM respectively. 
Although a great deal of information can not be obtained from these results, seemingly 
minor changes (R
3 
iBu→cPr and R4  iBu→ iPr) have resulted in a change in potency. This 
highlights the need for large libraries of inhibitors containing side chains with many simple 
variations in order to fully and effectively probe the hDM2 binding site.  
 
Figure 3.14 (a) Oligomers 48, 28 and 49 containing functionalised side chains. Dose-response 
curves for (b) acid functionalised oligomers 48 and 49 exhibiting IC50 values of 14.99 ± 0.89 
µM and 32.68 ± 0.01 µM respectively, (c) alcohol functionalised 28 exhibiting an IC50 value of 
> 250 µM. 
Oligomers 48 and 28 (Fig. 3.14a), containing a Asp and Ser analogue respectively, 
were screened against this target to deduce what effect the corresponding functionality may 
have on binding. Dose-response curves from competition assays for these oligomers are 
found in Figure 3.14b,c. It was pleasing to see that the acid functionalised oligomer 48 
demonstrated an increased potency compared with trimer 22 (IC50 = 14.99 ± 0.89 µM). This 
corresponds to results obtained from the Hamilton group, who observed increased binding 
for a terphenyl scaffold when flanked with carboxylic acid groups.
157
 Further studies have 
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shown that favourable electrostatic interactions can also be made with a nearby His 
residue.
158
 This positive result led to the synthesis of trimer 49 (Fig. 3.14a), containing an 
iBu→2Nap substitution. Despite a hypothesis that this may create more favourable 
hydrophobic contacts, a decrease in potency was observed (IC50 = 32.68 ± 0.01 µM) further 
suggesting 2Nap could be a poor Trp mimic. Incorporation of an alcohol moiety (28) led to a 
dramatic decrease in potency (IC50 = >250 µM) suggesting unfavourable interactions or 
simply poor affinity with the binding site.   
From data obtained in the previous screening studies, it was evident that including 
certain hydrogen bonding moieties could help increase their potency. Unclear from 48 and 
49, however, is at what position the functionality is most likely to make electrostatic 
contacts. Oligomers 50 and 51 (Fig. 3.15a) were subsequently synthesised using an 
appropriately loaded wang resin as a simple method to incorporate acid and base moieties 
onto the trimers, and to compare results directly with trimer 22. Dose-response curves from 
competition assays for these oligomers are found in Figure 3.15b.  Trimer 50 containing a 
C-terminal Asp exhibited improved inhibition with an IC50 value of 9.54 ± 0.54 µM. This 
could indicate possible favourable interactions from incorporating acid functionality, 
however, the change in the shape of the curve suggests there could be some form of 
cooperative binding occurring. Trimer 51 with a C-terminal Lys exhibited much poorer 
inhibition (the bottom plateau was fixed at -0.02 to determine the IC50  at  > 250 µM). 
Capping with an N-terminal Asp would be the appropriate next step to better understand 
what position the functionality is best positioned, however, the methodology to couple 
functionalised amino acids onto trimers is not yet developed.  
 
Figure 3.15 (a) C-terminally functionalised analogues of 22, Asp 50 and Lys 51, (b) 
Comparison in the dose-response curves of oligomers 22, 50 and 51: IC50  = 21.43 ± 1.22 µM, 
9.54 ± 0.54  and > 250 µM respectively. 
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3.4 Biophysical Data for Mcl-1/NOXA B assays 
A fluorescence anisotropy (FA) assay for this interaction has recently been developed 
in the group. This has provided optimised conditions and allowed the repetition of the 
protein titration and peptide displacements assays to generate reproducible results in my 
hands.  A fluorescein tag was used as the fluorophore on the NOXA B (FITC-Noxa B68-87 
synthesis: Dr. P. Prabhakaran) tracer molecule and Mcl-1172-327 (molecular cloning and 
expression: Dr. A. Bartlett) was used for the protein. 
3.4.1 Mcl-1 Titration 
Determining the Kd of this interaction was carried out having a [Mcl-1] range from 5 
µM – 0.15 nM and a constant [NOXA B*] of 50 nM. The plate was allowed to incubate for 
1.5 hours and results from this experiment can be found in Figure 3.16. A Kd value of 
148.19 ± 55.97 nM (see Appendix II) was obtained which is comparable to data previously 
obtained in the group (Kd = 32.46 ± 1.14 nM).   
Figure 3.16 (a) Average intensity fitted to a logistic model to calculate λ (λ = 2.20). (b) 
Protein titration curve of the Mcl-1/NOXA B interaction (Kd = 148.19 ±55.97 nM). 
3.4.2 NOXA B Displacement Assay 
As a positive control, it is imperative to perform the unlabelled peptide displacement 
assay to ensure binding data is reproducible, and comparable with previously obtained data. 
In this study, assays were carried out with 0% and 10% DMSO to understand if DMSO has 
an effect on binding. The [NOXA B] ranged from 15 µM – 34 nM and [NOXA B*] was 
constant at 50 nM across the plate. The plates were allowed to incubate and time course 
studies, taking readings at 45 minute intervals over 3 hours, were made: IC50 values were 
consistent within this incubation period. Dose-response curves from this set of experiments 
are shown in Figure 3.17: comparable IC50 values were obtained across the two DMSO 
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concentrations and were comparable with previously obtained results (IC50 = 707.42 ± 104  
nM 0 % and 533.14 ± 57 nM 10 % vs 704 ± 35 nM 10 %) 
Figure 3.17 NOXA B displacement curves at 0% and 10% DMSO concentrations; IC50 = 
707.42 ± 104.11 nM and 533.14 ± 57.10 nM respectively. 
3.4.3 3HABA Screening Library 
As this assay is in its infancy, there are no previous studies using 3HABA oligomers 
against this interaction and, hence, nothing to make comparisons against.  A small selection 
of oligomers (Fig. 3.18) seen previously screened against p53/hDM2 were chosen to assess 
the potential of the 3HABA scaffold in inhibiting this new interaction. As the fluorescence 
intensity changes during the protein titration (see Appendix I), EC50 values have been 
calculated by plotting fraction of ligand bound against [proteomimetic] (see Appendix II).   
Figure 3.18 Mcl-1/NOXA B 3HABA screening library. 
Oligomer 48 was designed to mimic the key binding residues of NOXA B. 
Synthesised on a Val loaded Wang resin, it also contains potential Ile, Leu and Glu mimics 
(iLeu, iBu and Asp monomers (14) respectively). Oligomer 49 has a very similar 
composition, however, with a large aromatic group at the R
2 
position which may give an 
indication to how large the binding pocket is. Unfortunately, as can be seen from the binding 
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curves for 48 and 49 (Fig. 3.19a,b), the data is fairly scattered at low [proteomimetic] with 
large error bars in places. This scattering may be due to aggregation of tracer molecules or 
proteins and / or precipitation of the protein by the proteomimetics. This is representative of 
competition assays from oligomers 47, 24 and 41 and data is not reasonable to fit.  
 
 
 
 
 
 
 
 
 
 
Figure 3.19 Dose-response curves for (a) 48: Fitting not possible (b) 49: Fitting not possible. 
The most promising dose-response curve was obtained from trimer 27 shown in 
Figure 3.20a. This oligomer contains only three alkyl side chains and demonstrated an EC50 
value of 4.66 µM, although there is still some fluctuation in this binding data. The dose-
response curves from the Mcl-1/NOXA B assay is directly compared with that from the 
p53/hDM2 assay, shown in Figure 3.20b. For both interactions, 27 exhibits relatively good 
binding indicating poor selectivity for these interactions with this oligomer. As no other 
binding data was obtained for the Mcl-1/NOXA B interaction, the question of the selectivity 
of the scaffold has not yet been addressed. 
Figure 3.20 (a) Dose-response curve for 27; EC50 = 4.66 ± 0.89 µM. (b) Comparison of the 
dose-response curves of 27 against the Mcl-1/NOXA B and p53/hDM2 interactions (EC50 = 
6.56 ± 0.20 µM).  
Although having deduced an EC50 value for the Mcl-1/NOXA B screen, the data as a 
whole is not particularly good. The poor binding data is not unique to the 3HABA scaffold 
as other screening from within the group using this assay has produced similar quality data. 
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Although the full library was not screened against this interaction, it is clear that the assay is 
not particularly robust and further screening was stopped.  
3.5 Conclusion 
In summary, a small library of 16 compounds was assembled to screen against the 
p53/hDM2 interaction and 6 compounds against the Mcl-1/NOXA B interaction. These were 
synthesised using a microwave assisted SPS methodology reported in Chapter 2. Although 
the methodology is robust with respect to alkyl and aromatic side chains, coupling of 
functionalised side chains is less efficient and requires purification by HPLC. The yield from 
this is low and prevented screening of the full library of compounds. Protein titration and 
peptide displacement assays were carried out for both PPIs before screening of the libraries 
commenced. Nice binding curves were obtained and several low µM inhibitors were 
identified when screening against the p53/hDM2 interaction (most potent inhibitor is 47; 
IC50 = 5.19 µM). Data from the Mcl-1/NOXA B screen, however, was too poor to extract 
reliable binding constants with trimer 27 producing the only data reasonable to fit (EC50 = 
4.66 µM). 
  Although library screening of the p53/hDM2 interaction was more successful than 
the Mcl-1/NOXA B screen, a much larger library would be necessary to make any real 
conclusions about what produces potent or poor inhibitors. However, some trends in binding 
affinities were identified and this will lead the way for a second library generation for the 
p53/hDM2 interaction. For example, incorporation of pCl-Bn and Asp mimetics at varying 
positions. Both these residues apparently improved the potency of the proteomimetic and a 
position-activity relationship study of such side chains could provide important results.  The 
introduction of natural amino acids as flanking residues on more oligomers could help 
improve solubility in addition to making key binding interactions. Furthermore, screening a 
wider range of functionalities with varying chain lengths and including chiral side chains 
will all add to understanding the restrictions imposed by the protein binding cleft. Future 
work would, hence, involve building a more diverse library and improve the SPS 
methodology for the incorporation of functionalised monomers and amino acids. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
4 Chapter 4 
 Design, Synthesis and Testing                                                   
of a Novel Bifacial Inhibitor 
A synthetic procedure developed in Section 4.2.1 contributed to work reported in a research 
article published in EurJOC.
125
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4.1 Introduction  
In the development of most conventional -helix mimetics described to date, a 
frequent feature or constraint was the need to design inhibitors which mimic side chains 
occurring on one face of the helix (i.e. at the i, i+3 (i+4), i+7 (i+8) positions and so on). A 
recent computational study carried out by the Arora group revealed that 62% of known 
multiprotein complexes feature a helix at the interface further highlighting the importance of 
α-helices in PPIs.15 In this 480 strong set, 60% interact via residues on a single face whilst a 
third contain key binding residues on two faces and approximately 10% require all three 
faces for interaction with the target protein. Using carefully designed stabilised helices or 
helical foldamers provides a solid foundation for multifacial inhibitors
1
 but due 
consideration should be given to designing multifacial proteomimetic inhibitors. As 
discussed in Chapter 1, there are a limited number of scaffolds which have been designed to 
address this challenge.
114, 155-158
 On development of work carried out in Chapters 2 and 3, it 
became apparent that potential bifacial mimics could be accessed through modification of 
the original 3HABA scaffold. A suitable test system on which to develop the new scaffold 
was needed and the work described in this chapter centres on that goal. 
An important group of interactions are the nuclear receptors and their coregulating 
peptides. This chapter has a focus on the estrogen receptor (ER), a transcription factor which 
regulates the growth and function of tissues found in the female reproductive system.
22
 It has 
also been associated with a variety of diseases including cancer, cardiovascular disease, 
obesity and osteoporosis, highlighting the importance of this target for therapeutic 
intervention.
159
 Approximately 70% of breast tumours develop due to the stimulatory effect 
of estrogens and so anti-estrogen therapies, such as tamoxifen, were developed.
160
 These 
drugs work in a competitive manner with the estrogen ligand, inducing agonistic as well as 
antagonistic effects depending on the tissue.
161
 In breast tissue, tamoxifen binds to the ER 
preventing the binding of estrogen. This has an antagonistic effect by inducing a change in 
the shape of the ER, shielding the coactivator binding region and in turn recruiting 
corepressor proteins; gene transcription and hence growth is halted.
162
 Initially these have a 
significant effect on the reduction of breast cancer; however, in more than 80% of treated 
women, tamoxifen resistance develops.
163, 164
 In the endometrium, tamoxifen acts as a partial 
agonist thereby increasing the risk of endometrial cancer in some women;
165
 an alternative 
therapy to anti-estrogen drugs is thus needed, which may be found in the ER/coactivator  
PPI.  
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Figure 4.1 (a) Helical epitope of  NCOA2 showing key leucine residues at the i, i + 3 and i + 4 
positions. Also displays Asp and Lys residues that interact with the charge clamp (PDB ID: 
2QZO). (b) Close up view of how key hydrophobic and charged residues on the NCOA2 
interact with the ERα LBD surface (PDB ID: 2QZO). (c) Top side view of NCOA2 showing 
key binding residues lying on two faces (PDB ID: 2QZO). (d) Top side view of p53 helix 
showing key binding residues lying on one face (PDB ID: 1YCR). 
Coactivators (p160 protein family) interact with the ERα activation function 2 (AF-
2) surface on the LBD via small amphipathic α-helical peptide sequences containing a 
common hydrophobic recognition motif; LXXLL (L = leucine, X = any amino acid) also 
known as the nuclear receptor box (NR box) (Fig. 4.1a).  The “X” residues in the NR box 
are not conserved and may provide a means to design selective inhibitors. X-ray crystal 
structures also show evidence of the peptide interacting with a charge clamp on the ER 
surface which could be utilised to further stabilise the complex (Fig. 4.1b).
166
 Unlike key 
residues in the p53/hDM2 or Bcl-xL/Bak complexes which are found on a single face of the 
helix, these key leucine residues are found on two faces as demonstrated in the nuclear 
receptor coactivator 2 (NCOA2) peptide (Fig. 4.1c-d). It has been proposed that these 
features may allow the ERα-coactivator interaction to be targeted by LXXLL motif-like 
inhibitors. Expanding on that, designing bifacial proteomimetics to project appropriate 
functionality in similar orientations to residues at the i, i+3 and i+4 positions is desired. 
4.2 Design 
Design of the coactivator mimetics builds on previously established work from the 
group. Chapters 2 and 3 expand on this work, developing a methodology and screening of a 
3HABA based scaffold reproducing the i and i + 4 (and i + 7) residues.  The Ahn group had 
also previously reported the synthesis of a novel amphiphilic variant of this scaffold in 
which they used an Elbs persulfate oxidation on a related 2-hydroxy-4-nitrobenzoic acid 
(2HNBA) starting material (53) to generate a para-dihydroxylated compound (54).
167
 It was 
reasoned that using a combination of the original 3-O-alkylated (56 or 17) and new  3,6-O-
dialkylated (55 or 57) building blocks, residues at the i, i+3 and i+4 positions could be 
mimicked; similar to those found in the NR box. To illustrate this, we assembled the 
Chapter 4: Design, Synthesis and Testing of a Novel Bifacial Inhibitor 
71 
 
3HABA and DHABA building blocks to form new dimer scaffolds 58 and 59; appropriate 
functionalisation produced dimers 60 and 61. These structures differ with respect to the 
position of the DHABA subunit; in 60 the lower, acid termini contains the DHABA building 
block (3HABA:DHABA) whilst in 61 the upper, amine termini contains the DHABA 
building block (DHABA:3HABA). 
 
Figure 4.2 (a) 2HNBA starting material 53 and new DHABA building block 54. (b) New 
DHABA based building blocks 55 (DHNBA) and 57 (DAHB) can be combined with original 
3HABA based building blocks 56 (3HNBA) and 17 (3AHB) blocks to generate new scaffolds 
58 and 59; building blocks can be suitably functionalised to form potential ERα inhibitors 60 
and 61. 
Molecular modelling was carried out using Maestro as an interface for a number of 
applications developed by Schrödinger.
168
 Initially a conformational search of dimers 60 and 
61 was run in which the structures were minimised by employing a Monte Carlo search in 
Macromodel® using the MMFFs (Merk Molecular Force Fields) method. Results of this 
experiment showed that in 60, the 3-O-alkoxy groups are syn whereas in 61, the 3-O-alkoxy 
groups are anti driven by a bifurcated H-bonding system (Fig. 4.3). Consequently, two 
adjacent side chains are displayed on the same face in both dimers and an alternating pattern 
of side chains was only seen in higher energy structures; ≥ +3.79 kJ mol-1 for 60 Anti and ≥ 
+9.92 kJ mol
-1
 for 61 Syn. This bias towards a particular conformation is caused by restricted 
rotation around the Ar-NH bond due to a S(5)-intramolecular hydrogen bond; rotation is 
therefore more likely to occur through the Ar-CO bond. This would also suggest that the 
presence of the bifurcated-like hydrogen bonding system would also restrict rotation around 
the Ar-CO bond in 61. This is corroborated in the molecular modelling with the syn 
conformer of 61 having a greater relative potential energy than the anti conformer of 60. The 
molecular modelling also infers that the S(5)-intramolecular hydrogen bond (2-NH-2-O3) in 
this system is more stable than the S(6)-intramolecular hydrogen bond (2-NH-1-O6) which 
could be attributable to steric clashes between the two isobutyl chains.  
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Figure 4.3 Low energy conformations of 60 (Syn) and 61 (Anti) and possible high energy 
conformations of 60 (Anti) and 61 (Syn). S(5) and S(6) hydrogen bonds are highlighted in 61 
Anti. 
The peptide moiety has several double-bonded resonance forms which endow 
peptides with permanent electric dipole moments. These can line up in secondary structures 
such as the α-helix, producing particularly large net dipoles which induce strong electric 
fields and can have an influence on its structure and function.
169
  In addition to the dipole 
moment, NCOA2 contains charged residues which interact with the charge clamp on the ER 
surface. These residues match up with the dipole moment in that a lysine and an aspartic 
acid residue is found at the N- and C-terminus respectively. Dimers 60 and 61 thus have the 
potential to match the dipole moment of the coactivator peptide whilst also presenting 
appropriate functionality towards the charge clamp. To determine how accurately the 
inhibitor designs mimic projection of hydrophobic functionality in the native coactivator 
peptides, the RMSD values were calculated with respect to the NCOA2 peptide (PDB ID: 
2QZO). To calculate the RMSD, three atom pairs were superimposed consisting of the 
alkoxy oxygen and the carbon of the leucine residues at the i, i + 3 and i + 4 positions. The 
orientation of the dimer in relation to the coactivator was also altered.  Figure 4.4 shows the 
superposition of the lowest energy conformations; 60 lies slightly across the helix and 
against the dipole moment of the peptide and 61 lies with a similar orientation but in line 
with the dipole moment of the peptide. The RMSD values for the lowest 1.5 kJ mol
-1
 energy 
conformations of 60 and 61 range from 1.62-1.70 and 0.94-1.07 Å respectively indicating 
that 61 is predicted to be a better mimic of NCOA2. Several important features, such as 
being of reasonable likeness to the native coactivator peptide and containing functionality 
which may interact with the charge clamp, provided a good starting point for ligand 
generation and efforts were directed to developing a synthesis. In addition to these features, 
a robust O-alkylation already established within the group would allow incorporation of a 
wide variety of side-chains to enhance probing of the binding surface.  
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Figure 4.4 (a) Superposition of NCOA2 peptide and the low energy conformation of 60 (b) 
Superposition of NCOA2 peptide and the low energy conformation of 61; (PDB ID: 2QZO).  
4.2.1 Synthesis 
The synthesis of these compounds was achieved using two building blocks, the 
3HABA based building blocks (Scheme 4.1) and the DHABA based building blocks 
(Scheme 4.2). The monoalkylated synthesis used methods previously developed in the 
group
114
. Simple alkylation using 1-bromo-2-methylpropane (or an appropriate alkyl halide) 
generates the alkylated product in good yield. The product from this reaction was then either 
reduced using tin (II) chloride (to get 3AHB intermediates) or hydrolysed using sodium 
hydroxide chloride (to get 3HNBA intermediates). These three simple reactions generate the 
two building blocks needed for the two separate scaffolds. 
Scheme 4.1 Synthesis of monoalkylated 3HABA based building blocks: 3HNBA 56 and 
3AHB 18). 
The synthesis of the dialkylated building blocks commenced with a dihydroxylation 
reaction following a procedure described by the Ahn group
167  
starting from 2HNBA 53.   
Reproducing this reaction using a cheaper alternative starting material 3-hydroxy-4-
nitrobenzoic acid 62 however, results in much easier isolation of the product (54). If a 
homoalkylated product is desired, the acid needs protecting in an esterification reaction and 
is then alkylated with the corresponding alkyl halide. An important point to note in terms of 
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targeting alternative PPIs, if a bifacial mimetic is required to display different 
functionalities, this can be achieved via ketal formation between the carboxylate and 2-
hydroxy group (63) This differentiates between the two hydroxyl groups and further 
alkylation and deprotection steps can deliver appropriate hetero-dialklated DHABA based 
building blocks.
124, 125
 
Scheme 4.2 Synthesis of DHABA based building blocks. 
The Mioskowski
170 
group previously reported aminolysis of esters using the catalyst 
TBD (1,5,7-triazabicyclo[4.4.0]dec-5-ene); one example reported contained an aniline. 
Successful aminolysis to 66 (Scheme 4.3) would mean that the final hydrolysis step forming 
56 and 55 is not necessary. Although the amine was not protected, it was hypothesised that 
the nitro ester would be more reactive towards aminolysis and so self reaction of 18 should 
not be seen. Several attempts at this reaction including increasing the temperature and 
catalyst loading were tried however analysis by LC-MS showed that conversion to the dimer 
occurred with less than 5% efficiency under all conditions. Due to the very poor reactivity 
this route was discontinued.  
 
 
 
 
Scheme 4.3 Attempted aminolysis conditions. 
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Akin to work carried out in Chapter 2, identifying if stable acyl chlorides of 55b and 
56b could be isolated was important. A stable acyl chloride of 55b was isolated and this 
carried through coupling, reduction and hydrolysis reactions to form dimer 61, however, the 
acyl chloride from 56b was too unstable to isolate. In situ acyl chloride formation with 
thionyl chloride (and building blocks 56b and 57b) in a microwave reactor was then 
attempted. Varying temperature, length of reaction and equivalents of thionyl chloride failed 
to result in significant conversion to 67. Ghosez’s reagent was subsequently attempted for 
use as the acylating agent, leading to successful formation of intermediate 67. Further 
reduction and hydrolysis reactions resulted in the desired amino acid dimer 60 (Scheme 4.4).  
 
Scheme 4.4 Synthesis of dimers 60 and 61. 
In addition to these dimers, the library was expanded to incorporate a variety of 
compounds which should have varied inhibitory potential (Fig. 4.5). For example, 71 which 
reproduces the i, i +4 and i+ 7 side chains was included as it was anticipated that it may be 
too large to fit in the binding pocket and should thus be a poor inhibitor. Both 72 and 73 
contain insufficient side chains to mimic the LXXLL motif and should exhibit poor 
inhibition. 72 however may be a poorer inhibitor than 73 due to a masked acid group which 
would prevent electrostatic contacts with the charge clamp.
166 
74 may show good or even 
better inhibition than the original dimers as it may better probe the shape complementarity of 
the binding cleft due to the larger benzyl side chain. 71 and 72 were synthesised following 
an analogous solution phase synthesis to those shown in Scheme 4.4.
114
 Compounds 73 and 
74 were synthesised using modified syntheses with Fmoc protected building blocks as 
shown in Scheme 4.5.  
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Figure 4.5 A series of compounds designed to investigate inhibition of the ERα/coactivator 
interaction. 
 
Scheme 4.5 Synthetic outline of dimer formation using Fmoc protected building blocks. 
4.2.2 Conformational Analyses 
The new dimers were submitted to thorough analyses by NMR spectroscopy in 
order to determine their conformational preferences in solution; allowing for comparison 
with previous molecular modelling studies. After assigning all proton peaks using a 
combination of 1D and 2D spectroscopic techniques, NOESY spectroscopy was used to 
determine the conformation through interactions between protons through space. The amide 
proton is key in helping to determine the conformation, and the strength of the NOE may 
help in understanding how populated the conformations are relative to each other. 
 Dimer 60 was shown to rotate around the Ar-CO, indicated by strong NOEs 
between protons b and c with amide proton d; the interaction between d and b, however, 
seems to be marginally stronger (Fig. 4.6). This is in contradiction to the low energy 
conformational search as it suggests that both conformations are possible, but the anti 
conformation is potentially more favourable when free in solution. Rotation around the Ar-
NH (S5) bond is more restricted.  There is an apparent weak interaction between protons e 
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and d at 30 mM concentration which disappears in more dilute solutions; however, the cross 
peaks are also much weaker in the more dilute solutions suggesting this may not be 
particularly significant interaction. Minimal or absent rotation around the Ar-NH bond is 
consistent with molecular modelling studies. Dimer 61 was shown to have restricted rotation 
around both the Ar-CO (S6) and Ar-NH (S5) bonds (Fig. 4.7). NOEs between protons b and 
d with amide proton c are not seen at any concentration, suggesting an anti conformation, 
which is in agreement with molecular modelling studies. 
 Figure 4.6 NOESY (500 MHz, CDCl3) spectra of dimer 60 at 30 mM, 20 mM and 10 mM 
concentrations. The 30 mM spectra shows the structure and 
1
H proton assignments and black 
circles highlighting any relevent NOEs. 
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Figure 4.7 NOESY (500 MHz, CDCl3) spectra of dimer 61 at 30 mM, 20 mM and 10 mM 
concentrations. The 30 mM spectra shows the structure and 
1
H proton assignments and black 
circles highlighting any relevent NOEs. 
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Figure 4.8 (a) Single X-ray crystal structure of 61. (b) Cyclic tetramer packing diagram of 61 
(stick) showing: aniline (NH) and carboxylic acid  hydrogen bonding (CO) and carboxylic acid 
(OH) and amide moieties (CO) hydrogen bonding (c) Cyclic tetramer packing diagram of 61 
(CPK) illustrating hydrophobic packing. 
Initially, NOESY spectra were obtained in DMSO which is more appropriate to the 
aqueous conditions experienced during biological testing. Several peaks were 
indistinguishable in this solvent and so a thorough conformational analysis was not possible, 
however, comparable results were obtained where possible (See section 6.8). In addition to 
solution phase conformational analyses, an X-ray crystal structure of 61 was obtained. 
Corroborating molecular modelling and NMR studies, Figure 4.8a shows the anti 
orientation, with respect to the 3-O-alkoxy groups, and confirms a bifurcated like hydrogen 
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bonding system.
125
 The crystal packing of the dimer was also studied and found to be 
substantially different from crystal packing seen from other 3-HABA based oligomers.
171
 
Typically packing is seen through side chain-side chain hydrophobic interactions,  however, 
dimer 61 packs with hydrogen bonding interactions between the aniline (NH) and carboxylic 
acid moieties (CO) and carboxylic acid (OH) and amide moieties (CO) on adjacent 
molecules. Within the chain packing structure, this forms cyclic tetramers with the 
hydrophobic side chains aggregating in the centre of the ring. This hydrophobic packing 
most likely contributes, in addition to the hydrogen bonding, to the observed packing 
structure (Fig. 4.8b-c).  
4.2.2.1 H/D exchange   
Unlike previous work from the group which has seen isolated S(5) and S(6) 
hydrogen bonding systems (as seen in 60), dimer 61 has a bifurcated S(5) / S(6) hydrogen 
bonding system. Interested in quantifying what extent this new hydrogen bonding motif 
might affect the conformation, H/D exchange studies were performed.  The experiment was 
performed on dimers 60 and 61 and data from a 2-O-alklated dimer 81  is included for direct 
comparison of an isolated S(6) system (Fig. 4.9).
171
  
 
Figure 4.9 Structures of dimers containing S(5), S(6) and S(5)/S(6) hydrogen bonding. 
The relative rates of a hydrogen/deuterium exchange in a 
1
H NMR study are 
affected by a number of parameters. Whilst an acidic proton is anticipated to exchange more 
rapidly, sterically hindered and strongly hydrogen bonded atoms are expected to have a 
slower rate of exchange.
172
 A 10% CD3OD/CDCl3 system was employed to ensure pseudo 
first order kinetics (Fig. 4.10) and the kinetic parameters for the compounds are given in 
Table 1. 
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 The half-life for the H/D exchange studies revealed that the amide proton in  81 
S(6) exchanges an order of magnitude more slowly than the amide proton of 60 S(5) and the 
amide proton of 61 S(5)/S(6) exchanges an order of magnitude more slowly than 81 S(6) and 
two orders of magnitude more slowly than 60 S(5). Comparable with previous studies, these 
results suggests a more stable hydrogen bond for the six-membered system relative to the 
five-membered analogue, and this stability is dramatically enhanced in the bifurcated system.   
Figure 4.10 (a) H/D exchange kinetics for dimers 60, 61 and 81. (b) Expansion of results in a, 
better demonstrating the difference between S(5) and S(6) hydrogen bonding systems. 
 
  
 
 
 
 
 
a 
b 
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Table 4.1 Results of kinetic results from H/D exchange studies. 'δH of amide proton measure 
in CDCl3. 
Compound δ NH' kH/D (min
-1
) t1/2 (min) 
60 S(5) 8.26 0.01485 ± 0.00017 46.7 ± 0.5 
61 S(5)/ S(6) 10.38 6.7857 x 10
-4
  ± 0.0000093 1021.5 ± 14 
81 S(6) 10.17 0.00387 ± 0.000077 179.1 ± 3.6 
 
4.2.3 Biological Testing 
Following synthesis, the compounds were sent for testing by collaborators at the 
Technische Univeriteit Eindhoven. This was carried out by a fluorescence polarisation 
competition assay which involved competing off a fluorescently labelled reference peptide 
based on coactivator SRC1 Box-2 bound to the ERβ LBD by one of the inhibitors. More 
specifically the ERβ-LBD concentration was constant at 400 nM, estradiol constant at 5 µM, 
and the fluorescently labeled SRC1Box2 constant at 100 nM. The inhibitor compounds were 
added in different concentrations across a dilution series (1 mM – 1 nM) however there were 
problems with solubility for compound 60, 72 and 74: measurements could not be performed 
higher than 50 µM for those compounds (Fig. 4.11).  The results were slightly disappointing 
in that no compound came close to disrupting the interaction as successfully as an unlabelled 
SRC1 Box-2 peptide. Some of the compounds are starting to inhibit in the high µM-range 
but full curves to determine IC50 and Ki were not reached. 
 
 
 
 
 
 
 
 
Figure 4.11 Preliminary results for biological testing using a fluorescence polarisation 
competition assay; a and b signify that different conditions were used during testing to 
improve solubility. 
61 
steroid receptor coactivator-1 Box-2 
71a 
60 
71b 
72 
73 74 
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4.3 Docking  
Interested to see how the inhibitors 60 and 61 might bind, a series of docking 
experiments was carried out. The LBD of ERα (PDB ID: 3ERD) was prepared for docking 
using the Prep Wiz function in Maestro.
155 
 Once the protein was refined, Glide was then 
used to generate a grid for docking. As the structure is dimeric, only 1 constituent monomer 
was used within the docking grid (Fig. 4.12a-b). Taking into account the size limitations of 
the grid and the fact that the molecule must lie entirely within it, the position where the 
coactivator binds was centred in the grid, however, much thought went into choosing an 
optimal position whilst minimising any bias. Figure 4.12c shows the docking grid (orange) 
surrounding the LBD at different angles. The protein and grid can then be used for all 
subsequent docking experiments. 
Figure 4.12 (a) Figure showing the binding interaction in one constituent monomer of the 
dimer: the larger structure is the ERα LBD and the smaller helical peptide is the NCOA2. 
Ribbons on the ERα LBD identify the binding region. (b) Figure showing a cartoon 
representation of a. This clearly shows the 3 helices (3, 5 and 12) important in binding.                   
(c) Figure showing the grid (orange box) used in the docking experiments from different 
angles. 
The next step is ligand preparation, carried out using LigPrep, which is a program 
developed by Schrödinger that converts two dimensional structures to 3D. This was used in 
conjunction with Epik to prepare the dimers and several other proposed ERα inhibitors for 
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docking; Epik is used to predict the ionisation states of each ligand and the energetic 
penalties associated with them. Having prepared the “ligands”, Glide was then used to dock 
the results into the prepared protein. Glide is a docking program, by Schrödinger, which uses 
a unique scoring function and docking protocol to estimate protein-ligand binding affinities. 
The score or “Glide GScore” is an empirical number calculated by the summation of a 
number of energetic terms. As a rule of thumb, the more negative the GScore the better. 
This, however, is explicitly used as a guideline as in practice, compounds with high negative 
scores do not always interact as well as those with lower negative scores. The predicted 
binding scores and energies can be used as a guide to assess a ligand’s ability to bind to a 
specified region on the protein surface. 
4.3.1 Docking Discussion 
In the case of most helix mediated protein-protein interfaces, the helix binding cleft 
is relatively flat and featureless.
173
 This makes generating “acceptable” docking scores (-5 or 
below) less likely than when compared with docking in an enzyme active site as most of the 
binding energy results from hydrophobic and lipophilic interactions.
174 
Along with other 
nuclear receptors, ligand binding on the ERα surface occurs through hydrophobic contacts 
but is reinforced by a charge clamp usually seen between a glutamic acid on helix 12 and 
lysine on helix 3
166
. Hence, designing inhibitors to exploit these electrostatic interactions 
presents a valuable contribution.  
The original aim of these docking experiments was to gain insight into how the 
dimers might bind to the ERα surface, in terms of both hydrophobic and electrostatic 
interactions. The docking studies may have also allowed for a comparison with other 
compounds designed, or compounds which have been shown, to inhibit the ERα-coactivator 
interaction. It should have also helped in determining what other features could be exploited 
in second generation ligands. Initially, it was conjectured that the docking experiment would 
have an influence on, or be able to change, the conformation of the compounds taking into 
account the protein surface and would thus, produce the same or similar docking scores. 
During preliminary docking experiments, however, it was noticed that the GScore value 
assigned to a particular molecule differed quite substantially. This was an important 
observation and in order to obtain more conclusive docking results, the lowest 1.5 kJ mol
-1
 
energy conformations generated in low energy conformational searches for 60 and 61 were 
processed by LigPrep and docked by Glide. Several observations were made during this 
process.  
Using 60 as an example, the lowest 1.5 kJ mol
-1
 energy conformations had the basic 
syn (with hydrogen bonding) configuration of a. After being processed by LigPrep, this was 
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modified generating a total of 4 main conformations (Fig. 4.13a-d) of which 2 are 
energetically unlikely based on results from the low energy conformational search and 
evidenced by NMR analysis. Seemingly, the new conformations assigned after LigPrep did 
not influence the docking conformation as many changed for a second time on docking; 
docked poses also bore all 4 conformations. This variation in docking poses per molecule 
indicates that docking merely the lowest energy conformation is not sufficient and docking a 
larger number of conformations results in realistic conformations and poses. In future 
studies, one might consider rigid docking of a low energy conformation or using a core or 
reference ligand which will restrict the docking within a given RMSD. 
 
Figure 4.13 Docking conformations of 60; a is the low energy conformation, b is higher 
energy conformation and c and d are highly unlikely docking poses. 
On analysis of 60, it was seen that 13 out of 89 docked poses had the ligand in its 
low energy conformation (Fig. 4.13a) with GScores ranging from -2.753 to -0.251 (Full 
GScore range from -3.168 to +0.754). This docking pose displays a good overlay with the 
native coactivator (Fig. 4.14a) but against the dipole moment of the coactivator peptide, akin 
to RMSD calculations. 16 out of 39 poses possessed the low energy conformation for 61. 
The best docked pose retains the low energy anti conformation and has a GScore of -3.707 
and values range from -3.707 to -0.921 (Fig. 4.14b). Although receiving a better GScore, the 
docking pose of 61 exhibits poorer mimicking of the coactivator peptide; only two of the 
side chains overlay nicely with the leucine residues and this also lies against the dipole 
moment of the coactivator. Figure 4.14c shows how 60 and 61 lie with respect to one 
another, in an almost mirror image like fashion. A number of equivalent docking studies 
were carried out with several ERα inhibitors to gain wider knowledge of available contact 
points on the receptor surface. α-Helix mimetic scaffolds pyridyl-pyridone175 82 and 
pyrimidine
109
 83 and HTS identified inhibitor, TPBM 
176
 84 were studied (Fig. 4.15). The 
docking poses were scrutinised and realistic docking poses were identified.  
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Figure 4.14 Docking poses of best scoring low energy conformations (a) left: 60, right: 
overlay of coactivator peptide and 60, (b) left: 61, right: overlay of coactivator peptide and 61. 
(c) overlay of 60 and 61; (PDB ID:3ERD). 
 
 
 
Figure 4.15 ER/coactivator interaction inhibitors: pyridyl-pyridone 82, pyrimidine 83 and 
TPBM 84. 
The XP visualisation tool breaks down the GScore and shows how the value is generated 
in energetic terms.  These terms are summarised in Table 4.2. The XP visualisation tool also 
shows the docking pose including any hydrogen bonds and their lengths (Summarised in 
Table 4.3). The GScores of the dimers, most similar in value to that of the pyridyl-pyridone 
scaffold 82 (-2.615), are not usually considered successful docking scores but are more 
typical of protein-protein interfaces.
174
 In contrast, GScores from 83 and 84 are found within 
the “acceptable” region and verging on docking scores most associated with enzyme active 
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site docking. Breakdown of the docking score and consideration of how the compounds 
dock provides reasoning for this.  
Table 4.2 Summary of energetic terms (XP docking) from compounds 60, 61, 82-84; ' 
rewards,'' penalties. 
 
Table 4.3 Summary of potential hydrogen bonding between inhibitors 60, 61, 82-84 and ERα 
LBD. 
 
 
Best docked conformations of compounds 
Energetic Term 60 61 82 83 84 
GScore -2.753 -3.707 -2.615 -7.516 -4.860 
Lipophilic pair term' -2.2 -2.9 -2.1 -2.1 -2.1 
Hydrophobic enclosure' -0.2 -0.2 0.0 -0.2 0.0 
Hydrophobically packed Hbond' 0.0 0.0 0.0 0.0 -0.8 
Hbond pair term' -0.9 -0.9 -1.0 -2.0 -1.7 
Electrostatic rewards' -0.3 -0.5 -0.1 -3.4 -0.7 
Low MW' 0.0 0.0 0.0 -0.5 -0.4 
Exposed hydrophobic ligand 
groups'' 
+0.4 +0.4 +1.7 +0.3 +0.5 
Rotatable bond'' +0.3 +0.3 +0.2 +0.3 +0.5 
Epik State penalty'' 0.0 0.0 0.0 +1.6 +0.1 
Compound H-Bond Amino Acid  (AA) Length (Å) AA Number 
60 1 Lys 1.777 362 
61 1 Lys 1.686 362 
82 1 Lys 1.892 362 
 2 Lys 2.132 362 
83 1 Glu 1.490 542 
 2 Glu 2.026 542 
 3 Glu 1.726 380 
84 1 Gln (CO) 1.796 375 
 2 Gln (NH2) 2.025 375 
 3 Lys 2.084 362 
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Comparing the electrostatic terms and predicted hydrogen bonding of 60 and 61, as 
demonstrated in Figure 4.16a, one can see that both make a single hydrogen bonding 
contact with the receptor surface (same Hbond pair term). The length of the Hbond in 61 is 
shorter and therefore stronger than that in 60; this correlates with a slightly higher 
electrostatic reward. 83 and 84 have much more favourable electrostatic terms; the 
hydrogen bond pair term and electrostatic rewards for pyrimidine are particularly 
noteworthy with a total reward of -5.4 versus -1.4 for 83 and 61 respectively. The 
uncharacteristic docking scores for the ERα are owing to compounds making a number of 
electrostatic interactions with the receptor surface. It is evident that there are other residues 
on the surface that the inhibitors can interact with in addition to the residues found in the 
charge clamp. Both 83 and 84 benefit from more extensive hydrogen bonding interactions 
with Gln (375) and Glu (542). Figure 4.16b identifies all residues on the receptor surface 
which form hydrogen bonds with docked compounds 60, 61, 82-84. Both dimers can 
successfully make hydrogen bonding interactions with the lysine in the charge clamp and in 
several low scoring poses, interactions with both elements in the charge clamp are possible. 
In these cases, poor placement of side chains result in hydrophobic penalties making 
hydrogen bonding with both elements of the charge clamp less likely. This demonstrates a 
fine balance between projecting the key hydrophobic functionality as well as key polar 
functionality with a correct orientation to maximise interactions with the hydrophobic cleft 
and charge clamp respectively.  
 
Figure 4.16 (a) Figure showing how 60 (stick) and 61 (ball and stick) dock on the ERα LBD 
including the hydrogen bonds with lysine. (b) Figure showing charge clamp residues Lys 362 
and Glu 380 and other functionalised surface residues available for hydrogen bonding (Gln 
375 and Glu 542). 
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4.3.2 Redesign 
Several modifications to the scaffold have been envisioned to produce a second 
generation of inhibitors. The first set of modifications has been designed to better probe the 
hydrophobic binding surface. This involves generating a variety of new building blocks, 
which when mixed with new and existing building blocks can produce a wide range of new 
scaffolds. The various building blocks are shown in Figure 4.17. Dimers 60 and 61, 
synthesised using 3HABA (85) and DHABA (86), can be modified by changing the position 
of side chain in the monoalkylated building block from the 3-O- to the 2-O- alkoxy position 
to produce 87 (2-HABA). Modification to the central amino acid character of the building 
blocks can produce para-dianiline (88 and 89) and para-diacid (90 and 91) constructs. 
Incorporation of a monoalkylated building block affords greater variety, as demonstrated in 
positioning of the alkyl chain at the 2- or 3- position. Removing a side chain may help to 
increase solubility by having less hydrophobic groups, however molecular modelling on 
each variant would be needed to decide which compounds to proceed with. Combining the 
new para-dianiline and para-diacid building blocks together, as well as with the original 
“amino acid” building blocks, could furnish up to 20 scaffolds.  
 
Figure 4.17 Potential building blocks for second generation scaffolds. 
Scaffold 92 was submitted to preliminary molecular modelling studies to understand 
how these modifications may change the inhibitory potential. A low energy conformational 
search was carried out as discussed previously, and it was found that the 2-O-alkoxy groups 
were displayed syn to one another, as demonstrated in Figure 4.17. The RMSD values of the 
lowest 1.5 kJ mol
-1 
energy conformations, with respect to the NCOA2 peptide, were 
calculated. These values ranged from 0.59-0.62 Å, which is significantly better than the 
RMSD values for 60 and 61. To illustrate this, Figure 4.18a shows a very good correlation 
between the projection of the side-chains in 92 and the NCOA2, which was not seen in 
earlier superpositions. Carried out using the Maestro interface as above, 92 was docked into 
the ERα LBD using Glide. Further demonstrating the inhibitory potential of 92, Figure 
4.18b shows an overlay of docking results with the native peptide. One can clearly see that 
the projection of the alkoxy side chains mimics the leucine side chains extremely well, 
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suggesting that these new scaffolds could present better inhibitors of the ERα /coactivator 
interaction. In addition to presenting a good mimetic, the dipole moment of 92 is in line with 
the dipole moment of the peptide and docking studies suggest the amine and acid moieties 
are positioned appropriately to make contacts with the charge clamp. In order to synthesise 
these new compounds, a new strategy containing unfamiliar chemistry would have needed to 
be developed. This was not progressed due to time constraints but has been taken on by 
another member of the group. 
Figure 4.18 (a) Superposition of NCOA2 peptide and the low energy conformation of 92.                 
(b) Overlay of docked 92 and NCOA2 (PDB ID:3ERD). 
A second set of potential modifications is to maximise electrostatic interactions with 
charged residues.  This would involve putting residues such as aspartic acid and lysine onto 
the acid and / or amine termini of a dimer, demonstrated in Figure 4.19 with 60 derivatives. 
With knowledge from initial molecular modelling studies, attaching a lysine onto the N-
termini could have dramatic improvements on docking scores. This would essentially extend 
the molecule taking advantage of a newly positioned amine group to make hydrogen 
bonding interactions with the Glu of the charge clamp or another Glu residue situated 
nearby. The Lys amine is also protonated at physiological pH, unlike the scaffold aniline, 
which would also allow for stronger interactions. In addition to making more favourable 
interactions, addition of such residues may also increase the solubility of the compounds. As 
mentioned in the biological testing, this is an important issue to be addressed if good 
inhibition is to be achieved. 
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Figure 4.19 Second generation modifications to: make or improve interactions with the charge 
clamp; increase solubility of dimers.  
4.4 Conclusion and Future Work 
To conclude, two new scaffolds have been designed, modelled, synthesised and 
tested. Due to poor solubility and biological data, an extensive docking study was carried out 
leading to a second generation of ligands. Significant knowledge has been gained in the 
docking studies which will make replication of docking experiments for new scaffolds rapid. 
Unlike other steroid receptors the androgen receptor (AR) utilises multiple 
mechanisms to activate gene transcription. The AR is able to bind coregulators through a 
canonical AR AF-2 domain via a restricted set of LXXLL coregulators, however, it 
preferentially binds to phenylalanine-rich motifs exhibiting a FXXLF (FXXFF) sequence in 
the AF-1 domain.
177
 Due to the almost identical projections of these side chains, it may be 
possible to develop inhibitors relevant to the AR/coactivator interaction by changing the side 
chain of the already existing scaffolds. A recent study by Raj and co-workers
178
 
demonstrated that a simple nitro / ester 3HABA based intermediate 93 (Fig.19), successfully 
targets the AR/PELP1 (LXXLL) interaction with an IC50 of 40 nM,  indicating the scaffolds 
could have potential inhibitory effects with alternative PPIs. However, in our own hands, 
similar scaffolds have failed to demonstrate selectivity or exhibit nanomolar inhibition of 
any helix mediated PPI 
 
 
 
 
 
 
 
Figure 4.20 Nitro / ester 3HABA based derivative 93 shown to inhibit the AR/PELP1 
interaction. 
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5.1 Thesis Summary and Future Directions 
As almost every biological process in the cell involves interactions between proteins, it is liable 
that a mutation during replication or malfunction in a biological process will eventually occur that 
results in the onset of disease: for example mutations in oncogenes can result in cancers, and viruses 
such as HIV contain enzymes which disrupt regular cellular activity. Secondary structures within 
proteins help characterise the interface between proteins and as the α-helix is the most abundant 
secondary structure in proteins, it is reasonable that this structure mediates a number of PPIs. Several 
helix mediated PPIs have been implicated in the development of the aforementioned diseases and 
have accordingly become an important focus of scientific research. Traditional small molecule 
therapeutics have resulted in some of the most potent inhibitors of PPIs, however, tailoring inhibitors 
for each PPI is not attractive as a general strategy for their inhibition.  Other approaches have sought 
to reproduce the helical structure by stabilisation of the helical peptide (constrained peptides and 
foldamers) or by recapitulating the key binding residues of the helix on a core non-peptidic scaffold 
(proteomimetics). Both strategies have produced a variety of scaffolds, disrupting many distinct PPIs, 
however, a true generic scaffold is still desired.  
The Wilson group developed a 3-O-alkylated oligobenzamide scaffold which replicated the 
spatial projection of residues at the i, i+3 (i+4) and i+7 (i+8) positions: classified within the 
proteomimtic strategy. When screened against the well characterised p53/hDM2 interaction, several 
low micromolar inhibitors were identified. In order to better understand what necessitates strong 
binding, a library of compounds, containing varied functionalities, to carry out SAR studies is a 
favourable approach. In this context, a SPS is described herein which discusses the synthesis of a 
range of Fmoc protected 3HABA building blocks, amenable to standard Fmoc SPS procedures, and 
the development of an automated, microwave assisted SPS methodology. In the study, various 
techniques to activate monomers with different side chains were developed. The most successful was 
stable acyl chloride formation of monomers with alkyl and aromatic side chains. Oligomers 
synthesised using the acyl chlorides were obtained in high yields (70-99 %) and in over 95 % purity in 
most cases simply after cleavage from the resin and precipitation. Monomers with acid labile 
protecting group generally required in situ acyl chloride formation due to them being highly unstable, 
requiring purification by HPLC. In future studies, methods for their purification will need to be 
addressed to obtain higher yields. Oligomer assembly was compatible with a range of natural and 
unnatural functionalities and a hexamer was successfully synthesised and characterised in high purity. 
Molecular modelling studies demonstrated the potential for longer oligomers to mimic extended 
helices such as those found in the gp41 hexameric coiled coil assembly. Ultimately, a rhobust SPS 
method for oligomer formation of deactiviated anilines was developed and is an important advance in 
the field.
126
 There are currently no other SPS procedures for the scaffold which have as wide substrate 
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tolerance and can produce oligomers in high yields or purities sufficient for biological testing
150
 and 
as such, the methodology was published in a major chemistry journal.   
After assessing the scope of the methodology, an SAR oligomer library was constructed. This 
was largely focused on designing potential inhibitors of the model p53/hDM2 interaction, and 
screening was achieved via fluorescence anisotropy competition assays against this PPI. The SAR 
study produced some promising data, with good dose-response curves and some apparent trends in 
reactivity across the series. Two significant areas for future development are a larger SAR or position-
AR study for the pCl-Bn side chain and for the incorporation of acid containing side chains through 
3HABA monomers of natural amino acids (Asp or Glu): trimers containing these functionalities 
exhibited improved potency compared to the most potent inhibitor in the original study.
116
 The 
positive results in acid containing oligomers support earlier studies that inhibitors for this interaction 
could benefit from containing more functionality than simply mimicking the Phe19, Typ23 and Leu26 
hydrophobic residues.
135, 158
 Future studies should focus on further methodology development to 
incorporate such amino acids on the N-terminal position on trimers: this will not only improve future 
SAR studies but will also lead the way for incorporation of oligomers into proteins. A handful of 
oligomers were designed/identified as potential inhibitors of the Mcl-1/NOXA B interaction and a 
further set of competition assays were carried out against this PPI. Most data from this study was not 
reasonable to fit, however, a low micromolar inhibitor of this interaction was identified. Without other 
binding data, this has little implication and much larger SAR studies will be necessary to better 
understand binding requirements of this PPI. Future SAR studies can also help to determine the 
selectivity of the scaffold with respect to a variety of PPIs as competition assays for other helix 
mediated PPIs are currently being developed in the Wilson group. Further biophysical studies might 
include ITC which would help characterise these interactions, proteolytic stability and cell penetration 
studies of oligomers and obtaining crystal structures of oligomers bound to the proteins.  
Over 40 % of helix mediated PPIs involve key binding residues located on more than one face, 
however, there are very few scaffolds in the literature designed to mimic more than one face of the 
putative helix.
108, 112, 118, 124
 Extending our approach to mimic multiple faces, the 3-O-oligobenzamide 
scaffold was modified, resulting in two novel bifacial dimer scaffolds as inhibitors of the 
ERα/coactivator interaction. The development of the scaffold is discussed from initial molecular 
modelling, synthesis, structural characterisation and biophysical studies from our collaborators. 
Subsequent computational docking studies were carried out to develop more potent inhibitors and this 
led to second generation ligands with improved in silico properties. Although the project is in its 
infancy, the scaffolds have shown potential as bifacial mimics and there are still many features which 
can undergo optimisation. In addition to the iBu side chains discussed, the new scaffolds can be 
synthesised incorporating a wide range of functionality to carry out more involved SAR studies. 
Docking studies also identified numerous charged amino acid residues surrounding the binding cleft, 
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including the charge clamp Asp and Lys residues, and future work should involve incorporation of 
acid and base moieties to exploit these favourable electrostatic interactions. It is anticipated that 
biophysical evaluation of these second generation compounds will identify potent inhibitors of the 
ERα/coactivator interaction and modification of side chains could also result in inhibitors of other 
steroid receptor/coactivator complexes (such as the AR/coactivator interaction).  
On a wider scale, in addition to the 3-O-alkylated scaffold and the bifacial scaffolds 
investigated in this thesis, two other scaffolds (2-O-alkylated, N-alkylated) are undergoing biophysical 
evaluation as potential helix mimetics within the group. Biophyscial testing of hybrid oligomers 
constituting the 3-O, 2-O-, N-alkylated scaffolds and natural amino acids is currently under 
investigation and it is envisoned that a thorough SAR study involving these and possible 
incorporation of DHABA building blocks, creating bifacial mimics, could lead to inhibitors of helix 
mediated PPIs with improved biophysical properties (such as selectivity, potency and proteolytic 
stability). 
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General Experimental Points 
All reagents were obtained from commercial sources and used without further purification unless 
otherwise stated. All solvents used were HPLC grade. Dry solvents were bought from Aldrich. 
Analytical TLC was performed using 0.2 mm silica gel 60 F254 pre-coated aluminium sheets (Merck) 
and visualised using UV irradiation or, in the case of amine intermediates, by staining with a 
ninhydrin solution. Flash column chromatography was carried out on silica gel 60 (35 to 70 micron 
particles, FluoroChem). Solvent ratios are described where appropriate. Solvents were removed under 
reduced pressure using a rotary evaporator at diaphragm pump pressure. Samples were freed of 
remaining traces of solvents under high vacuum. 
1
H and 
13
C NMR spectra were measured on a Bruker 
DPX300 or a Bruker Avance 500 spectrometer using an internal deuterium lock. Chemical shifts are 
reported in parts per million (ppm) downfield from TMS in δ units and coupling constants are given 
in hertz (Hz). Coupling constants are reported to the nearest 0.1 Hz. TMS is defined as 0 ppm for 
1
H 
NMR spectra and the centre line of the triplet of CDCl3 was defined as 77.10 ppm for 
13
C NMR 
spectra. When describing 
1
H NMR data the following abbreviations are used; s = singlet, d = doublet, 
t = triplet, q = quartet, m = multiple, br. = broad, app. = apparent. Melting points were determined 
using a Reichert Austria melting point microscope and are uncorrected. Microanalyses were obtained 
on a Carlo Erba Elemental Analyser MOD 1106 instrument, found composition is reported to the 
nearest 0.05%. Infrared spectra were recorded on a Perkin-Elmer FTIR spectrometer and samples 
analysed as solids (unless otherwise stated). Mass spectra (HRMS) were recorded in-house using a 
Micromass GCT Premier, using electron impact ionisation (EI) or a Bruker Daltonics micrOTOF, 
using electron spray ionisation (ES). LC-MS experiments were run on a Bruker Daltronics esquire
TM
 
series spectrometer, samples ionised by electrospray and analysed by a quadrupole ion trap mass 
spectrometer. All experiments were run through za C18 column on an acetonitrile/water gradient 
(typically 0-100% acetonitrile over 3 minutes).  Intermediates 16a, 16e, 16h, 17a and 17e have 
previously been described.
114, 116, 155 
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6.1 General Procedures 
6.1.1 Monomer Synthesis  
Procedure A (RBr Alkylation)To a stirred solution of methyl-3-hydroxy-4-nitrobenzoate 15 (1 eq.) 
and potassium carbonate (3 eq.) in dimethylformamide (20 mL / g) is added RBr (1.2 eq.) and the 
resulting mixture stirred at 50 ºC overnight under a nitrogen atmosphere. The resultant red liquid is 
allowed to cool and poured into water (40 mL / g) and extracted with ethyl acetate. The combined 
organic fractions are thoroughly washed with water and further washed by brine, dried (magnesium 
sulfate), filtered and evaporated to dryness. 
Procedure B (Mitsunobu) A stirred solution containing methyl-3-hydroxy-4-nitrobenzoate 15 (1 eq.), 
ROH (1.1 eq.) and triphenylphosphine (1.5 eq.) in anhydrous tetrahydrofuran (30 mL / g) is cooled to 
0 °C. Diisopropyl azodicarboxylate (1.5 eq.) is added and the resulting solution allowed to warm to 
room temperature and left stirring overnight under a nitrogen atmosphere. Organic solvents are 
removed under reduced pressure and the product is purified via column chromatography. 
Procedure C (Tin Reduction) To a stirred solution containing either i) nitro/ester or ii) nitro/acid (1 
eq.) in ethyl acetate (20 mL / g) tin(II) chloride dihydrate (6 eq.) is added and the resulting mixture 
stirred at 50 ºC overnight, under a nitrogen atmosphere (with a calcium chloride drying tube 
attached). On completion, the reaction mixture is allowed to cool and poured over ice. The pH is 
made slightly basic (~pH 8) by addition of a saturated sodium bicarbonate solution and the resulting 
basic mixture is allowed to stir for an hour. The aqueous mixture is extracted with ethyl acetate and 
the combined organic fractions washed thoroughly with brine, dried (magnesium sulfate), filtered and 
evaporated to dryness 
Procedure D (Hydrogenation) A solution containing either i) nitro/ester or ii) nitro/acid (1 eq.) in 
methanol (20 mL / g) and palladium on carbon (10 wt%) is evacuated and flushed with nitrogen (3 
times) and left under vacuum. Hydrogen is drawn into and the flask and the reaction is left stirring 
at room temperature overnight. On completion, the reaction mixture is filtered through a celite pad 
and evaporated to dryness. 
Procedure E (Cobalt assisted reduction) To a solution containing either i) nitro/ester or ii) 
nitro/acid (1 eq.) in methanol, cobalt (II) chloride hexahydrate (3 eq.) is added and allowed to 
dissolve. Sodium borohydride (6 eq.) is added slowly and allowed to stir for 30 minutes. A further 
portion of cobalt (II) chloride hexahydrate (3 eq.) and sodium borohydride (6 eq.) is added as above. 
The solution is filtered through a celite pad which is washed with dichloromethane and the filtrate 
thoroughly washed with 1M hydrochloric acid to remove the metal. The organic solvents are washed 
with brine, dried (magnesium sulfate), filtered and evaporated to dryness. 
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Procedure F (NaOH Saponification) To a solution containing either i) amine/ester or ii) nitro/ester (1 
eq.) in a 1:1 mixture of methanol: tetrahydrofuran (25 mL / g), a 10 % sodium hydroxide solution (5 
mL / g) is added and the resulting mixture is allowed to stir at RT overnight. Addition of further 
portions of the hydroxide solution may be necessary. The organic solvents are removed under reduced 
pressure and water is added to dissolve the solid. The resulting solution is extracted with 
dichloromethane (unreacted starting material) and the aqueous layer acidified via the addition of 
hydrochloric acid (conc) to pH 4. The resulting precipitate is extracted into dichloromethane and the 
combined organic extracts are washed with water and further washed with brine, dried (magnesium 
sulfate), filtered and evaporated to dryness. 
Procedure G (LiOH Saponification) To a solution containing either i) amine/ester or ii) nitro/ester 
(1 eq.) in a 1:1 mixture of tetrahydrofuran / water (25 mL / g), a saturated lithium hydroxide solution 
(1 eq.) is added and the resulting mixture is allowed to stir at RT overnight. The organic solvent is 
removed under reduced pressure and an additional amount of water is added. The resulting solution is 
extracted with dichloromethane (unreacted starting material) and the aqueous layer acidified via the 
addition of 1M potassium bisulfate solution to pH 4. The resulting precipitate is extracted into 
dichloromethane and the combined organic extracts are washed with water and further washed with 
brine, dried (magnesium sulfate), filtered and evaporated to dryness. 
Procedure H (Fmoc protection) A solution of 18 (1 eq.) in anhydrous tetrahydrofuran (20 mL / g) is 
held at a reflux under a nitrogen atmosphere. A solution of fluorenylmethyloxycarbonyl chloride (1.5 
eq.) in anhydrous tetrahydrofuran (10 mL / g) is then added dropwise and the resulting solution is 
stirred at reflux overnight. The reaction mixture is cooled to ambient temperature, concentrated and 
the resulting precipitate collected via filtration. 
Procedure I (Fmoc protection) A solution of 18 (1 eq.) and sodium bicarbonate (3 eq.) in anhydrous 
tetrahydrofuran (20 mL / g) is held at a reflux under a nitrogen atmosphere. A solution of 
fluorenylmethyloxycarbonyl chloride (1.5 eq.) in anhydrous tetrahydrofuran (10 mL / g) is then added 
dropwise and the resulting solution is stirred at reflux overnight. Sodium bicarbonate is removed via 
hot filtration and the reaction mixture is allowed to cool to room temperature, concentrated under 
reduced pressure and the resulting precipitate collected via filtration. 
6.1.2 Solid Phases Synthesis 
Acyl Chloride Formation – Method A To a stirred solution of an Fmoc protected building block in 
anhydrous dichloromethane (20 mL / g), thionyl chloride (10 eq.) is added and the resulting mixture 
refluxed overnight. The organic solvents and thionyl chloride are removed under reduced pressure and 
the resulting solid re-dissolved in chloroform. Hexane is added to precipitate the acyl chloride which 
is collected via filtration and stored under an inert atmosphere. 
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Acyl Chloride Preactivation – Method B To a solution containing Fmoc protected monomers (14, 1 
eq.) functionalised with acid sensitive protecting groups in NMP (2.5 mL), 0.9 eq. of Ghosez’s 
reagent is added. The resulting mixture is stored under an inert atmosphere for 3 hours at 50 ºC before 
the addition to the resin and microwave treatment. 
Acyl Chloride In Situ Formation- Method C To a solution containing Fmoc protected monomers 
(14, 1 eq.) in NMP (2.5 mL), 1 eq. of thionyl chloride is added immediately before addition to the 
resin and microwave treatment 
General Points for Solid Phase Synthesis: Fmoc-Gly-Wang resin (0.79 mmol/g, 100-200 mesh; 
carrier: polystyrene, crosslinked with 1% DVB), Fmoc-Ile-Wang resin (0.59 mmol/g, 100-200 mesh; 
carrier: polystyrene, crosslinked with 1% DVB) was purchased from Merck. All solvents used were 
HPLC grade. Anhydrous N-methyl-2-pyrrolidone was purchased from Alfa Aeser and stored in a 
schlenk tube on molecular sieves under a nitrogen atmosphere. Acyl chlorides were synthesised as in 
Method A for acyl chloride formation and stored under an inert atmosphere. 1-Chloro-N, N, 2-
trimethyl-1-propenylamine (Ghosez’s reagent) was purchased from Sigma-Aldrich. Oligomer 
formation was carried out on a CEM Liberty automated microwave peptide synthesiser. The volume 
of the reaction mixture in the reaction vessel was 2.5 mL. Manual SPS was carried out in 1.5 mL 
‘Extract-Clean’ polypropylene reservoirs fitted with 20 mm polyethylene frits, both available from 
Alltech. 
General Procedure for Oligomer Formation – Single Coupling Fmoc protected pre-loaded Wang 
resin (127 mg, 0.1 mmol, 1 eq.) is loaded onto a CEM™ microwave peptide synthesiser after being 
swelled for a total of 30 minutes in NMP and DCM solutions. A series of washes (3 x NMP), 
deprotection (2 x 20 % Piperidine/NMP, total of 3.5 minutes at 75 °C) and further washes (5 x NMP) 
prepares the resin for coupling. Fmoc protected acyl chloride X (0.4 mmol, 4 eq.) obtained by pre-
activation or prepared separately is dissolved in NMP (2.5 mL), delivered to the reaction vessel and 
submitted to microwave irradiation at 50 °C for 30 minutes. A final series of filtered washes of the 
reaction vessel (3 x NMP) finishes a coupling cycle. 
General Procedure for Oligomer Formation – Double Coupling Fmoc protected pre-loaded Wang 
resin (127 mg, 0.1 mmol, 1 eq.) is loaded onto a CEM™ microwave peptide synthesiser after being 
swelled for a total of 30 minutes in NMP and DCM solutions. A series of washes (3 x NMP), 
deprotection (2 x 20 % Piperidine/NMP, total of 3.5 minutes at 75 °C) and further washes (5 x NMP) 
prepares the resin for coupling. Fmoc protected acyl chloride X (0.2 mmol, 2 eq.) obtained by pre-
activation or prepared separately is dissolved in NMP (2.5 mL), delivered to the reaction vessel and 
submitted to microwave irradiation at 50 °C for 30 minutes. A second solution containing Fmoc 
protected acyl chloride X (0.2 mmol, 2 eq.) (preactivated or isolated) in NMP (2.5 mL) is delivered to 
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the reaction vessel and submitted to microwave power at 50 °C for 30 minutes. A final series of 
filtered washes of the reaction vessel (3 x NMP) finishes a coupling cycle. 
General Procedure for Cleavage After the required number of cycles, a final Fmoc deprotection is 
carried out and then the resin is removed from the synthesiser and transferred to a reservoir for 
manual cleavage. The resin is washed with dichloromethane (10 x 1 mL) and cleaved with a 1.5 mL 
cleavage cocktail consisting of trifluoroacetic acid-dichloromethane-triisopropylsilane with varying 
ratios depending on the side chains. If no protecting groups are present, a simple 1:1 trifluoroacetic 
acid-dichloromethane mixture is sufficient without the need for a scavenger. A 95:5 dichloromethane-
trifluoroacetic acid solution was used with trimers containing naphthyl / indole side chains. 
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6.2 Characterisation of Monomers (Chapters 2 and 3) 
Monomers 14 (d, k, o, q, r) and their intermediates were originally synthesised by Panchami 
Prabhakaran (d, o, q, r)  and Valeria Azzarito (k) and (monomers 14k and 14o later synthesised by 
myself). These were included for completeness of Chapter 2 experimental: all monomers and 
intermediates were, however, characterised by me. 
4-Amino-3-isopropoxybenzoic acid 18a 
Procedure F; Methyl-4-amino-3-isopropyloxybenzoate 17a (9.00 g, 43.0 mmol) in a 1:1 mixture of 
methanol-tetrahydrofuran (220 mL), 10% aqueous sodium hydroxide solution (50 mL). Work-up 
afforded the title compound (7.56 g, 38.7 mmol, 90%) as a colourless amorphous powder; (Found C, 
61.30; H, 6.75; N, 7.01%. C10H13NO3 requires C, 61.53; H, 6.75; N, 7.18%); δH (300 MHz, CDCl3) 
1.36 (6H, d, J = 6.8, Hβ), 3.85 (2H, br. s, NH2), 4.63 (1H, sept, J = 6.1, Hα), 6.68 (1H, d, J = 8.2, H5), 
7.53 (1H, s, H2), 7.61 (1H, d, J = 8.2, H6); δC (75MHz,  CDCl3); 21.3, 70.9, 113.2, 114.5, 118.4, 
124.2, 124.4, 144.1, 169.6; υmax/cm
-1
 (solid state) = 3335,  2520, 1769, 1659, 1577, 1443, 1262, 1111, 
976; ESI-MS found m/z 196.09 [M+H]
+
; 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-isopropoxybenzoic acid 14a 
Procedure H; 4-Amino-3-isopropoxybenzoic acid 18a (7.00 g, 35.9 mmol) in tetrahydrofuran (140 
mL), fluorenylmethyloxycarbonyl chloride (13.92 g, 53.8 mmol) in tetrahydrofuran (100 mL). Work 
up yielded the title compound (12.28 g, 29.4 mmol, 82%) as a colourless amorphous solid; (Found C, 
71.80, H, 5.65; N, 3.25%. C25H23NO5 requires C, 71.93; H, 5.55; N, 3.36%); δH (300 MHz, CDCl3) 
1.43 (6H, d, J = 6.9, Hβ), 4.34 (1H, t, J = 6.9, FHβ), 4.54 (2H, d, J = 6.9, FHα), 4.73 (1H, sept, J = 
6.9, Hα), 7.34 (2H, t, J = 7.5, FHAr4), 7.43 (2H, t, J = 7.5, FHAr3), 7.55 (1H, s, H2), 7.60-7.75 (4H, 
m, H5, H6 + FHAr5), 7.80 (2H, d, J = 8.4, FHAr2), 8.16 (1H, s, NH); δC (75MHz, CDCl3); 21.9, 46.9, 
66.7, 71.5, 114.3, 120.5, 125.5, 125.6, 126.3, 127.5, 128.1, 132.8, 141.1, 144.0, 147.4, 153.7, 167.3; 
υmax/cm
-1
 (solid state) = 3333, 2975, 1709, 1599, 1542, 1497, 1442, 1337, 1240, 1105, 1053, 978; ESI-
HRMS found m/z 418.1649 [M+H]
+
, C25H24NO5 requires 418.1654; 
Methyl 3-isobutoxy-4-nitrobenzoate 16b 
Procedure A; Methyl-3-hydroxy-4-nitrobenzoate 15 (10.00 g, 50.72 mmol) and potassium carbonate 
(2l.0 g, 151.9 mmol) in dimethylformamide (200 mL), 1-bromo-2-methylpropane (6.62 mL, 60.9 
mmol). Following work-up, the resulting solid was crystallised (methanol/ hexane) to yield the title 
compound (9.17 g, 36.2 mmol, 71%) as pale yellow crystals; m.p. 68.5-69.0  C (methanol/ hexane); 
δH (300 MHz,CDCl3) 1.06 (6H, d, J =  6.9, Hγ), 2.16 (1H, sept, J = 6.6, Hβ), 3.93 (2H, d, J = 6.3, Hα), 
3.96 (3H, s, CO2Me), 7.66 (1H, dd, J = 8.4, 1.5, H6), 7.72 (1H, d, J = 1.5, H2), 7.81 (1H, d, J =8.4, 
H5); δC (75MHz, CDCl3) 17.5, 28.6, 51.2, 74.4, 113.8, 119.5, 123.6, 133.1, 140.8, 150.5, 163.7; 
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υmax/cm
-1
 (solid state) = 2955, 1726, 1609, 1524, 1237, 750; ESI-HRMS found m/z 276.0851 
[M+Na]
+
, C12H15NNaO5 requires 276.0842;  
Methyl 4-amino-3-isobutoxybenzoate 17b 
Procedure C; Methyl 3-isobutoxy-4-nitrobenzoate 16b (5.00 g, 19.7 mmol), tin(II) chloride dihydrate 
(26.73 g, 118.5 mmol) in ethyl acetate (150 mL). Following standard work-up the resulting solid was 
crystallised (dichloromethane/ hexane) to yield the title compound (3.36 g, 15.1 mmol, 76%) as 
colourless crystalline plates; m.p. 62.3-63.5  C (dichloromethane/ hexane); (Found C, 64.30; H, 7.65; 
N, 6.35%. C12H17NO3 requires C, 64.55; H, 7.67; N, 6.27%); δH (300 MHz, CDCl3) 1.05 (6H, d, J = 
6.6, Hγ), 2.13 (1H, sept, J = 6.6, Hβ), 3.82 (2H, d, J = 6.3, Hα), 3.86 (3H, s, CO2Me), 4.24 (2H, s, 
NH2), 6.67 (1H, d, J = 8.4, H5), 7.43 (1H, d, J = 1.5, H2), 7.53 (1H, dd, J = 8.4, 1.5, H6); δC (75MHz, 
CDCl3) 19.8, 28.7, 52.1, 75.1, 112.4, 113.5, 119.8, 124.3, 141.6, 146.0, 167.8; υmax/cm
-1
 (solid state) = 
3461, 3342, 2950, 1688, 1622, 1523, 1441, 1269, 1034, 766, 635; ESI-HRMS found m/z 224.1287 
[M+H]
+
, C12H18NO3 requires 224.1281; 
4-Amino-3-isobutoxybenzoic acid 18b 
Procedure F; Methyl 4-amino-3-isobutoxybenzoate 17b (1.80 g, 8.1 mmol) in a 1:1 mixture of 
methanol-tetrahydrofuran (50 mL), 10% aqueous sodium hydroxide (17 mL). Following acidification, 
the precipitate was filtered, dissolved in chloroform and dried with magnesium sulfate. The solution 
was filtered and the organic solvents removed under reduced pressure yielding a pink solid which was 
crystallised (dichloromethane/ hexane) to yield the title compound (1.22 g, 5.8 mmol, 72%) as pale 
pink microcrystals; m.p. 118.7-119.6  C (dichloromethane/ hexane); (Found C, 63.15; H, 7.15; N, 
6.60%. C11H15NO3 requires C, 63.14; H, 7.23; N, 6.69%); δH (300 MHz, CDCl3) 1.08 (6H, d, J = 6.7, 
Hγ), 2.16 (1H, sept, J = 6.7, Hβ), 3.85 (2H, d, J = 6.6, Hα), 6.71 (1H, d, J = 8.2, H5), 7.5 (1H, d, J = 
1.8, H2), 7.65 (1H, dd, J = 8.1, 1.8, H6); δC (75MHz, CDCl3) 19.4, 28.3, 74.7, 112.4, 113.0, 118.4, 
124.9, 142.1, 145.5, 172.4; υmax/cm
-1
 (solid state) = 3497, 3384, 2813, 1659, 1611, 1306, 765; ESI-
HRMS found m/z 210.1122 [M+H]
+
, C11H16NO3 requires 210.1125. 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-isobutoxybenzoic acid 14b 
Procedure H; 4-Amino-3-isobutoxybenzoic acid 18b (3.00 g, 14.3 mmol) in tetrahydrofuran (100 
mL), fluorenylmethyloxycarbonyl chloride (5.56 g, 21.5 mmol) in tetrahydrofuran (50 mL). Work up 
yielded the title compound (5.25 g, 12.2 mmol, 85%) as a colourless amorphous solid; (Found C, 
72.10; H, 5.80; N, 3.15%. C26H25NO5 requires C, 72.37; H, 5.84; N, 3.25%); δH (300 MHz, DMSO-
d6) 1.04 (6H, d, J = 6.7, Hγ), 2.15 (1H, sept, J = 6.6, Hβ), 3.84 (2H, d, J = 6.6, Hα), 4.26 (1H, t, J = 
7.0, FHβ), 4.46 (2H, d, J = 7.0, FHα), 7.26 (2H, t, J = 7.5, FHAr4), 7.36 (2H, t, J = 7.5, FHAr3), 7.48-
7.51 (2H, m, H5 + H2), 7.56 (2H, d, J = 7.3, FHAr5), 7.67-7.74 (3H, m, H6 + FHAr2) 8.08 (1H, br. s, 
NH); δC (125MHz, DMSO-d6) 18.9, 27.5, 46.4, 66.3, 74.6, 112.3, 120.1, 120.3, 122.1, 125.1, 126.0,  
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127.0, 127.7, 131.3, 140.7, 143.6, 148.6, 153.3, 166.9; υmax/cm
-1
 (solid state) = 3337, 2955,  1710, 
1677, 1435, 1290, 736; ESI-HRMS found m/z 454.1615 [M+Na]
+
, C26H25NNaO5 requires 454.1625. 
Methyl 3-(cyclopropylmethoxy)-4-nitrobenzoate 16c 
Procedure A; Methyl-3-hydroxy-4-nitrobenzoate 15 (10.00 g, 50.7 mmol), potassium carbonate (2l.00 
g, 151.9 mmol) in dimethylformamide (200 mL), (bromomethyl)cyclopropane (5.91 mL, 60.9 mmol). 
Following work-up the resultant yellow solid which was crystallised (ethyl acetate) to yield the title 
compound (10.34 g, 41.2 mmol, 81 %) as large pale yellow rectangular crystals; m.p. 93.7-95.1  C 
(ethyl acetate); (Found C, 57.30; H, 5.20; N, 5.55%. C12H13NO5 requires C, 57.37; H, 5.22; N, 
5.58%); δH (300 MHz, CDCl3) 0.43 (2H, m, Hγ), 0.70 (2H, m, Hγ'), 1.34 (1H, m, Hβ), 3.99 (3H, s, 
CO2Me), 4.07 (1H, d, J = 6.8, Hα) 7.70 (1H, dd, J = 8.2, 1.5, H2), 7.74 (1H, d, J = 1.6, H6), 7.83 (1H, 
d, J = 8.3, H5); δC (75MHz, CDCl3) 3.74, 10.3, 53.2, 75.0, 116.4, 121.7, 125.6, 135.1, 143.2, 152.2, 
165.7; υmax/cm
-1
 (solid state) = 3111, 1726, 1607, 1522, 1307, 1247, 750; ESI-HRMS found m/z 
274.0689 [M+Na]
+
, C12H13NaNO5 requires 274.0686. 
Methyl 4-amino-3-(cyclopropylmethoxy)benzoate 17c 
Procedure C; Methyl 3-(cyclopropylmethoxy)-4-nitrobenzoate 16c (10.00 g, 39.8 mmol), tin(II) 
chloride dihydrate (53.89 g, 238.9 mmol) in ethyl acetate (150 mL). Following work-up, the resulting 
solid was crystallised (ethyl acetate/ hexane) to yield the title compound (5.77 g, 26.1 mmol, 65%) as 
colourless microcrystals; m.p. 81.5-82.4  C (ethyl acetate/ hexane); (Found C, 65.05; H, 6.85; N, 
6.35%. C12H15NO3 requires C, 65.14; H, 6.83; N, 6.33%); δH (300 MHz, CDCl3) 0.29 (2H, m, Hγ), 
0.56 (2H, m, Hγ'), 1.22 (1H, m, Hβ), 3.78 (3H, s, CO2Me), 3.81 (2H, d, J = 7.1, Hα), 4.20 (2H, br. s, 
NH2), 6.59 (1H, d, J = 8.1, H5), 7.34 (1H, d, J = 1.7, H2), 7.46 (1H, dd, J = 8.1, 1.7, H6); δC (75MHz, 
CDCl3) 3.6, 10.7, 52.1, 73.7, 113.0, 113.6, 119.8, 124.4, 141.8, 145.9, 167.7; υmax/cm
-1
 (solid state) = 
3491, 3355, 2998, 1682, 1614, 1296, 762; ESI-HRMS found m/z 222.1130 [M+H]
+
, C12H16NO3 
requires 222.1125. 
4-Amino-3-(cyclopropylmethoxy)benzoic acid 18c 
Procedure F; Methyl 4-amino-3-(cyclopropylmethoxy)benzoate 17c (4.64 g, 20.1 mmol) in a 1:1 
mixture of methanol : tetrahydrofuran (120 mL), 10% aqueous sodium hydroxide (30 mL). The 
resulting precipitate was filtered, dissolved in chloroform and dried with magnesium sulfate. The 
solution was filtered and the organic solvents removed under reduced pressure yielding a beige solid 
which was crystallised (chloroform/ methanol/ hexane) to yield the title compound (3.65 g, 17.6 
mmol, 84%) as large pale orange crystals; m.p. 154.5-155.9  C (chloroform/ methanol/ hexane); 
(Found C, 63.25; H, 6.25; N, 6.65%. C11H13NO3 requires C, 63.76; H, 6.32; N, 6.76%); δH (300 MHz, 
CDCl3) 0.40 (2H, m, Hγ), 0.69 (2H, m, Hγ'), 1.33 (1H, m, Hβ), 3.95 (2H, d, J = 7.0, Hα), 6.72 (1H, d, 
J = 7.3, H5), 7.50 (1H, d, J = 1.7, H2), 7.66 (1H, dd, J = 7.3, 1.7, H6); δC (75MHz, CDCl3) 3.6, 10.7, 
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73.8, 113.3, 113.5, 118.8, 125.5, 142.7, 145.8, 172.8;  υmax/cm
-1
 (solid state) = 3501, 3383, 2900, 
1666, 1614, 1305, 765; ESI-HRMS found m/z 208.0962 [M+H]
+
, C11H14NO3 requires 208.0968. 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(cyclopropylmethoxy)benzoic acid 14c  
Procedure H; 4-Amino-3-(cyclopropylmethoxy)benzoic acid 18c (3.13 g, 15.1 mmol) in 
tetrahydrofuran (100 mL), fluorenylmethyloxycarbonyl chloride (5.87 g, 22.7 mmol) in chloroform 
(30 mL). Work up yielded the title compound (5.26 g, 12.3 mmol, 81%) as a colourless amorphous 
solid; (Found C, 72.55; H, 5.25; N, 2.95%. C26H23NO5 requires C, 72.71; H, 5.40; N, 3.26%); δH (300 
MHz, CDCl3) 0.42 (2H, m, Hγ), 0.73 (2H, m, Hγ'), 1.37 (1H, m, Hβ), 3.98 (2H, d, J = 7.1, Hα), 4.37 
(1H, t, J = 6.8, FHβ), 4.58 (2H, d, J = 6.9, FHα), 7.36 (2H, t, J = 7.4, FHAr4), 7.45 (2H, t, J = 7.4, 
FHAr3), 7.57 (1H, d, J = 1.7, H2), 7.66-7.69 (3H, m, H5 + FHAr5), 7.75 (1H, d, J = 8.5, H6), 7.82 
(2H, d, J = 7.4, FHAr2); δC (75MHz, CDCl3) 3.7, 10.6, 47.5, 67.8, 74.5, 113.0, 117.6, 120.5, 124.3, 
124.5, 125.4, 127.6, 128.3, 133.0, 141.8, 144.1, 146.9, 153.5, 169.9; υmax/cm
-1
 (solid state) = 3329, 
2807,1707, 1675, 1541, 1250, 735; ESI-HRMS found m/z 430.1628 [M+H]
+
, C26H24NO5 requires 
430.1649. 
Methyl 3-(sec-butoxy)-4-nitrobenzoate 16d 
Procedure B; Methyl-3-hydroxy-4-nitro-benzoate 15 (2.42 g, 12.28 mmol), S(+)-sec-butanol (1.00 g, 
13.5 mmol), triphenylphosphine (4.82 g, 18.4 mmol) with diisopropyl azodicarboxylate (3.61 mL, 
18.4 mmol) in tetrahydrofuran (80 mL). Work up followed by column chromatography yielded the 
product (2.73 g, 10.81 mmol, 88%) as a pale yellow liquid; δH (500 MHz, CDCl3) 1.00 (3H, t, J = 7.4, 
Hγ), 1.36 (3H, d, J = 6.1, CHα(CH3)), 1.69-1.83 (2H, m, Hβ + Hβ'), 3.96 (3H, s, CO2Me), 4.56 (1H, 
m, Hα), 7.64 (1H, d, J = 8.3, H6), 7.73 (1H, s, H2), 7.76 (1H, d, J = 8.3, H5); δC (125MHz, CDCl3) 
9.5, 18.9, 29.0, 52.8, 77.7, 116.7, 120.9, 125.1, 134.4, 143.6, 151.1, 165.4, υmax/cm
-1
 (solid state) = 
2980, 1731, 1606, 1531, 1294, 1108, 1094; ESI-HRMS found m/z 276.0823[M+Na]
+
, C12H15NO5 
requires 276.0842.   
4-((((9H-Fluoren-9-yl) methoxy)carbonyl)amino)-3-(sec-butoxy)benzoic acid 14d 
4-Amino-3-(sec-butoxy)benzoic acid 18d was obtained from methyl 4-amino-3-(sec-butoxy)benzoate 
17d by procedure F without purification/ isolation. Methyl 4-amino-3-(sec-butoxy)benzoate 17d was 
in turn obtained from methyl 3-(sec-butoxy)-4-nitrobenzoate 16d by procedure C without 
purification/ isolation. Procedure H; 4-amino-3-(sec-butoxy)benzoic acid 17d (2.00 g, 9.56 mmol) in 
tetrahydrofuran (100 mL), fluorenylmethyloxycarbonyl chloride (3.45 g, 13.4 mmol) in 
tetrahydrofuran (30 mL).  The crude material obtained after the reaction was purified by colum 
chromatography to yield the title compound (3.18 g, 7.37 mmol, 77%) as an off-white amorphous 
solid; (Found C, 71.60; H, 5.90; N, 3.10%. C26H25N1O5 requires C, 72.37; H, 5.84; N, 3.25%); δH (500 
MHz,CDCl3) 1.05 (3H, t, J = 7.4, Hγ), 1,39 (3H, d, J = 6.0, CHαCH3), 1.75 (1H, m, Hβ), 1.84 (1H, m, 
Hβ'), 4.34 (1H, t, J = 7.0, FHβ), 4.48-4.53 (3H, m, Hα + FHα), 7.33 (2H, t, J = 7.3, FHAr4), 7.43 (2H, 
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t, J = 7.3,FHAr3), 7.56-7.63 (4H, m, H2, H5 + FHAr5), 7.74 (1H, d, J = 8.5, H6), 7.80 (2H, d, J  = 
7.5, FHAr2), 8.15 (1H br. s, NH); δC (125MHz, CDCl3) 9.7, 19.3, 29.1, 47.1, 67.5, 113.7, 117.4, 
120.1, 123.0, 124.1, 125.0, 127.2, 127.9, 133.7, 143.7, 145.5, 153.0, 171.7, υmax/cm
-1
 (solid state) = 
3427, 2960, 2565, 1747, 1690, 1595, 1535, 1483, 1416, 1345, 1301, 1213, 1189, 1058; []D
24
 -12.8 
(c = 1, chloroform); ESI-HRMS found m/z 430.1660 [M-H]-, C26H24NO5 requires 430.1654.  
Methyl 4-amino-3-(benzyloxy)benzoate 17e 
Procedure C; Methyl-3-benzyloxy-4-nitrobenzoate 16e (4.00 g, 13.9 mmol), tin(II) chloride dihydrate 
(18.84 g, 83.6 mmol) in ethyl acetate (100 mL). Following initial work-up, the solvents were removed 
under reduced pressure and the resultant orange oil was passed through a bed of silica (20% diethyl 
ether / dichloromethane) and the solvents removed. The resultant solid was crystallised from hexane 
to yield the title compound (2.58 g, 10.0 mmol, 72%) as colourless square plates; m.p. 82.2-83.6  C 
(hexane); (Found C, 69.75; H, 5.85; N, 5.2%. CHN requires C, 70.02; H, 5.88; N, 5.44%); δH (300 
MHz, CDCl3), 3.90 (3H, s, CO2Me), 4.34 (2H, br s, NH2), 5.14 (2H, s, Hα), 6.72 (1H, d, J = 6.6, H5), 
7.30-7.50 (5H, m, HAr2, HAr3 + HAr4), 7.60-7.63 (2H, m, H6 + H2); δC (75 MHz, CDCl3) 52.1, 
70.9, 113.1, 113.7, 119.7, 124.8, 128.2, 128.6, 129.0, 137.1, 141.9, 145.7, 167.7; υmax/cm
-1
 (solid 
state) = 3517, 3395, 2930, 1688, 1432, 1279, 1128, 796; ESI-HRMS found m/z 258.1117 [M+H]
+
, 
C15H16NO3 requires 258.1125. 
4-Amino-3-(benzyloxy)benzoic acid 18e   
Procedure F; Methyl 4-amino-3-(benzyloxy)benzoate 17e (5.44 g, 21.1 mmol), in a 1:1 mixture of 
methanol: tetrahydrofuran (135 mL), 10% aqueous sodium hydroxide (40 mL). Following 
acidification, the precipitate was filtered, dissolved in chloroform and dried (magnesium sulphate). 
This solution was then filtered and the organic solvents removed under reduced pressure to yield the 
title compound (3.90g, 16.0 mmol, 76%) as a colourless amorphous powder; δH (300 MHz, MeOD-d4) 
5.17 (2H, s, Hα), 6.75 (1H, d, J = 4.9, H5), 7.34 (1H, t, J = 4.5, HAr4), 7.39-7.42 (2H, t, J = 4.5, 
HAr3), 7.49-7.53 (4H, m, H6, H2 + HAr2); δC (75MHz, MeOD-d4) 70.4, 113.0, 113.1, 118.5, 124.8, 
127.6, 127.9, 128.5, 137.4, 143.2, 145.3, 169.5;  υmax/cm
-1
 (solid state) 3353, 2920, 2256, 1690, 1619, 
1522, 1442, 1252, 1146, 1024, 879; ESI-HRMS found m/z 244.0973 [M+H]
+
, C14H14NO3 requires 
244.0986; 
4-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-3-(benzoyloxy)benzoic acid 14e 
Procedure H; 4-Amino-3-(benzyloxy)benzoic acid 18d (7.00 g, 28.8 mmol) in tetrahydrofuran (100 
mL), fluorenylmethyloxycarbonyl chloride (11.17 g, 43.2 mmol) in tetrahydrofuran (100 mL). 
Following work up, the resulting solid was crystallised  from a 1.5:1 solution of chloroform / 
methanol to yield the title compound (12.32 g, 26.5 mmol, 92%) as colourless microcrystals; m.p. 
242.3-243.8  C (chloroform / methanol); δH (500 MHz, DMSO-d6) 4.37 (1H, t, J = 6.9, FHβ), 4.50 
(2H, d, J = 6.9, FHα), 5.31 (2H, s, Hα), 7.36-7.40 (3H, m, HAr4 +FHAr4), 7.43-7.50 (4H, m, HAr3 + 
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FHAr3), 7.56-7.58 (3H, m, H5 + HAr2), 7.62 (1H, s, H2), 7.75-7.81 (3H, m, H6 + FHAr5) 7.96 (2H, 
d, J =7.5, FHAr2), 8.96 (1H, br. s, NH); δC (125MHz, DMSO-d6); 46.9, 66.7, 70.3, 113.5, 120.5, 
121.2, 122.8, 125.6, 126.5, 127.4, 127.6, 128.1, 128.8, 132.1, 137.1, 141.1, 144.0, 146.4, 148.7, 153.8, 
167.2; υmax/cm
-1
 (solid state) = 3332, 2891, 1671, 1597, 1501, 1435, 1346, 1217, 1104, 984, 878;  ESI-
HRMS found m/z 488.1488 [M+Na]
+
, C29H23NNaO5 requires 488.1468; 
Methyl 3-((4-(tert-butyl)benzyl)oxy)-4-nitrobenzoate 16f  
Procedure A; Methyl-3-hydroxy-4-nitro-benzoate 15 (3.40 g, 17.3 mmol) potassium carbonate (7.15 
g, 51.7 mmol), in dimethlyformamide (70 mL), 4-tert butyl benzyl bromide (4.10 mL, 22.4 mmol). 
Work up yielded the title compound (5.98 g, 169.0 mmol, 98%) as a pale yellow amorphous solid; 
(Found C, 66.25; H, 6.35; N, 4.10%. C19H21N1O5 requires C, 66.46; H, 6.16; N, 4.08%); δH (500 
MHz, CDCl3) 1.33 (9H, s, C(CH3)3), 3.96 (3H, s, CO2Me), 5.25 (2H, s, Hα), 7.44-7.39 (4H, m, HAr2 
+ HAr3), 7.73 (1H, dd, J = 8.4, 1.3, H6), 7.86-7.88 (2H, m, H2 + H5); δC (75MHz, CDCl3) 31.3, 34.7, 
52.8, 71.4, 116.1, 121.6, 125.3, 125.7, 127.2, 132.0, 134.8, 142.9, 151.55, 151.58, 165.2; υmax/cm
-1
 
(solid state) = 2963, 1725, 1608, 1538, 1439, 1372, 1291, 1247, 1111, 1087; ESI-HRMS found m/z 
366.1315 [M+Na]
+
, C19H21NNaO5 requires 366.1317. 
Methyl 4- amino-3-((4-(tert-butyl) benzyl)oxy)-4-nitrobenzoate 17f 
Procedure C: Methyl 3-((4-(tert-butyl)benzyl)oxy)-4-nitrobenzoate 16f (5.70 g, 16.6 mmol), tin(II) 
chloride dihydrate (18.60 g, 82.7 mmol) in ethyl acetate (120 mL).  Work up yielded the title 
compound (4.59 g, 14.7 mmol, 88%) as a yellow amorphous solid; δH (500 MHz, CDCl3) 1.35 (9H, s, 
C(CH3)3), 3.88 (3H, s, CO2Me), 4.26 (2H, br. s, NH2), 5.09 (2H, s, Hα), 6.69 (1H, d, J = 8.4, H5), 
7.39-7.45 (4H, m, HAr2 + HAr3), 7.57-7.59 (2H, m, H2 + H6); δC (125MHz, CDCl3) 31.4, 34.6, 51.7, 
70.4, 112.6, 113.3, 119.5, 124.3, 125.6, 127.8, 133.7, 141.4, 145.4, 151.3, 167.3; υmax/cm
-1
 (solid 
state) = 3476, 3352, 3199, 2958, 1682, 1620, 1593, 1523, 1441, 1316, 1151, 1109, 1034; ESI-HRMS 
found m/z 336.1577 [M+Na]
+
, C19H23NNaO5 requires 336.1576. 
4- Amino-3-((4-(tert-butyl)benzyl)oxy)-4-nitrobenzoic acid 18f 
Procedure F; 4-amino-3-((4-(tert-butyl)benzyl)oxy)-4-nitrobenzoicacid 17f (4.50 g, 14.3 mmol) in a 
1:1 mixture of methanol-tetrahydrofuran (110 mL), 10% aqueous sodium hydroxide (25  mL). Work 
up yielded the title compound (4.05 g, 13.5 mmol, 94%) as a beige amorphous solid; δH (500 MHz, 
CDCl3) 1.35 (9H, s, C(CH3)3), 5.11 (2H, s, Hα), 6.71 (1H, d, J = 8.0, H5), 7.39-7.45 (4H, m, HAr2 + 
HAr3), 7.62 (1H, d, J = 1.5, H2), 7.66 (1H, dd, J = 8.0, 1.5, H6); υmax/cm
-1
 (solid state) = 3468, 3367, 
2962, 1671, 1614, 1519, 1442, 1407, 1370, 1442, 1407, 1370, 1220, 1148, 1107; ESI-HRMS found 
m/z 322.1414 [M+Na]
+
, C18H21NNaO3 requires 322.1419. 
4-((((9H-Fluoren-9-yl) methoxy)carbonyl)amino)-3-((4-(tert-butyl)benzyl)oxy)benzoic acid  14f 
Procedure H; 4-amino-3-((4-(tert-butyl) benzyl)oxy)-4-nitrobenzoicacid 18f (3.50 g, 11.7 mmol) in 
tetrahydrofuran (70 mL), fluorenylmethyloxycarbonyl chloride (4.53 g, 17.5 mmol) in tetrahydrofuran 
Chapter 6: Experimental Section 
 
112 
 
(45 mL). Work up yielded the title compound (5.20 g, 10.0 mmol, 85%) as a white amorphous solid; 
(Found C, 75.85; H, 6.00; N, 2.60%. C33H31NO5 requires C, 75.99; H, 5.99; N, 2.69%); δH (500 MHz, 
CDCl3) 1.37 (9H, s, C(CH3)3), 4.31 (1H, t, J = 7.0, FHβ ), 4.52 (2H, d, J = 7.0, FHα), 5.17 (2H, s, 
Hα), 7.31(2H, t, J = 7.5, FHAr4), 7.39-7.42 (4H, m, HAr3 + FHAr3), 7.48 (2H, d, J = 8.2, HAr2), 
7.56 (1H, m, H5), 7.60 (2H, d, J = 7.6, FHAr5),  7.71 (1H, s, H2), 7.77-7.79 (3H, m, H6 + FHAr2); δC 
(75MHz, CDCl3) 31.3, 34.7, 46.9, 67.4, 70.9, 112.5, 117.3, 120.1, 123.2, 124.6, 125.0, 125.8, 127.1, 
127.75, 127.8, 132.7, 133.0, 141.3, 143.6, 146.3, 151.7, 152.9, 171.2; υmax/cm
-1
 (solid state) = 3430, 
2958, 1740, 1681, 1595, 1534, 1489, 1351, 1242, 1224, 1199, 1058; ESI-HRMS found m/z 520.2139 
[M-H]
-
, C33H30NO5 requires 520.2124. 
Methyl 3-((4-chlorobenzyl)oxy)-4-nitrobenzoate 16g 
Procedure A; Methyl-3-hydroxy-4-nitrobenzoate 15 (10.00 g, 50.7 mmol), potassium carbonate (2l.0 
g, 151.9 mmol) in dimethylformamide (200 mL), 1-(bromomethyl)-4-chlorobenzene (12.5 g, 60.8 
mmol). Following work-up, the resulting solid was crystallised (dichloromethane/ methanol) to yield 
the title compound (14.83 g, 46.1 mmol, 91%) as pale yellow crystalline plates; m.p. 133.7-134.8 C 
(dichloromethane/ methanol); (Found C, 55.75; H, 3.70; N, 4.30%. C15H12NO5Cl requires C, 56.00; 
H, 3.76; N, 4.35%); δH (300 MHz, CDCl3) 4.00 (3H, s, CO2Me), 5.29 (2H, s, Hα), 7.42 (4H, m, HAr2 
+ HAr3), 7.76 (1H, d, J = 8.4, H6), 7.84 (1H, s, H2), 7.90 (1H, d, J = 8.4, H5); δC (75MHz, CDCl3) 
53.4, 71.0, 116.3, 122.4, 125.9, 128.9, 129.4, 133.9, 134.7, 135.3, 142.9, 151.6, 166.5; υmax/cm
-1
 (solid 
state) =3059, 1726. 1610, 1524, 1296, 1035, 808, 485; ESI-HRMS found m/z 344.0306 [M+Na]
+
, 
C15H12ClNNaO5 requires 344.0296. 
Methyl 4-amino-3-((4-chlorobenzyl)oxy)benzoate 17g 
Procedure C; Methyl 3-((4-chlorobenzyl)oxy)-4-nitrobenzoate 16g (5.00 g, 15.5 mmol), tin(II) 
chloride dihydrate (21.00 g, 93.1 mmol) in ethyl acetate (100 mL). Following work up, the resulting 
solid was crystallised (dichloromethane/ hexane) to yield the title compound (3.03 g, 10.4 mmol, 
67%) as pale yellow microcrystals; m.p. 118.9-119.6 C (dichloromethane/ hexane); (Found C, 61.80; 
H, 4.75; N, 4.70%. C15H14ClNO3 requires C,61.76; H, 4.84; N, 4.80%); δH (300 MHz, CDCl3) 3.86 
(3H, s, H CO2Me), 4.25 (2H, s, NH2), 5.09 (2H, s, Hα), 6.69 (1H, d, J = 8.1, H5), 7.37 (4H, m, HAr2 
+ HAr3), 7.52 (1H, d, J = 1.5, H2), 7.57 (1H, dd, J = 8.1+ 1.5, H6); δC (125MHz, CDCl3) 50.1, 68.1, 
111.0, 111.8, 117.9, 122.9, 127.2, 127.5, 132.4,  133.5, 139.7, 143.4, 165.5; υmax/cm
-1
 (solid state) = 
3502, 3380, 2944, 1690, 1445, 1292, 1104, 800, 484; ESI-HRMS found m/z 292.0740 [M+H]
+
, 
C15H15ClNO3 requires 292.0735. 
4-Amino-3-((4-chlorobenzyl)oxy)benzoic acid 18g 
Procedure F; Methyl 4-amino-3-((4-chlorobenzyl)oxy)benzoate 17g (2.34 g, 8.02 mmol) in a 1:1 
mixture of methanol-tetrahydrofuran (60 mL), 10% aqueous sodium hydroxide (18 mL). The resulting 
precipitate was filtered, dissolved in chloroform and dried with magnesium sulfate. The solution was 
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filtered and the organic solvents removed under reduced pressure yielding the title compound (2.06 g, 
7.4 mmol, 93%) as a colourless amorphous solid; (Found C, 60.60; H, 4.40; N, 4.90%. C14H12ClNO3 
requires C, 60.55; H, 4.36; N, 5.04%); δH (500 MHz, MeOD-d4) 5.16 (2H, s, Hα), 6.74 (1H, d, J = 8.5, 
H5), 7.40 (2H, d, J = 8.5, HAr3), 7.49 (2H, d, J = 8.5, HAr2), 7.51-7.54 (2H, m, H6 + H2); δC 
(125MHz, MeOD-d4) 70.6, 114.2,  114.2, 119.5, 126.0, 129.7, 130.3, 134.8, 137.4, 144.4, 146.2, 
170.5; υmax/cm
-1
 (solid state) = 3438, 3293, 2563, 1688, 1296, 764, 495; ESI-HRMS found m/z 
278.0565 [M+H]
+
, C14H13ClNO3 requires 278.0578. 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-((4-chlorobenzyl)oxy)benzoic acid 14g 
Procedure H; 4-Amino-3-((4-chlorobenzyl)oxy)benzoic acid 18g (1.92 g, 6.9 mmol) in 
tetrahydrofuran (100 mL), fluorenylmethyloxycarbonyl chloride (2.68 g, 10.4  mmol) in chloroform 
(30 mL). Work up yielded the title compound (2.93 g, 5.9 mmol, 85%) as a colourless amorphous 
solid; (Found C, 69.65; H, 4.40; N, 2.65%. C29H22ClNO5 requires C, 69.67; H, 4.44; N, 2.80%); δH 
(300 MHz, DMSO-d6) 4.32 (1H, t, J = 6.9, FHβ), 4.46 (2H, d, J = 6.9, FHα), 5.25 (2H, s, Hα), 7.32 
(2H, t, J = 7.5, FHAr4), 7.29-7.35 (4H, m, HAr3 + FHAr3), 7.41-7.58 (4H, m, H5, H2 + HAr2), 7.69 
(1H, d, J = 8.2, H6), 7.74 (2H, d, J = 7.5, FHAr5), 7.91 (2H, d, J = 7.5, FHAr2), 9.01 (1H, s, NH); δC 
(75MHz, DMSO-d6) 46.5, 66.2, 69.0, 113.1, 120.1, 121.1, 122.5, 125.2, 126.2, 127.1, 127.7, 128.4, 
129.3, 131.7, 132.4, 135.8, 140.7, 143.7, 148.3, 153.5, 166.8; υmax/cm
-1
 (solid state) = 3305, 2805, 
1697, 1678, 1544, 1256, 739, 484; ESI-HRMS found m/z 522.1065 [M+Na]
+
, C29H22ClNaNO5 
requires 522.1079. 
Methyl 4-amino-3-(naphthalen-2-ylmethoxy)benzoate 17h 
Procedure C; Methyl-3-(2-napthyl)methoxy-4-nitrobenzoate 16h (6.25 g, 18.5 mmol), tin(II) chloride 
dihydrate (25.00 g, 110.8 mmol) in ethyl acetate (130 mL). Work afforded the title compound (4.38 g, 
14.3 mmol, 77%) as a cream amorphous solid; (Found C, 74.4; H, 5.55; N, 4.35%. C19H17NO3 
requires C, 74.25.; H, 5.58; N, 4.65%); δH (500 MHz, CDCl3) 3.83 (3H, s, CO2Me), 4.31 (2H, br s, 
NH2), 5.26 (2H, s, Hα), 6.67 (1H, d, J = 8.1, H5), 7.45-7.60 (5H, m, HAr), 7.80-7.86 (4H, m, HAr); δC 
(75MHz, CDCl3) 52.0, 71.1, 113.1, 113.7, 119.7, 124.8, 125.9, 126.6, 126.7, 127.1, 128.1, 128.4, 
128.8, 133.6, 133.7, 134.5, 142.0, 156.7, 167.6; υmax/cm
-1
 (solid state) = 3373, 2862, 1698, 1618, 
1440, 1254, 1023; ESI-MS found m/z 308 [M+H]
+
; 
4-Amino-3-(naphthalen-2-ylmethoxy)benzoic acid 18h 
Procedure F; Methyl 4-amino-3-(naphthalen-2-ylmethoxy)benzoate 17h (4.00g, 13.0 mmol) in a 1:1 
mixture of methanol-tetrahydrofuran (100 mL), 10% aqueous sodium hydroxide (25 mL). Following 
acidification, the precipitate was filtered, dissolved in chloroform and dried with magnesium sulfate. 
This solution was filtered and the organic solvents removed under reduced pressure and the solid was 
crystallised (chloroform/ methanol) to yield the title compound (3.19 g, 10.9 mmol, 84 %) as a 
colourless microcrystals; m.p. 161.8-163.5 (chloroform/ methanol); δH (500 MHz, DMSO-d6) 5.32 
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(2H, s, Hα), 6.70 (1H, d, J = 8.2, H5), 7.38 (1H, d, J = 8.2, HAr), 7.45 (1H, s, H2), 7.50-7.54 (2H, m, 
HAr), 7.63 (1H, d, J =  8.1, H6), 7.91-7.95 (3H, m, HAr), 8.04 (1H, s, HAr); δC (75 MHz, DMSO-d6); 
69.8, 112.9, 113.1, 117.7, 124.6, 125.8, 126.1, 126.4 126.6, 127.9, 128.1, 128.3, 132.9, 133.2, 135.2, 
143.3, 144.4, 167.9; υmax/cm
-1
 (solid state) = 3401, 3000, 1678, 1613, 1521, 1441, 1263, 1149, 1025, 
764; ESI-HRMS found m/z 316. 0983 [M+Na]
+
, C18H15NNaO3 requires 316.0944; 
 4-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-3-(naphthalen-2-ylmethoxy)-benzoic acid 14h 
Procedure H; 4-Amino-3-(naphthalen-2-ylmethoxy)benzoic acid 18h (3.10 g, 10.6 mmol) in 
tetrahydrofuran (150 mL), fluorenylmethyloxycarbonyl chloride (4.10 g, 15.9 mmol) in 
tetrahydrofuran (50 mL). Following work up, the resulting solid which was crystallised  (chloroform/ 
methanol) to yield the title compound (5.22 g, 9.1 mmol, 96%) as colourless microcrystals; m.p. 
201.1-202.3  C (chloroform/ methanol); δH (300 MHz, DMSO-d6) 4.31 (1H, t, J = 6.9, FHβ), 4.46 
(2H, d, J = 6.9, FHα), 5.36 (2H, s, Hα), 7.29 (2H, t, J = 7.4, FHAr4), 7.45 (2H, t, J = 5.4, FHAr3), 
7.50-7.56 (3H, m, HAr), 7.63 (1H, s, H2), 7.66 (1H, d, J = 8.4, H6), 7.72-7.74 (3H, m, ArCH), 7.85-
7.96 (5H, m, ArCH), 8.04 (1H, s, H8), 8.93 (1H, s, NH); δC (75 MHz, DMSO-d6); 46.9, 66.7, 70.4, 
113.6, 120.5, 121.3, 122.9, 125.6, 125.8, 126.4, 126.5, 126.7, 127.4, 128.0, 128.1, 128.2, 128.4, 132.2, 
132.9, 133.1, 132.7, 141.1, 144.0, 148.8, 153.8, 167.2; υmax/cm
-1
 (solid state) = 3423, 2927, 1673, 
1602, 1440, 1216, 1034, 816, 762; ESI-HRMS found m/z 516.1800 [M+H]
+
, C33H26NO5 requires 
516.1805. 
Methyl 4-nitro-3-(4-trifluoromethyl)benzyloxy)benzoate 16i                 
Procedure A; Methyl-3-hydroxy-4-nitrobenzoate 15 (1.00 g, 5.1 mmol), potassium carbonate (2.l0 g, 
15.2 mmol) in dimethylformamide (20 mL), 4-(trifluoromethyl) benzyl bromide (0.94 mL, 6.0 mmol) 
Following initial work-up, the solvents were removed under reduced pressure, dissolved in methanol, 
filtered to remove starting material and left to crystallise by slow evaporation to yield the title 
compound (1.05g, 3.0 mmol, 61%) as pale yellow plates; mp. 97.8-100.2°C (methanol); (Found C, 
54.25; H, 3.35; N, 3.80%. C16H12NO5F3 requires C, 54.09.; H, 3.40; N, 3.94%); δH (500 MHz, CDCl3) 
3.98 (3H, s, CO2Me), 5.26 (2H, s, Hα), 7.53 (d, 2H, J = 8.2, HAr3), 7.60 (2H, d, J = 8.2, HAr2), 7.67 
(1H, d, J = 8.2, H6), 7.74 (1H, s, H2),  7.81 (1H, d, J = 8.2, H5); δC (125 MHz, CDCl3); 54.7, 72.3, 
117.7, 124.0, 125.8 (q, J = 270), 127.4, 127.6, 129.0, 132.4 (q, J = 32.5), 136.8, 140.9, 144.6, 152.9, 
166.9;  υmax/cm
-1
 (solid state) = 3429, 2955, 1923, 1723 1591, 1334, 831, 590, 493; ESI-HRMS found 
m/z 378.0569 [M+Na]
+
, C16H12F3NNaO3 requires 378.0560; 
Methyl 4-amino-3-(4-(trifluoromethyl)benzyloxy)benzoate 17i 
Procedure C; Methyl 4-nitro-3-(4-trifluoromethyl)benzyloxy)benzoate 16i (1.00 g, 2.9 mmol), tin(II) 
chloride dihydrate (3.81 g, 16.9 mmol) in ethyl acetate (30 mL). Work up resulted in the title 
compound (0.93 g, 1.5 mmol, 97%) as a yellow amorphous solid; δH (500 MHz, MeOD-d4) 3.79 (3H, 
s, CO2Me) 4.19 (2H, s, NH2), 5.12 (2H, s, Hα), 6.63 (1H, d, J = 8.2, H5), 7.46 (1H, d, J = 1.4, H2), 
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7.49-7.52 (3H, m, H6 + HAr2), 7.59 (2H, d, J = 8.1, HAr3); δC (75 MHz, CDCl3) 52.6, 70.5, 113.5, 
114.4, 120.4, 125.5, 126.6, 128.6, 129.7, (q, J = 270), 131.0 (q, J = 32.3) 141.5, 142.1, 145.7, 170.0; 
υmax/cm
-1
 (solid state) = 3490, 3380, 2927, 1740, 1704, 1615, 1262, 1066, 705, 505; ESI-HRMS found 
m/z 326.0869 [M+H]
+
, C16H15F3NO3 requires 326.0999; 
4-Amino-3-(4-(trifluoromethyl)benzyloxy)benzoic acid 18i 
Procedure F; Methyl 4-amino-3-(4-(trifluoromethyl)benzyloxy)benzoate 17i (0.90 g, 2.7 mmol) in a 
1:1 mixture of methanol : tetrahydrofuran (24 mL), 10% aqueous sodium hydroxide (6.0 mL). 
Following acidification, the resulting precipitate was filtered, dissolved in chloroform and dried with 
magnesium sulfate. This solution was filtered and the organic solvents removed under reduced 
pressure yielding a pale yellow solid which was crystallised (chloroform) yielding the title compound 
(0.53 g, 1.7 mmol, 62%) as fine colourless microcrystals; m.p. 192.4 – 194.1°C (chloroform); δH (500 
MHz, MeOD-d4) 5.14 (2H, s, Hα), 6.63 (1H, d, J = 8.4, H5), 7.40-7.42 (2H, m, H6 + H2), 7.58 (4H, 
m, HAr2, + HAr3); δC (75 MHz, CDCl3) 70.9, 79.9, 114.6 (q, J =  8.0), 119.9, 126.1 (q, J = 269.3), 
126.5, 126.8 (q, J = 3.8), 129.2, 131.4 (q, J = 32.0), 143.5, 144.8, 146.4, 170.9; υmax/cm
-1
 (solid state) 
= 3434, 3291, 3116, 2926, 2526, 2159, 2026, 1688, 1296, 1108, 765; ESI-HRMS found m/z 312.0856 
[M+H]
+
, C15H13F3NO3 requires 312.0842; 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-((4-(trifluoromethyl)benzyl)oxy)benzoic acid 
14i 
Procedure H; 4-amino-3-(4-(trifluoromethyl)benzyloxy)benzoic acid 18i (0.46 g, 1.5 mmol) in 
chloroform (100 mL), fluorenylmethyloxycarbonyl chloride (0.58 g, 2.2 mmol) in chloroform (50 
mL). Work up yielded the title compound (0.60 g, 1.1 mmol, 76%) as a colourless amorphous solid; 
(Found C, 67.55; H, 4.05; N, 2.25%. C30H22F3NO5 requires C, 67.54; H, 4.16; N, 2.63%); δH (500 
MHz, DMSO-d6) 4.32 (1H, t, J = 6.9, FHβ), 4.46 (2H, d, J = 6.9, FHα), 5.37 (2H, s, Hα), 7.31 (2H, t, 
J = 7.5, FHAr4), 7.43 (2H, t, J = 7.5, FHAr3), 7.60 (2H, d, J = 10.5, H5 + H2), 7.70 (1H, d, J = 8.4, 
H6), 7.75 (6H, m, HAr2, HAr3 + FHAr5), 7.91 (2H, J = 6.3, FHAr2), 9.10 (1H, s, NH);  δC (75MHz, 
DMSO-d6) 46.7, 66.6, 69.3, 113.4, 120.4, 121.7, 122.8, 125.6, 126.7, 127.4, 128.1, 128.2, 128.5, 
129.1 (q, J = 30), 132.1, 141.1, 142.0, 144.0, 148.7, 153.9, 167.2; υmax/cm
-1
 (solid state) = 3309, 3200-
2200 (br), 1697, 1543, 1256, 1114, 739; ESI-HRMS found m/z 534.1500 [M+H]
+
, C30H23F3NO5 
requires 534.1523; 
Methyl 4-nitro-3-(3-trifluoromethyl)benzyloxy)benzoate 16j                  
Procedure A; Methyl-3-hydroxy-4-nitrobenzoate 15 (1.00 g, 5.1 mmol), potassium carbonate (2.l0 g, 
15.2 mmol) in dimethylformamide (20 mL), 3-(trifluoromethyl) benzyl bromide (0.94 mL, 6.0 mmol) 
Following preliminary work-up, the organic solvent was removed under reduced pressure and the 
solid dissolved in methanol, filtered to remove 4-(trifluoromethyl) benzyl bromide starting material 
and left to crystallise by slow evaporation to yield the title compound (1.25 g, 3.5 mmol, 69%) as pale 
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yellow microcrystals; m.p. 105.9 – 107.4 °C (methanol); (Found C, 54.10; H, 3.35; N, 3.80%. 
C16H12NO5F3 requires C, 54.09; H, 3.40; N, 3.94%); δH (500 MHz, CDCl3) 3.90 (3H, s, CO2Me), 5.26 
(2H, s, Hα), 7.48 (1H, apparent t, J = 7.5, HAr5), 7.55 (1H, d, J = 7.5, HAr4), 7.63 (1H, d, J = 7.5, 
HAr6), 7.66-7.68 (2H, m,  H6 + HAr2), 7.75 (1H, s, H2), 7.82 (1H, d, J = 8, H5); δC (75 MHz, 
CDCl3) 53.3, 71.0, 116.4 (d, J = 10.4), 122.6 (d, J = 11.8), 124.3 (q, J = 162.4), 124.3 (d, J = 9.3), 
125.9, 126.1, 129.8 (d, J = 11.7), 130.8 (d, J = 11.8), 131.5 (q, J = 19.4), 135.4, 136.5, 143.1, 151.5, 
165.4; υmax/cm
-1
 (solid state) = 3439, 2955, 1952, 1737, 1365, 1229; ESI-MS found 378.1 [M+Na]
+
; 
Methyl 4-amino-3-(3-(trifluoromethyl)benzyloxy)benzoate 17j 
Procedure C; Methyl 4-nitro-3-(3-trifluoromethyl)benzyloxy)benzoate 16j (1.00 g, 2.9 mmol), tin(II) 
chloride dihydrate (3.81 g, 16.9 mmol) in ethyl acetate (30 mL). Work-up yielded the title compound 
(0.93 g, 2.9 mmol, 97%) as a colourless amorphous solid; δH (300 MHz, CDCl3) 3.90 (3H, s, CO2Me), 
4.31 (2H, s, NH2), 5.21 (2H, s, Hα),  6.75 (1H, d, J = 8.1, H5), 7.54-7.62 (2H, m, H6 + HAr6), 7.64-
7.69, (3H, m, HAr2, HAr4 + HAr5), 7.76 (1H, s, H2); δC (75 MHz, CDCl3) 52.2, 70.2, 113.0, 113.9, 
119.9, 124.8, 124.9, 125.1, 125.4, 125.5, 131.4, 138.0, 141.7, 145.3, 167.6; υmax/cm
-1
 (solid state) = 
3492, 3356, 2957, 1888, 1772, 1691, 1614, 1266, 1110, 764; ESI-HRMS found m/z 348.0817 
[M+Na]
+
, C16H14F3NNaO3 requires 348.0818; 
4-Amino-3-(3-(trifluoromethyl)benzyloxy)benzoic acid 18j 
Procedure F; Methyl 4-amino-3-(3-(trifluoromethyl)benzyloxy)benzoate 17j (0.63 g, 1.9 mmol) in a 
1:1 mixture of methanol-tetrahydrofuran (20 mL), 10% aqueous sodium hydroxide (11 mL). 
Following acidification, the precipitate was filtered, dissolved in chloroform and dried with 
magnesium sulfate.. This solution was filtered and the organic solvents removed under reduced 
pressure yielding a pale yellow solid which was crystallised (chloroform) to yield the title compound 
(0.55 g, 1.8 mmol, 92%) as a colourless amorphous solid; (Found C, 57.40; H, 3.90; N, 4.25%. 
C15H12NO3F3 requires C, 57.88; H, 3.89; N, 4.50%); δH (300 MHz, MeOD-d4) 5.12 (2H, s, Hα), 6.63 
(1H, d, J = 8.7, H5), 7.39-7.42 (2H, m, H6 + HAr6), 7.44-7.53 (2H, m, H2 + HAr5), 7.64-7.68 (2H, 
m, HAr2 + HAr4); δC (75 MHz, MeOD-d4) 70.8, 114.5, 149.6, 119.8, 125.5, 126.0, 126.0 (q, J = 270), 
126.4, 130.7, 132.3 (q, J = 32), 132.6, 140.3, 144.7, 146.3, 170.8; υmax/cm
-1
 (solid state) = 3515, 3418, 
3379, 2927, 1879, 1761, 1673, 1524, 1227, 920, 765, 576; ESI-HRMS found m/z 312.0835 [M+H]
+
, 
C15H13F3NO3 requires 326.1004; 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-((3-(trifluoromethyl)benzyl)oxy)benzoic acid 
14j 
Procedure H; 4-Amino-3-(3-(trifluoromethyl)benzyloxy)benzoic acid 18j (0.42 g, 1.4 mmol) in 
chloroform (100 mL), fluorenylmethyloxycarbonyl chloride (0.58 g, 2.2 mmol) in chloroform (50 
mL). Work up yielded the title compound (0.53 g, 1.0 mmol, 73%)  as a colourless amorphous solid; 
δH (300 MHz, DMSO-d6) 4.31 (1H, t, J = 7.0, FHβ), 4.45 (2H, d, J = 7.0, FHα), 5.35 (2H, s, Hα), 7.30 
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(2H, t, J = 6.4, FHAr4), 7.42 (2H, t, J = 6.4, FHAr3), 7.53 (1H, dd, J = 8.1, 1.5, H5), 7.60 (1H, d, J = 
1.5, H2), 7.65-7.75 (4H, m, H6, HAr5 + FHAr5), 7.85-7.92 (3H, m, HAr6 + FHAr2), 7.97 (1H, s, 
HAr2), 9.14 (1H, s, NH); δC (125MHz, DMSO-d6) 46.5, 66.3, 69.0, 113.2, 120.1, 121.3, 122.6, 124.2 
(q, J = 2.6), 124.6 (q, J = 2.6), 125.2, 126.7, 127.4, 128.1, 129.8, 131.3 (q, J = 29.9) 131.9, 132.1, 
138.7, 141.1, 144.0, 148.8, 153.9, 167.2; υmax/cm
-1
 (solid state) = 3347, 3200-2200 (br), 1705, 1436, 
1334, 1120, 739; ESI-HRMS found m/z 534.1505 [M+H]
+
, C30H23F3NO5 requires 534.1523; 
Methyl 3-((4-(tert-butoxy)benzyl)oxy)-4-nitrobenzoate 16k   
Procedure B; Methyl-3-hydroxy-4-nitrobenzoate 15 (3.50 g, 11.7 mmol), (4-(tert-butoxy) phenyl) 
methanol (0.96 g, 5.4 mmol) triphenylphosphine (2.12 g, 8.1 mmol) with diisopropyl 
azodicarboxylate (1.59 mL, 8.1 mmol) in tetrahydrofuran (100 mL). Column chromatography yielded 
the title compound (1.80 g, 5.0 mmol, 95%) as pale yellow solid; δH (500 MHz, CDCl3) 1.39 (9H, s, 
C(CH3)3), 3.99 (3H, s, CO2Me), 5.26 (2H, s, Hα), 7.04 (2H, d, J = 8.2, HAr3), 7.39 (2H, d, J = 8.2, 
HAr2), 7.73 (1H, d, J = 8.2, 1.6, H6), 7.86-7.88 (2H, m, H2 + H5); δC (75MHz, CDCl3) 28.9, 52.8, 
71.4, 78.7, 116.3, 121.7, 124.2, 125.3, 128.1, 129.7, 134.8, 142.9, 151. 5, 155.7, 165.2; υmax/cm
-1
 
(solid state) = 3309, 2980, 1725, 1508, 1237, 895, 744; ESI-HRMS found m/z 382.1255 [M+Na]
+
, 
C19H21NNa1O6 requires 382.1267. 
3-((4-(Tert-butoxy)benzyl)oxy)-4-nitrobenzoic acid 17k  
Procedure F; Methyl 3-((4-(tert-butoxy)benzyl)oxy)-4-nitrobenzoate 16k  (2.24 g, 6.2 mmol) in a 1:1 
mixture of methanol-tetrahydrofuran (60 mL), 10% aqueous sodium hydroxide (15 mL). Work up 
yielded the title compound (1.96 g, 5.7 mmol, 91%) as a yellow solid; δH (500 MHz, MeOD-d4)1.36 
(9H, s, C(CH3)3), 5.18 (2H, s, Hα), 6.96 (2H, d, J = 8.5, HAr3), 7.29 (2H, d, J = 8.4, HAr2), 7.71 (dd, 
J = 8.5, 1.5, H6), 7.79-7.81 (2H, m, H2 + H5); δC (125MHz, MeOD-d4) 29.3, 72.3, 79.8, 117.6, 123.0, 
125.2, 126.0, 128.9, 129.5, 132.1, 144.6, 152.4, 156.8, 167.7; υmax/cm
-1
 (solid state) = 2977, 1692, 
1607, 1520, 1506, 1434, 1294, 1250, 1162, 1109; ESI-HRMS found m/z 344.1156 [M-H]
-
, C18H18NO6 
requires 344.1134. 
4-Amino-3-((4-(tert-butoxy)benzyl)oxy)benzoic acid 18k  
Procedure E; 3-((4-(tert-butoxy)benzyl)oxy)-4-nitrobenzoic acid 17k (0.50 g, 1.5 mmol), 
cobalt chloride hexahydrate (2.07 g, 8.7 mmol) and sodium borohydride (0.68 g, 174.0 
mmol) in methanol (100 mL). Work up yielded the title compound (336 mg, 1.1 mmol, 74%) 
as an orange amorphous solid; δH (500 MHz, CDCl3) 1.36 (9H, s, C(CH3)3), 5.00 (2H, s, Hα), 6.64 
(1H, d, J = 8 , H5), 6.95 (2H, d, J = 8.5, HAr3), 7.27 (2H, d, J = 8.5, HAr2), 7.54 (1H, d, J = 1.6, H2), 
7.58 (1H, dd, J = 8.2, 1.6, H6); δC (125MHz, CDCl3) 28.9, 70.4, 78.7, 113.1, 113.3, 118.4, 124.1, 
125.3, 128.7, 131.2, 142.1, 145.3, 155.5, 171.7; υmax/cm
-1
 (solid state) = 3491, 3384, 2978, 2932, 
1692, 1613, 1509, 1421; ESI-HRMS found m/z 338.1355 [M+H]
+
, C18H21NNaO4 requires 338.1363. 
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4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-((4-(tert-butoxy)benzyl)oxy)benzoic acid 14k  
Procedure I; 4-amino-3-((4-(tert-butoxy)benzyl)oxy)benzoic acid 18k (288 mg, 0.9 mmol), sodium 
bicarbonate (153 mg, 1.8 mmol) in tetrahydrofuran (15 mL) and fluorenylmethyloxycarbonyl chloride 
(354 mg, 1.4 mmol) in tetrahydrofuran (10 mL). The pure product was precipitated from a 
dichloromethane-hexane solution to leave a grey amorphous solid (302 mg, 0.6 mmol, 62%); δH (500 
MHz, CDCl3) 1.31 (9H, s, C(CH3)3), 4.23 (1H, t, J = 6.8, FHβ), 4.45 (2H, d, J = 6, FHα), 5.07 (2H, s, 
Hα), 6.99 (2H, d, J = 8.2, HAr2), 7.23-7.29 (4H, m, HAr3 + FHAr4), 7.35 (2H, t, J = 7.3, FHAr3), 
7.47 (1H, br. s, H5), 7.53 (2H, d, J = 7.3, FHAr5), 7.62 (1H, s, H2), 7.69-7.72 (3H, m, H6 + FHAr2), 
8.10 (1H, br. s, NH); δC (125MHz, CDCl3) 28.89, 47.01, 67.43, 71.00, 78.81, 128.69, 112.85, 117.38, 
120.07, 123.20, 124.21, 124.62, 124.97, 127.14, 127.84, 130.36, 141.34, 143.59, 146.28, 155.86, 
170.40, υmax/cm
-1
 (solid state) = 3421, 2973, 1742, 1674, 1594, 1538; ESI-HRMS found m/z 560.2030 
[M+Na]
+
, C33H31NNaO6requires 560.2044. 
3-(2-(1H-Indol-3-yl)ethoxy)-4-aminobenzoic acid 18l 
Methyl 3-(2-(1H-indol-3-yl)ethoxy)-4-nitrobenzoate 16l was obtained from methyl-3-hydroxy-4-
nitrobenzoate 15 by procedure B without purification/isolation. Methyl 3-(2-(1H-indol-3-yl)ethoxy)-
4-aminobenzoate 17l was obtained from methyl 3-(2-(1H-indol-3-yl)ethoxy)-4-nitrobenzoate 16l by 
procedure C without purification/isolation. Procedure F; Methyl 3-(2-(1H-indol-3-yl)ethoxy)-4-
aminobenzoate 17l (2.50 g, 8.1 mmol) in a 1:1 mixture of methanol-tetrahydrofuran (65 mL), 10% 
aqueous sodium hydroxide (15 mL). Work up yielded the title compound (1.90 g, 6.4 mmol, 80%) as 
a cream amorphous solid; δH (500 MHz, DMSO-d6) 3.18 (2H, t, J = 6.7, Hβ), 4.19 (2H, t, J = 6.7 Hα), 
5.46 (2H, br. s, NH2), 6.62 (1H, d, J = 8.1, H5), 6.98 (1H, m, IHAr3), 7.07 (1H, m, IHAr4), 7.30-7.36 
(4H, m, H2, H6, IHAr5 + ICHNH), 7.61 (1H, d, J = 7.7, IHAr2), 10.87 (1H, s, ICHNH); (125 MHz, 
DMSO-d6) 24.8, 68.4, 110.6, 111.4, 111.9, 112.1, 117.3, 118.2, 118.3, 120.9, 123.3, 124.0, 127.3, 
136.1, 142.8, 144.2, 167.5; υmax/cm
-1
 (solid state) =3488, 3387, 250, 1882 (br) 1667, 1614, 1447, 
1274, 745; ESI-HRMS found m/z 319.1048 [M+Na]
+
, C17H16N2NaO3 requires 319.1053. 
3-(2-(1H-Indol-3-yl)ethoxy)-4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)benzoic acid 14l 
Procedure H; 3-(2-(1H-indol-3-yl)ethoxy)-4-aminobenzoic acid 18l (1.58 g, 5.33 mmol) in 
tetrahydrofuran (50 mL), fluorenylmethyloxycarbonyl chloride (2.07 g, 87.00 mmol) in 
tetrahydrofuran (20 mL). Work up yielded the title compound as a light grey amorphous solid (2.25 g, 
4.3 mmol, 81%); δH (500 MHz, DMSO-d6) 3.25 (2H, t, J = 6.9, Hβ), 4.30-4.38 (3H, m, Hα + FHβ), 
4.47 (2H, d, J = 6.9, FHα), 6.97 (1H, m, IHAr3), 7.06 (1H, m, IHAr4), 7.28 (1H, d, J = 2.1, ICHNH), 
7.31-7.36 (3H, m, IHAr5 + FHAr4), 7.44 (2H, t, J = 7.4, FHAr3), 7.49-7.54 (2H, m, H2 + H5), 7.62 
(1H, d, J = 7.7, IHAr2), 7.74-7.77 (3H, m, H6 + FHAr5), 7.92 (2H, d, J = 7.5, FHAr2), 8.86 (1H, s, 
FNH), 10.92 (1H, s, ICHNH); (125MHz, DMSO-d6) 24.6, 46.5, 66.4, 69.0, 110.3, 111.4, 112.4, 
118.2, 118.5, 119.7, 120.2, 121.0, 122.3, 123.2, 125.3, 125.9, 127.2, 127.3, 127.8, 131.6, 136.2, 140.8, 
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143.7, 148.0, 153.3, 166.9; υmax/cm
-1
 (solid state) = 3358, 2951, 1908, 1714, 1673, 1439,1231, 1053, 
736; ESI-HRMS found m/z 541.1727 [M+Na]
+
, C32H26N2NaO5 requires 541.1734. 
Methyl 3-(2-(tert-butoxy)-2-oxoethoxy)-4-nitrobenzoate 16m 
Procedure A; Methyl-3-hydroxy-4-nitrobenzoate 15 (5.00 g, 25.4 mmol), potassium carbonate (3.50 
g, 25.4 mmol) in dimethylformamide (100 mL), tert-butyl 2-bromoacetate (4.44 mL, 30.4 mmol). 
Following work up, the resulting solid was crystallised (ethyl acetate) to yield the title compound 
(6.26 g, 20.1mmol, 79 %) as large pale yellow crystals; m.p. 73.9-74.9 C (ethyl acetate); (Found C, 
54.05; H, 5.50; N, 4.50%. C14H17NO7 requires C, 54.02; H, 5.50; N, 4.50%); δH (300 MHz, CDCl3) 
1.50 (9H, s, C(CH3)3), 3.97 (3H, s, CO2Me), 4.74 (2H, s, Hα), 7.63 (1H, d, J = 1.5, H2), 7.75 (1H, dd, 
J = 8.4, 1.5, H6), 7.89 (1H, d, J = 8.4, H5); δC (75MHz, CDCl3) 28.0, 52.9, 66.5, 79.9, 83.4, 115.7, 
122.3, 125.6, 134.7, 150.9, 165.0, 166.3; υmax/cm
-1
 (solid state) = 2981, 1730, 1533,1305, 1225,745; 
ESI-HRMS found m/z 334.0908 [M+Na]
+
, C14H17NNaO7 requires 334.0897. 
3-(2-(Tert-butoxy)-2-oxoethoxy)-4-nitrobenzoic acid 17m 
Saponification of 16m preceded reduction to prevent hydrolysis of the 
t
Butyl group. Procedure G; 
Methyl 3-(2-(tert-butoxy)-2-oxoethoxy)-4-nitrobenzoate 16m (3.00 g, 9.6 mmol) in tetrahydrofuran 
(100 mL), lithium hydroxide (0.40 g, 9.6 mmol) in water (100 mL). Following acidification the 
resulting precipitate was filtered, dissolved in chloroform and dried with magnesium sulfate. The 
solution was filtered and the organic solvents removed under reduced pressure yielding the title 
compound (1.72 g, 5.8 mmol, 60%) as a white amorphous powder; (Found C, 52.55; H, 5.00; N, 
4.60%. C13H15NO7 requires C, 52.53; H, 5.09; N, 4.71%); δH (300 MHz, CDCl3) 1.42 (9H, s, C(CH3)3, 
4.69 (2H, s, Hα), 7.62 (1H, d, J = 1.5, H2),  7.76 (1H, dd, J = 8.1, 1.5, H6), 7.83 (1H, d, J = 8.1, H5); 
δC (75 MHz, CDCl3) 28.0, 66.5, 83.5, 116.2, 123.1, 125.7, 133.5, 150.9, 166.3, 169.4; υmax/cm
-1
 (solid 
state) = 3118-2555, 2984, 1740, 1695, 1532, 1432, 1265, 788; ESI-HRMS found m/z 320.0740 
[M+Na]
+
, C13H15NNaO7 requires 320.0741. 
4-Amino-3-(2-(tert-butoxy)-2-oxoethoxy)benzoic acid 18m  
Procedure D; 3-(2-(tert-butoxy)-2-oxoethoxy)-4-nitrobenzoic 17m (2.00 g, 6.7 mmol) in methanol 
(20 mL), 10% palladium on charcoal (200 mg, 10 wt%) in methanol (10 mL) ) and hydrogen gas. 
Work up yielded the title compound (1.66 g, 6.2 mmol, 81%) as a beige amorphous powder; δH (500 
MHz, MeOD-d4) 1.53 (9H, s, C(CH3)3), 4.65 (2H, s, Hα), 6.74 (1H, d, J  = 8.3, H5), 7.39 (1H, d, J = 
1.8, H2), 7.54 (1H, dd, J = 8.2, 1.7, H6); δC (125MHz, MeOD-d4) 28.3, 31.2, 67.5, 114.5, 116.7, 
118.8, 119.4, 125.7, 126.5, 145.7, 170.4; υmax/cm
-1
 (solid state) = 3523, 3427, 3123-2565, 2988, 1740, 
1685, 1537, 1454, 1276, 788; ESI-HRMS found m/z 268.1181 [M+H]
+
, C13H18NO5 requires 268.1179. 
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4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-(tert-butoxy)-2-oxoethoxy)benzoic acid 
14m 
Procedure I; 4-amino-3-(2-(tert-butoxy)-2-oxoethoxy)benzoic acid 18m (1.00 g, 3.7 mmol), sodium 
bicarbonate (0.35 g, 4.1 mmol) in tetrahydrofuran (50 mL), fluorenylmethyloxycarbonyl chloride 
(0.87 g, 3.4  mmol) in chloroform (30 mL). The resulting precipitate was removed via filtration to 
yield the title compound (1.62 g, 3.3 mmol, 98%) as a colourless amorphous solid; (Found C, 68.40; 
H, 5.50; N, 2.80%. C28H27NO7 requires C, 68.70; H, 5.56; N, 2.86%); δH (300 MHz, CDCl3) 1.54 (9H, 
s, C(CH3)3), 4.34 (1H, t, J = 7.1, FHβ), 4.55 (2H, d, J = 7.1, FHα), 4.70 (2H, s, Hα), 7.36 (2H, t, J = 
7.2, FHAr4) 7.45 (2H, t, J = 7.2, FHAr3), 7.58 (1H, d, J = 1.6, H2), 7.71 (2H, d, J = 7.3, FHAr5), 
7.80-7.86 (3H, m, H6 + FHAr2), 8.18-8.29 (2H, m, NH + H5); δC (75MHz, CDCl3) 28.1, 47.0, 67.4, 
67.6, 83.2, 114.6, 117.8, 120.1, 123.2, 125.2, 125.8, 127.2, 127.8, 134.2, 141.4, 143.7, 146.1, 153.1, 
167.9, 171.2; υmax/cm
-1
 (solid state) = 3422, 3200-2200 (br), 1740, 1682, 1533, 1182, 760; ESI-HRMS 
found m/z 512.1675 [M+Na]
+
, C28H27NNaO7 requires 512.1680. 
Methyl 3-(2-(methoxymethoxy)ethoxy)-4-nitrobenzoate 16n  
Procedure A; Methyl-3-hydroxy-4-nitrobenzoate 15 (3.00 g, 15.2 mmol), potassium carbonate (3.15 
g, 22.8 mmol), in dimethylformamide (60 mL), 2-(methoxymethoxy)ethanol (1.97 mL, 16.7 mmol). 
Work up afforded the title compound (3.65 g, 12.8 mmol, 89 %) as a yellow glassy solid; (Found C, 
50.80; H, 5.21; N, 4.75%. C19H21N1O5 requires C, 50.33; H, 5.30; N, 4.91%); δH (500 MHz, CDCl3) 
3.26 (3H, s, OMe); 3.87-91 (5H, m, Hβ + CO2Me), 4.28  (2H, t, J = 5.0, Hα), 4.64 (2H, s, OCH2O), 
7.63 (1H, dd, J = 8.5, 1.0, H6), 7.71 (1H, d, J = 1, H2), 7.77 (1H, d, J = 8.5, H5); δC (125MHz, 
CDCl3) 52.8, 55.3, 65.2, 69.4, 96.6, 115.7, 121.6, 125.4, 134.8, 142.6, 151.7, 165.1; υmax/cm
-1
 (solid 
state) = 2993, 2964, 2941, 2890, 1726, 1613, 1591, 1528, 1431, 1369, 1292, 1241, 1114, 1055, 1025; 
ESI-HRMS found m/z 308.074 [M+Na]
+
, C12H15NNaO7 requires 308.0746 
Methyl 4-amino-3-(2-(methoxymethoxy)ethoxy)benzoate 17n 
Procedure D; Methyl 3-(2-(methoxymethoxy)ethoxy)-4-nitrobenzoate 16n (3.50g, 12.3 mmol) in 
methanol (70 mL), 10% palladium on charcoal (350 mg, 10 wt%) in methanol (20 mL) and hydrogen 
gas. Work up yielded the title compound (3.01 g, 11.8 mmol, 96%) as a colourless oil; δH (500 MHz, 
CDCl3) 3.42 (3H, s, OMe); 3.88 (3H, s, CO2Me), 3.94 (2H, t, J = 4.5, Hβ), 4.25 (2H, t, J = 4.5, Hα), 
4.15 (2H, br. s, NH2), 4.73 (2H, s, OCH2O), 6.70 (1H, d, J = 8.2, H5), 7.50 (1H, d, J = 1.8, H2), 7.58 
(1H, dd, J = 8.2, 1.8, H6); δC (125MHz, CDCl3) 51.6, 55.3, 66.1, 68.2, 96.6, 113.1, 113.3, 119.4, 
124.6, 141.7, 145.1, 167.2; υmax/cm
-1
 (solid state) = 3481, 3366, 2949, 2887, 1704, 1619, 1521, 1442, 
1294, 1264, 1217, 1152, 1108, 1037; ESI-HRMS found m/z 278.0999 [M+Na]
+
, C11H15NNaO5 
requires 278.1004. 
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Methyl 4-amino-3-(2-(methoxymethoxy)ethoxy)benzoic acid 18n 
Procedure G; Methyl 4-amino-3-(2-(methoxymethoxy)ethoxy)benzoate 17n (3.00 g, 11.8 mmol) in a 
1:1 mixture of methanol : tetrahydrofuran (80 mL), lithium hydroxide (1.00 g, 23.3 mmol) in water (5 
mL). Work up yielded the title compound (2.02 g, 8.4 mmol, 76%) as a colourless amorphous solid; 
δH (300 MHz, CDCl3) 3.33 (3H, s, OMe), 3.86 (2H, t, J = 4.5, Hβ), 4.16 (2H, t, J = 4.5, Hα), 4.65 (2H, 
s, OCH2O), 6.66 (1H, d, J = 8.1, H5), 7.43 (1H, d, J = 1.7, H2),7.52 (1H, dd, J = 8.1, 1.7, H6); δC 
(75MHz, CDCl3) 55.3, 66.1, 68.2, 96.5, 113.3, 113.4, 118.2, 125.6, 142.5, 145.0, 172.1; υmax/cm
-1
 
(solid state) = 3346, 2938, 1711, 1679, 1622, 1595, 1524, 1445, 1302, 1267, 1233, 1148, 1112, 1044; 
ESI-HRMS found m/z 242.1023 [M+H]
+
, C11H16NO5 requires 242.1028. 
4-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-3-(2-(methoxymethoxy)ethoxy)benzoic acid 14n 
Procedure I; Methyl 4-amino-3-(2-(methoxymethoxy)ethoxy)benzoic acid 18n (2.20 g, 9.1 mmol), 
sodium bicarbonate (1.03 g, 27.4 mmol) in tetrahydrofuran (50 mL) and fluorenylmethyloxycarbonyl 
chloride (3.54 g, 13.7 mmol) in tetrahydrofuran (30 mL). The reaction mixture was concentrated and 
column chromatography yielded the title compound (2.28 g, 4.9 mmol, 54%) as a colourless 
amorphous solid; (Found C, 67.40, H:5.40, N: 2.85%. C26H25NO7 requires C, 67.38, H: 5.44, N: 
3.02%); δH (500 MHz, CDCl3) 3.29 (3H, s, OMe), 3.88 (2H, t, J = 4.5, Hβ), 4.20 (2H, t, J = 4.5, Hα), 
4.23 (1H, t,  J = 6.6, FHβ), 4.50 (2H, d, J = 6.6, FHα), 4.62 (2H, s, OCH2O), 7.26 (2H, t, J = 7.5, 
FHAr4), 7.35 (2H, t, J = 7.4, FHAr3), 7.56-7.58 (2H, m, H2 + H5), 7.75 (2H, d, J = 7.3, FHAr5), 7.86 
(1H, br. s, H6) 7.93 (2H, d, J = 7.6, FHAr2), 8.63 (1H, s, NH); δC (125MHz, CDCl3) 46.4, 54.5, 65.5, 
66.1, 68.8, 95.7, 113.5, 119.2, 120.1, 122.8, 125.0, 125.6, 127.0, 127.7, 132.0, 140.7, 143.5, 147.6, 
153.0, 166.7; υmax/cm
-1
 (solid state) = 3299, 2945, 1709, 1682, 1597, 1539, 1499, 1415, 1300, 1246, 
1114, 1088, 1043; ESI-HRMS found m/z 464.1673 [M+H]
+
, C26H26NO7 requires 464.1709. 
Methyl 3-(3-(methylthio)propoxy)-4-nitrobenzoate 16o 
 
Procedure B; Methyl-3-hydroxy-4-nitrobenzoate 15 (5.00 g, 25.3 mmol), 3-(methylthio)propan-1-ol 
(2.87 mL, 30.4 mmol) triphenylphosphine (9.95 g, 38.0 mmol) with diisopropyl azodicarboxylate 
(7.45 mL, 38.0 mmol) in tetrahydrofuran (150 mL). Column chromatography yielded the title 
compound (6.51 g, 22.8 mmol, 90%) as pale yellow solid; δH (300 MHz, CDCl3) 2.13-2.21 (5H, m, 
Hβ, SCH3), 2.78 (2H, t, J = 6.9, Hγ), 4.00 (3H, s, CO2Me), 4.33 (2H, t, J = 5.7, Hα), 7.72 (1H, dd, J = 
8.4, H6), 7.79 (1H, d, J = 1.2, H2), 7.87 (1H, d, J = 8.4, H5); δC (75MHz, CDCl3) 15.5, 28.1, 30.3, 
52.8, 67.8, 115.4, 121.4, 125.3, 134.8, 142.4, 151.7, 165.2; υmax/cm
-1
 (solid state) = 2953, 2857, 1719, 
1609, 1587, 1520, 1433, 1390, 1296, 1237, 1113; ESI-HRMS found m/z 308.0563 [M+Na]
+
, 
C12H15NNaO5S requires 308.0569. 
Methyl 4-amino3-(3-(methylthio)propoxy)benzoate 17o  
Procedure D; Methyl 3-(3-(methylthio)propoxy)-4-nitrobenzoate 16o (4.00 g, 12.3 mmol) in ethyl 
acetate (150 mL) and methanol (50 mL), 10% palladium on charcoal (400 mg, 10 wt%) and hydrogen 
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gas. Following work up, column chromatography yielded the title compound (2.62 g, 10.3 mmol, 
73%) as a beige amorphous solid; δH (300 MHz, CDCl3) 2.01-2.10 (5H, m, Hβ, SCH3), 2.63 (2H, t, J 
= 7.2, Hγ), 3.79 (3H, s, CO2Me), 4.09 (2H, t, J = 6.1, Hα), 4.17 (2H, br. s, NH2), 6.60 (1H, d, J = 8.1, 
H5), 7.38 (1H, d, J = 1.8, H2), 7.47 (1H, dd, J = 8.1, 1.8, H6); δC (125MHz, CDCl3) 15.5, 28.6, 30.8, 
51.6, 66.7, 112.1, 113.1, 119.3, 124.1, 141.2, 145.1, 167.2; ESI-HRMS found m/z 256.1002 [M+H]
+
, 
C12H18NO3S requires 256.1007. 
4-Amino-3-(3-(methylthio)propoxy)benzoic acid 18o 
Procedure F; Methyl 4-amino3-(3-(methylthio)propoxy)benzoate 17o  (2.50 g, 9.8 mmol) in a 1:1 
mixture of methanol- tetrahydrofuran (60 mL), 10% aqueous sodium hydroxide (15 mL). Work up 
yielded the title compound (2.27 g, 9.4 mmol, 96%) as a cream amorphous solid; δH (500 
MHz,CDCl3) 2.12-2.17 (5H, m, Hβ, SCH3), 2.71 (2H, t, J
 = 7.2, Hγ), 4.19 (2H, t, J = 6.1, Hα), 6.70 
(1H, d, J = 8.3, H5), 7.51 (1H, d, J = 1.8, H2), 7.64 (1H, dd, J = 8.3, 1.8, H6); δC (125MHz, CDCl3) 
15.7, 28.7, 31.0, 66.9, 112.6, 113.2, 118.4, 125.2, 142.1, 145.2, 171.95; υmax/cm
-1
 (solid state) = 3461, 
3334, 2869, 2551, 1667, 1615, 1583, 1526, 1446, 1414, 1365, 1300, 1267, 1225, 1148, 1113, 1031; 
ESI-HRMS found m/z 264.0665 [M+Na]
+
, C11H15NNaO3S requires 264.0670. 
4-(((9H-Fluoren-9-yl) methoxy)carbonylamino)-3-(3-(methylthio)propoxy)benzoic acid 14o 
Procedure H; 4-Amino-3-(3-(methylthio)propoxy)benzoic acid 18o (1.70 g, 7.1 mmol), in 
tetrahydrofuran (50 mL) and fluorenylmethyloxycarbonyl chloride (2.72 g, 10.6 mmol) in 
tetrahydrofuran (30 mL). The crude material obtained after concentration was suspended in hexane 
and filtered (3 times). The solid obtained was then washed with methanol to get the title compound 
(2.94g, 6.3 mmol, 90%) as a colourless amorphous solid; (Found C, 67.45.; H, 5.35; N, 2.95; S 
6.85%. C26H25NO5S requires C, 67.37; H, 5.44; N, 3.02; S, 6.92%); δH (500 MHz,CDCl3) 2.19 (3H, s, 
SCH3), 2.21 (2H, p, J = 6.4, Hβ), 2.74 (2H, t, J = 6.7, Hγ), 4.26 (2H, t, J = 6.1, Hα), 4.33 (1H, t, J = 
6.8, FHβ), 4.56 (2H, d, J = 6.8, FHα), 7.35 (2H, t, J = 7.5, FHAr4), 7.44 (2H, t, J = 7.5, FHAr3), 7.61 
(1H, d, J = 1.7, H2), 7.65 (2H, d, J = 7.5, FHAr5), 7.70 (1H, br. s, H6), 7.77 (1H, d, J = 8.1, H5), 7.80 
(2H, FHAr2), 8.18 (1H, br. s, NH); δC (125MHz, CDCl3) 15.9, 28.3, 31.2, 47.1, 67.4, 67.8, 112.1, 
117.3, 120.1, 123.2, 124.5, 125.0, 127.2, 127.9, 133.0, 141.4, 143.7, 146.3, 153.0, 177.6; υmax/cm
-1
 
(solid state) = 3311, 2954, 2915, 1712, 1682, 1597, 1535, 1499, 1416, 1338, 1300, 1281, 1245, 1227, 
1104, 1088, 1046, 1032; ESI-HRMS found m/z 486.1341 [M+Na]
+
, C26H25NNaO5S requires 
486.1351. 
Methyl 4-nitro-3-(2-oxo-2-(tritylamino)ethoxy)benzoate 16p  
Procedure A; Methyl-3-hydroxy-4-nitrobenzoate 15 (1.17 g, 5.9 mmol), potassium carbonate (2.46 g, 
17.8 mmol), in dimethylformamide (40 mL), 2-bromo-N-tritylacetamide (2.25 g, 5.9 mmol). Work-up 
afforded the title compound (2.73 g, 5.5 mmol, 93 %) as a yellow amorphous solid; δH (500 MHz, 
CDCl3) 3.90 (3H, s, CO2Me), 4.60 (2H, s, Hα), 7.18-7.26 (15H, m, C(C6H5)3), 7.66 (1H, d, J = 1.4, 
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H2), 7.72 (1H, dd, J = 8.5, 1.4, H6), 7.95 (1H, d, J = 8.5, H5), 8.06 (1H, s, NH); δC (125MHz, CDCl3) 
53.0, 68.3, 70.7, 115.6, 122.9, 126.4, 127.2, 128.1, 128.7, 135.8, 144.2, 150.2, 164.6, 165.0; υmax/cm
-1
 
(solid state) = 3408, 3056, 1958, 1728, 1697, 1522, 1234, 700; ESI-HRMS found m/z 519.1525 
[M+Na]
+
, C29H24N2NaO6 requires 519.1527. 
Methyl 4-amino-3-(2-oxo-2-(tritylamino)ethoxy)benzoate 17p  
Procedure D; Methyl 4-nitro-3-(2-oxo-2-(tritylamino)ethoxy)benzoate 16p (2.70 g, 5.4 mmol) in 
ethyl acetate (60 mL), 10% palladium on charcoal (270 mg, 10 wt%) and hydrogen gas. Work up 
yielded the title compound (2.45 g, 5.3 mmol, 96%) as a beige solid; (Found C, 74.15; H, 5.75; N, 
5.65%. C29H26N2O4 requires C, 74.66; H, 5.64; N, 6.00%); δH (500 MHz, CDCl3) 3.80 (3H, s, 
CO2Me), 4.45 (2H, s, Hα), 6.71 (1H, d, J = 8.2, H5), 7.09-7.10 (6H, m, ArH), 7.15-7.22 (9H, m, 
ArH), 7.45 (1H, d, J = 1.4, H2), 7.53-7.55 (2H, m, H6 + NH); δC (125MHz, CDCl3) 51.9, 68.7, 70.4, 
113.7, 114.6, 120.4, 125.6, 127.2, 128.1, 128.6, 140.6, 143.9, 144.3, 166.7, 166.7; υmax/cm
-1
 (solid 
state) = 3488, 3370, 3033, 1966, 1691, 1619, 1520, 1434, 1258, 698; ESI-HRMS found m/z 489.1799 
[M+Na]
+
, C29H26N2NaO6 requires 489.1785. 
4-Amino-3-(2-oxo-2-(tritylamino)ethoxy)benzoic acid 18p  
Procedure F; Methyl 4-amino-3-(2-oxo-2-(tritylamino)ethoxy)benzoate 17p (2.40 g, 5.1 mmol) in a 
1:1 mixture of methanol-tetrahydrofuran (60 mL), 10% aqueous sodium hydroxide (15 mL). Work up 
yielded the title compound (1.46 g, 3.2 mmol, 63%) as a colourless amorphous solid; δH (500 MHz, 
DMSO-d6) 4.71 (2H, s, Hα), 5.53 (2H, br. s, NH2) 6.64 (1H, d, J = 8.5, H5), 7.15-7.26 (15H, m, 
C(C6H5)3),7.38-7.39 (2H, m, H2 + H6) 8.69 (1H, brs, NH); δC (125MHz, CDCl3) 69.2, 71.7, 93.4, 
115.0, 115.5, 125.8, 128.1, 128.7, 129.0, 130.0, 141.2, 145.6, 145.7, 170.3, 175.6; ESI-HRMS found 
m/z 451.1667 [M-H]
-
, C28H23N2O4 requires 451.1663. 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-oxo-2-(tritylamino)ethoxy)benzoic acid 
14p  
Procedure I; 4-Amino-3-(2-oxo-2-(tritylamino)ethoxy)benzoic acid 18p (1.40 g, 3.1 mmol), sodium 
bicarbonate (350 mg, 9.3 mmol) in tetrahydrofuran (50 mL) and fluorenylmethyloxycarbonyl chloride 
(1.20 g, 4.6 mmol) in tetrahydrofuran (10 mL). Work up  yielded the title compound (1.52 g, 2.3 
mmol, 73%) as a colourless amorphous solid; δH (500 MHz, DMSO-d6) 4.29 (1H, t, J = 6.6, FHβ), 
4.45 (2H, d, J = 6.6, FHα), 4.85 (2H, s, Hα), 7.13-7.14 (6H, m, ArH), 7.14-7.23 (9H, m, ArH), 7.29 
(2H, t, J = 7.4, FHAr4), 7.41 (2H, t, J = 7.4, FHAr3), 7.55-7.56 (2H, m, H2 + H6), 7.73 (2H, d, J = 
7.6, FHAr5), 7.78 (1H, br. s, H5), 7.90 (2H, d, J = 7.6, FHAr2), 8.83 (1H, s, NH), 9.05 (1H, s, FNH); 
δC (125MHz, DMSO-d6) 46.7, 66.3, 67.6, 69.4, 113.4,119.8, 120.1, 123.0, 125.2, 125.7, 126.5, 127.1, 
127.5, 127.7, 128.4, 132.0, 140.7, 143.6, 144.4, 147.3, 153.3, 166.8, 167.1; υmax/cm
-1
 (solid state) = 
3397, 3261, 3059, 1951, 1736, 1668, 1530, 1221, 1190, 1046, 739, 699; ESI-HRMS found m/z 
697.2284 [M+Na]
+
, C43H34N2NaO6 requires 697.2309. 
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Methyl 3-(2-((tert-butoxycarbonyl)amino)ethoxy)-4-nitrobenzoate 16q  
Procedure B; Methyl-3-hydroxy-4-nitrobenzoate 15 (3.00 g, 15.2 mmol), tert-butyl (2-
hydroxyethyl)carbamate (2.59 mL, 16.7 mmol), triphenylphosphine (6.00 g, 22.8 mmol) with 
diisopropyl azodicarboxylate (4.48 mL, 22.8 mmol) in tetrahydrofuran (90 mL). Column 
chromatography yielded the title compound (4.14 g, 12.2 mmol, 80%) as a pale yellow solid; (Found 
C, 53.00; H5.90; N, 8.20%. C15H20N2O7 requires C, 52.94; H, 5.92; N, 8.23%); δH (500 MHz, CDCl3); 
1.45 (9H, s, C(CH3)), 3.61 (2H, m, Hβ), 3.96 (3H, s, CO2Me), 4.24 (2H, t, J = 4.8, Hα),  5.09 (1H, br. 
s, NH), 7.71-7.73 (2H, m, H2 + H6), 7.87 (1H, d, J = 8.3, H5); δC (125MHz, CDCl3); 28.4, 39.7, 52.9, 
69.4, 79.8, 115.7, 121.8, 125.5, 135.1, 142.3, 151.6, 155.9, 165.0; υmax/cm
-1
 (solid state) = 3375, 2973, 
1724, 1703, 1605, 1518, 1494, 1454, 1441, 1392, 1359, 1304, 1280, 1246, 1171, 1117, 1089, 1072; 
ESI-HRMS found m/z 363.1160 [M+Na]
+
, C15H20N2NaO5 requires 363.1168. 
Methyl 4-amino-3-(2-((tert-butoxycarbonyl)amino)ethoxy)benzoate 17q 
Procedure D; Methyl 3-(2-((tert-butoxycarbonyl)amino)ethoxy)-4-nitrobenzoate 16q (2.00 g, 5.9 
mmol) in 1:1 ethyl acetate-methanol (40 mL), 10% palladium on charcoal (200 mg, 10 wt%) and 
hydrogen gas. Work up yielded the title compound (1.6 g, 5.4 mmol, 91%) as a beige solid; δH (500 
MHz, CDCl3) 1.49 (9H, s, C(CH3)), 3.59 (2H, m, Hβ), 3.86 (3H, s, CO2Me), 4.12 (2H, t, J = 5.1, Hα), 
4.28 (2H, br. s, NH2), 4.91 (1H, br. s, NH), 6.68 (1H, d, J = 8.2, H5),  7.43 (1H, s, H2), 7.56 (1H, d, J 
= 8.2, H6); δC (75MHz,  CDCl3); 28.4, 40.1, 51.7, 67.97, 79.60, 113.2, 113.3, 119.4, 124.4, 141.2, 
144.9, 156.0, 167.2; υmax/cm
-1
 (solid state) = 3439, 3387, 3063, 2948, 1712, 1696, 1670, 1601, 1523, 
1482, 1422, 1352, 1267, 1251, 1207, 1122, 1017; ESI-HRMS found m/z 333.1421 [M+Na]
+
, 
C15H22N2NaO5 requires 333.1426. 
4-Amino-3-(2-((tert-butoxycarbonyl)amino)ethoxy)benzoic acid 18q 
Procedure G; Methyl 4-amino-3-(2-((tert-butoxycarbonyl)amino)ethoxy)benzoate 17q (1.00 g, 3.2 
mmol) in a 1:1 mixture of methanol- tetrahydrofuran (20 mL), lithium hydroxide (270 mg, 6.5 mmol) 
in water (5 mL). Work up yielded the title compound (0.92 g, 3.1 mmol, 96%) as a colourless 
amorphous solid; δH (500 MHz, MeOD-d4) 1.47 (9H, s, C(CH3)), 3.51 (2H, t, J = 5.1, Hβ), 4.05 (2H, 
t, J = 5.1, Hα), 6.71 (1H, d, J = 8.2, H5), 7.42 (1H, s, H2), 7.51 (1H, d, J = 8.2, H6); δC (125MHz, 
MeOD-d4); 28.7, 41.0, 68.9, 80.2, 113.3, 113.9, 119.3, 125.9, 144.4, 146.4, 158.7, 170.6; υmax/cm
-1
 
(solid state) = 3347, 2972, 1675, 16171584, 1518, 1444, 1402, 1368, 1293, 1271, 1222, 1161, 1123, 
1057; ESI-HRMS found m/z 297.1445 [M+H]
+
, C14H21N2O5 requires 297.1450. 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3(2((tertbutoxycarbonyl)amino)ethoxy)benzoic 
acid 14q 
Procedure I; 4-Amino-3-(2-((tert-butoxycarbonyl)amino)ethoxy)benzoic acid 18q (1.40 g, 3.1 mmol), 
sodium bicarbonate (1.19 g, 14.2 mmol) in tetrahydrofuran (30 mL) and fluorenylmethyloxycarbonyl 
chloride (1.83 g, 7.1 mmol) in tetrahydrofuran (20 mL). The reaction mixture was concentrated and 
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column chromatography yielded the title compound (1.83 g, 3.5 mmol, 75%) as a colourless 
amorphous solid; (Found C, 66.95; H, 5.80; N, 5.25%. C29H30N2O7 requires C, 67.17; H, 5.83; N, 
5.40%); δH (500 MHz, DMSO-d6) 1.39 (9H, s, C(CH3)), 3.42 (2H, m, Hβ), 4.03 (2H, m, Hα), 4.36 
(1H, t, J = 7.0, FHβ), 4.50 (2H, d, J = 7.0, FHα), 7.31-7.37 (3H, m, H2 + FHAr4), 7.42-7.45 (3H, m, 
H6 + FHAr3), 7.50 (1H, d, J = 8.4, H5), 7.78 (2H, d, J = 7.5, FHAr5),  7.83 (1H, br. s, NH), 7.93 (2H, 
d, J = 7.5, FHAr2), 9.01 (1H, s, FNH); δC (125MHz,  DMSO-d6) 27.95, 46.2, 66.2, 68.2, 77.7, 111.3, 
118.6, 119.9, 122.1, 124.8, 125.1, 126.9, 127.5, 131.3, 140.5, 143.4, 147.2, 153.1, 155.6, 166.6; 
υmax/cm
-1
 (solid state) = 3423, 3361, 2986, 2947, 1741, 1682, 1605, 1532, 1489, 1440, 1347, 1297, 
1248, 1227, 1198, 1132, 1053; ESI-HRMS found m/z 541.1945 [M+Na]
+
, C29H30N2NaO7 requires 
541.1951. 
3-((5-((Tert-butoxycarbonyl)amino)pentyl)oxy)-4-nitrobenzoic acid 17r 
Methyl 3-((5-((tert-butoxycarbonyl)amino)pentyl)oxy)-4-nitrobenzoate 16r was obtained from 
methyl-3-hydroxy-4-nitrobenzoate 15 by procedure B without further purification / isolation. 
Procedure F; methyl 3-((5-((tert-butoxycarbonyl)amino)pentyl)oxy)-4-nitrobenzoate 16r  (5.80 g, 
15.2 mmol) in a 1:1 mixture of methanol-tetrahydrofuran (150 mL) and 10% aqueous sodium 
hydroxide (30 mL). Work up yielded the title compound (4.95 g, 13.4 mmol, 89% over two steps) as a 
cream amorphous solid; δH (500 MHz, CDCl3) 1.45-1.56 (13H, m, Hγ, Hδ + C(CH3)), 1.87 (2H, m, 
Hβ), 3.16 (2H, m, Hε), 4.16 (2H, t, J = 6.1, Hα), 7.72 (1H, d, J = 7.7, H6), 7.75 (1H, s, H2), 7.81 (1H, 
d, J = 7.7, H5); δC (125MHz, CDCl3) 23.1, 28.4, 29.6, 40.4, 41.5, 69.7, 79.5, 115.8, 121.8, 125.2, 
134.4, 142.9, 156.3, 158.3, 168.4; υmax/cm
-1
 (solid state) = 3377, 2980, 2944, 1693, 1521, 1308, 1249, 
1177; ESI-HRMS found m/z 391.1495 [M+Na]
+
 C17H24N2NaO7 requires 391.1481.  
4-Amino-3-((5-((tert-butoxycarbonyl)amino)pentyl)oxy)benzoic acid 18r 
Procedure D; 3-((5-((tert-butoxycarbonyl)amino)pentyl)oxy)-4-nitrobenzoic acid 17r (4.90 g, 13.4 
mmol) a 1:2 mixture of ethyl acetate-methanol (90 mL), 10% palladium on charcoal (490  mg, 10 
wt%) and hydrogen gas. Work up yielded the title compound (4.50 g, 13.3 mmol, 91%) as a beige 
amorphous solid; (Found C, 59.00; H, 7.70; N, 8.60%. C17H25N2O7 requires C,
 
60.34; H, 7.74; N, 
8.28%); δH (500 MHz, MeOD-d4) 1.43 (9H, s, C(CH3)), 1.53 (4H, m, Hγ + Hδ), 1.85 (2H, m, Hβ), 
3.07 (2H, t, J = 6.2, Hε), 4.04 (2H, t, J = 6.3, Hα), 6.69 (1H, d, J = 8.2, H5), 7.41 (1H, s, H2), 7.48 
(1H, d, J = 8.2, H6); δC (125MHz, MeOD-d4) 28.5, 28.8, 29.2, 30.1, 41.3, 69.3, 79.9, 113.3, 113.4, 
119.6, 125.5, 125.6, 144.2, 146.7, 151.0, 158.6, 170.8; υmax/cm
-1
 (solid state) = 3492, 3347, 2940, 
1703, 1690, 1657, 1620, 1588, 1576, 1518, 1417, 1367, 1308, 1268, 1237, 1169, 1153, 1029; ESI-
HRMS found m/z 337.1769 [M-H]
-
 C17H25N2O7 requires 337.1763.  
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4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-((5-((tert-butoxycarbonyl) amino) 
pentyl)oxy)benzoic acid 14r 
Procedure I; 4-amino-3-((5-((tert-butoxycarbonyl)amino)pentyl)oxy)benzoic acid 18r (4.00 g, 11.8 
mmol), sodium bicarbonate (2.98 g, 34.2 mmol) in tetrahydrofuran (80 mL) and 
fluorenylmethyloxycarbonyl chloride (4.58 g, 17.8 mmol) in tetrahydrofuran (40 mL). Precipitation of 
the product via hexane yielded the title compound (5.50 g, 9.8 mmol, 79%) as a colourless amorphous 
solid; δH (500 MHz, CDCl3) 1.44 (9H, s, C(CH3)), 1.54 (2H, m, Hγ), 1.60 (2H, m,  Hδ), 1.91 (2H, m, 
Hβ), 3.17 (2H, m, Hε), 4.13 (2H, t, J = 6.6, Hα), 3.34 (1H, t, J = 6.9, FHβ), 4.55 (3H, m, NH + FHα), 
7.34 (2H, t, J = 7.4, FHAr4), 7.43 (2H, t, J = 7.5, FHAr3), 7.49 (1H, br. s, H6), 7.57 (1H, d, J = 1.5, 
H2), 7.64 (2H, d, J = 7.5, FHAr5), 7.75 (1H, d, J = 8.3, H5), 7.80 (2H, d, J = 7.5, FHAr2), 8.14 (1H, 
br. s, FNH); δC (125MHz, CDCl3) 14.2, 21.1, 23.3, 28.4, 28.7, 29.9, 47.1, 60.4, 67.4, 68.8, 94.9, 
112.0, 117.3, 120.1, 124.2, 125.0, 127.2, 127.9, 141.4, 143.7, 146.4, 149.3, 153.0, 156.0, 171.2; 
υmax/cm
-1
 (solid state) =3334, 2937, 1706, 1672, 1595, 1531, 1496, 1431, 1281, 1243, 1214, 1173, 
1085, 1045; ESI-HRMS found m/z 559.2460 [M-H]
-
 C32H35N2O7 requires 559.2450.  
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbenzoic acid 14s 
Procedure H; 4-Amino-3-methylbenzoic acid 19 (3.00 g, 19.9 mmol) was dissolved in 
tetrahydrofuran (100 mL), fluorenylmethyloxycarbonyl chloride (7.70 g, 29.8 mmol) in 
tetrahydrofuran (50 mL). Work up yielded the title compound (7.12 g, 19.1 mmol, 96%) as a 
colourless amorphous solid; (Found C, 73.90; H, 5.10; N, 3.65%. C23H19NO4 requires C, 73.98; H, 
5.13; N, 3.75%); δH (300 MHz, DMSO-d6) 2.26 (3H, s, ArCH3), 4.32 (1H, t, J = 7.5, FHβ), 4.48 (2H, 
d, J = 7.5, FHα), 7.34 (2H, t, J = 7.5, FHAr4), 7.41-7.47 (3H, m, H2 + FHAr3) 7.64-7.76 (4H, m, H6, 
H5 + FHAr5), 7.90 (2H, d, J = 7.5, FHAr2), 9.21 (2H, s, NH); δC (75MHz, DMSO-d6) 17.8, 46.6, 
65.9, 120.2, 123.3, 125.2, 126.4, 127.1, 127.4, 127.7, 130.6, 131.5, 140.6, 140.8, 143.7, 153.9, 167.0; 
υmax/cm
-1
 (solid state) = 3271, 2831, 1701, 1685, 1528, 1253, 736; ESI-HRMS found m/z 374.1390 
[M+H]
+
, C23H20NO4 requires 374.1387. 
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6.3 Characterisation of Oligomers (Chapter 2 and Chapter 3) 
NH2-[O-iPr-(3-HABA)]-[O-iPr-(3-HABA)]-[O-iPr-(3-HABA)]-Gly-CO2H 20   
δH (500 MHz, DMSO-d6) 1.32 (6H, d, J = 6.0, 1-Hβ), 1.35 (6H, d, J = 6.0, 3-Hβ), 1.39 (6H, d, J = 6.0, 
2-Hβ), 3.93 (2H, d, J = 4.5, 4-Hα), 4.60 (1H, sept, J = 6.0, 1-Hα), 4.72 (1H, sept, J = 6.0, 1.9, 3-Hα), 
4.79 (1H, sept, J = 6.0, 1.5, 2-Hα), 5.43 (2H, br. s, 1-NH2), 6.72 (1H, d, J = 8.1, 1-H5), 7.32-7.35 (2H, 
m, 1-H2, 1-H6), 7.51-7.61 (4H, m, 2-H2, 2-H6, 3-H2, 3-H6), 8.12 (1H, app t, J = 8.1, 3-H5), 8.29 
(1H, app t, J = 7.5, 2-H5), 8.81 (1H, t, J = 5.8, 4-NH), 8.94 (1H, s, 3-NH), 9.27 (1H, s, 2-NH); δC 
(125MHz, DMSO-d6) 21.79, 21.82, 21.9, 41.2, 70.36, 71.39, 71.41 112.2, 122.6, 112.8, 119.9, 120.0, 
120.3, 120.9, 121.4, 121.6, 129.2, 129.9, 131.1, 132.2, 143.24, 146.9, 147.0, 147.8, 147.9, 164.2, 
164.4, 165.8, 171.3; ESI-HRMS found m/z 629.2558 [M+Na]
+
, C32H38N4O8Na requires 629.2582. 
NH2-[O-Bn-(3-HABA)]-[O-Bn-(3-HABA)]-[O-Bn-(3-HABA)]-Gly-CO2H 21 
δH (300 MHz, DMSO-d6) 3.95 (2H, d, J = 5.6, 4-Hα), 5.14 (2H, s, 1-Hα), 5.26 (2H, s, 2-Hα), 5.29 
(2H, s, 3-Hα), 6.78 (1H, d, J = 8.2, 1-H5) 7.26-7.64 (19H, m, ArCH), 7.73 (2H, m, 3-HAr2), 8.00 
(1H, d, J = 8.3, 2-H5), 8.15 (1, d, J  = 8.3, 3-H5), 8.88 (1H, t, J = 5.6, 4-NH), 9.20 (1H, s, 2-NH), 9.57 
(1H, s, 3-NH); δC (125MHz, DMSO-d6) 41.2, 69.5, 70.2, 70.3, 111.1, 111.6, 111.8, 113.2, 120.0, 
120.4, 121.2, 121.6, 122.7, 127.4, 127.5, 127.6, 127.8, 127.9, 128.0, 128.4, 129.7, 130.3, 130.5, 131.4, 
136.6, 136.8, 137.0, 144.7, 148.7, 149.6, 164.3, 164.5, 165.8, 171.4; ESI-HRMS found m/z 751.2785 
[M+H]
+
, C44H39N4O8 requires 751.2762. 
NH2-[O-Bn-(3-HABA)]-[O-2-CH2-Nap-(3-HABA)]-[O-iPr-(3-HABA)]-Gly-CO2H 22  
δH (300 MHz,DMSO-d6) 1.35 (6H, d, J = 6.0, 3-Hβ), 3.95 (2H, d, J = 5.8, 4-Hα), 4.73 (1H, sept, J = 
6.0, 3-Hα), 5.11 (2H, s, 1-Hα), 5.52 (2H, s, 2-Hα), 6.76 (1H, d, J = 8.1, 1-H5), 7.31-7.41 (3H, m, 
ArCH), 7.43-7.46 (3H, m, 1-H6 + ArCH), 7.50-7.56 (4H, m, 3-H6 + 1-H2 + ArCH), 7.60 (1H, d, J = 
1.6, 3-H2), 7.63 (1H, dd, J = 8.3, 1.6, 2-H6), 7.73 (1H, dd, J = 8.3, 1.6, ArCH), 7.79 (1H, d, J = 1.8, 
2-H2), 7.88 (2H, m, ArCH), 7.94 (1H, d, J = 8.3, 2-HAr2), 8.10 (2H, m, 3-H5 + 2-HAr8), 8.21 (1H, d, 
J = 8.3, 2-H5), 8.84 (1H, t, J = 6.0, 4-NH), 9.27 (1H, s, 2-NH), 9.34 (1H, s, 3-NH); δC (125 MHz, 
DMSO-d6) 21.8, 41.2, 69.5, 70.4, 71.5, 111.2, 111.8, 112.6, 113.1, 119.9, 120.2, 121.5, 121.6, 121.8, 
125.3, 125.9, 126.2, 126.4, 127.4, 127.6, 127.7, 128.1, 128.4, 129.9, 130.1, 131.1, 131.5, 132.6, 132.8, 
134.4, 136.9, 144.6, 148.1, 148.9, 164.2, 164.6, 165.9, 171.4; ESI-HRMS found m/z 751.2774 [M-H]
-
, 
C44H39N4O8 requires 751.2773. 
NH2-[O-iPr-(3-HABA)]-[O-2-CH2-Nap-(3-HABA)]-[O-Bn-(3-HABA)]-Gly-CO2H 23  
δH (500 MHz, DMSO-d6) 1.13 (6H, d, J = 6.0, 1-Hβ), 3.94 (2H, d, J = 5.8, 4-Hα), 4.40 (1H, sept, J = 
6.0, 1-Hα), 5.27 (2H, s, 3-Hα), 5.39 (2H, s, 2-Hα), 6.71 (1H, d, J = 8.1, 1-H5), 7.27 (1H, t, J = 7.3, 3-
HAr4), 7.31 (1H, d, J = 1.7, 1-H2), 7.34-7.38 (3H, m, 1-H6 + 3-HAr3), 7.52-7.57 (5H, m, 3-HAr2 + 
ArCH), 7.61 (1H, dd, J = 8.4, 1.6, 2-H2), 7.68-7.70 (2H, m, 2-H2 + 2-H6), 7.78 (1H, d, J = 1.5, 3-
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H2), 7.87 (1H, m, ArCH), 7.92-7.95 (2H, m, ArCH), 8.01 (1H, d, J = 8.1, 3-H5), 8.06 (1H, s, HAr2), 
8.18 (1H, d, J = 8.3, 2-H5), 8.83 (1H, t, J = 5.8, 4-NH), 9.18 (1H, s, 2-NH), 9.54 (1H, s, 3-NH); δC 
(125 MHz, DMSO-d6) 21.6, 41.2, 70.2, 70.4, 70.4, 111.5, 111.7, 112.5, 113.5, 120.0, 120.4, 121.4, 
121.6, 121.7, 122.8, 125.5, 126.3, 126.3, 126.4, 127.4, 127.4, 127.6, 127.7, 127.9, 128.1, 128.4, 128.4, 
129.8, 130.3, 130.5, 131.4, 132.6, 132.8, 134.1, 136.7, 141.9, 143.7, 148.9, 149.7, 164.4, 164.6, 165.9, 
171.3; ESI-HRMS found m/z 751.2803 [M-H]
-
, C44H39N4O8 requires 751.2773.  
NH2-[O-Bn-(3-HABA)]-[O-pCl-Bn-(3-HABA)]-[O-iPr-(3-HABA)]-Gly-CO2H 24  
δH (500 MHz, DMSO-d6) 1.37 (6H, d, J = 6.0, 3-Hβ), 3.95 (2H, d, J = 5.8, 4-Hα), 4.74 (1H, sept, J = 
6.0, 3-Hα), 5.16 (2H, s, 1-Hα), 5.35 (2H, s, 2-Hα), 6.76 (1H, d, J = 8.3, 1-H5), 7.34 (1H, t, J = 7.5, 1-
HAr4), 7.39-7.46 (5H, m, 1-H6, 1-HAr3, 2-HAr3), 7.49-7.56 (4H, m, 1-H2, 1-HAr2, 3-H6), 7.60-7.63 
(4H, m, 2-H6, 2-HAr2 + 3-H2), 7.71 (1H, d, J = 1.7, 2-H2),  8.10 (1H, d, J = 8.3, 2-H5), 8.19 (1H, d, 
J = 8.3, 3-H5), 8.83 (1H, t, J = 6.0, 4-NH), 9.19 (1H, s, 2-NH), 9.31 (1H, s, 3-NH); δC (125MHz, 
DMSO-d6) 21.8, 41.2, 68.3, 69.5, 71.4, 111.2, 111.7, 112.6, 112.8, 119.9, 120.2, 121.3, 121.6, 121.7, 
121.9, 127.5, 127.8, 128.4, 128.4, 129.3, 129.8, 130.1, 131.1, 131.5, 132.6, 135.8, 137.0, 144.5, 148.1, 
148.7, 164.2, 164.6, 165.8, 171.4; ESI-HRMS found m/z 735.2243 [M-H]
-
, C40H36ClNO6 requires 
735.2227. 
NH2-[O-pCl-Bn-(3-HABA)]-[O-mCF3-Bn-(3-HABA)]-[O-iPr-(3-HABA)]-Gly-CO2H 25  
δH (500MHz, DMSO-d6) 1.34 (6H, d, J = 6.2, 3-Hβ), 3.93 (2H, d, J = 5.8, 4-Hα), 4.71 (1H, sept, J = 
6, 3-Hα), 5.13 (2H, s, 1-Hα), 5.41 (2H, s, 2-Hα), 6.71 (1H, d, J = 8.1, 1-H5), 7.39 (1H, dd, J = 8.0, 
1.5, 1-H6), 7.44 (2H, d, J = 8.5, 1-HAr2), 7.48 (1H, d, J = 1.5, 1-H2), 7.51-7.54 (3H, m, 1-HAr3, 3-
H6), 7.58 (1H, d, J = 1.5, 3-H2), 7.59-7.63 (2H, m, 2-H6, 2-HAr5), 7.67 (1H, d, J = 7.0, 2-HAr6), 
7.72 (1H, d, J = 1.5, 2-H2), 7.85 (1H, d, J = 7.0, 2-HAr4), 8.00 (1H, s, HAr2), 8.07 (1H, d, J = 8.3, 3-
H5), 8.14 (1H, d, J = 8.3, 2-H5), 8.81 (1H, t, J = 5.8, 4-NH), 9.27 (1H, s, 2-NH), 9.31 (1H, s, 3-NH); 
δC (125MHz, DMSO-d6) 22.3, 41.8, 69.2, 69.8, 72.0, 112.0, 112.2, 113.2, 113.3, 120.7, 121.4, 121.7, 
122.1, 122.4, 122.6, 124.4, 124.7 (J = 272.4), 125.1, 128.9, 129.8, 129.8 (J = 32), 130.0, 130.6, 130.6, 
131.6, 131.8, 132.0, 132.8, 136.6, 138.8, 142.3, 144.9, 148.6, 149.5, 164.7, 165.1, 166.4, 171.9; ESI-
HRMS found m/z 803.2133[M-H]
-
, C41H35ClF3 N4O8 requires 803.2101. 
NH2-[O-Bn-(3-HABA)]-[O-pCF3-Bn-(3-HABA)]-[O-iPr-(3-HABA)]-Gly-CO2H 26  
δH (500MHz, DMSO-d6) 1.33 (6H, d, J = 6, 3-Hβ), 3.93 (2H, d, J = 4.9, 4-Hα), 4.70 (1H, sept, J = 
6.2, 3-Hα), 5.14 (2H, s, 1-Hα), 5.45 (2H, s, 2-Hα), 5.51 (2H, br. s, 1-NH2), 6.71 (1H, d, J = 8.1, 1-
H5), 7.32 (1H, t,  J = 7, 1-HAr4), 7.36-7.41 (4H, m, 1-H2, 1-H6, 1-HAr2), 7.47-7.53 (3H, m, 1-HAr3, 
3-H6), 7.58 (1H, s, 3-H2), 7.61 (1H, dd, J = 8.4, 1.6,  2-H6), 7.69 (1H, s, 2-H2), 7.73 (2H, d, J =8.3, 
2-HAr3), 7.79 (2H, d,  J  = 8.1, 2-HAr2), 8.07 (1H, d, J = 8.1, 3-H5), 8.17 (1H, d, J = 8.3, 2-H5), 8.81 
(1H, t, J = 4.9, 4-NH), 9.22 (1H, s, 2-NH), 9.29 (1H, s, 3-NH); δC (125MHz, DMSO-d6) 21.8, 41.2, 
69.2, 69.5, 71.4, 111.2, 111.6, 112.5, 112.6, 119.9, 120.2, 120.8, 121.9, 121.9, 124.2 (J = 272.3) 
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125.3, 127.4, 127.7, 128.4, 128.4 (J = 31.7), 129.9, 130.1, 131.1,  131.5, 137.0, 141.7, 142.4, 144.3, 
148.1, 148.7, 164.2, 164.7, 165.8, 171.4; ESI-HRMS found m/z 771.2633 [M+H]
+
, C41H38F3N4O8 
requires 771.2636. 
NH2-[O-iPr-(3-HABA)]-[O-iLeu-(3-HABA)]-[O-iPr-(3-HABA)]-Gly-CO2H 27 
δH (500 MHz, DMSO-d6) 0.97 (3H, t, J = 7.5, 2-Hγ), 1.31-1.36 (15H, m, 1-Hβ, 2-CHα(CH3) + 3-Hα), 
1.67-1.81 (2H, m, 2-Hβ + 2-Hβ'), 3.93 (2H, d, J = 5.6, 4-Hα), 4.60 (1H, m, 2-Hα), 4.72 (2H, sept, J = 
6.0, 1-Hα, 3-Hα), 6.74 (1H, d, J = 8.1, 1-H5), 7.32-7.35 (2H, m, 1-H2 + 1-H6), 7.52-7.59 (4H, m, 2-
H2, 2-H6, 3-H2 + 3-H6), 8.11 (1H, d, J = 8.3, 2-H5), 8.29 (1H, d, J = 8.3, 3-H5), 8.80 (1H, t, J = 5.7, 
4-NH), 8.95 (1H, s, 2-NH), 9.27 (1H, s, 3-NH); δC (125MHz, DMSO-d6) 9.4, 18.9, 21.86, 21.93, 28.6, 
41.2, 70.4, 71.4, 76.1, 112.1, 112.6, 113.2, 119.9, 120.0, 120.3, 121.3, 121.6, 129.4, 129.9, 131.2, 
132.2, 143.5, 147.2, 147.9, 164.2, 164.4, 165.8, 171.4; ESI-HRMS found m/z 643.2738 [M+Na]
+
, 
C33H40N4NaO8 requires 643.2744.   
NH2-[O-iPr-(3-HABA)]-[O-CH2-CH2-OH-(3-HABA)]-[O-iPr-(3-HABA)]-Gly-CO2H 28 
δH (500 MHz, DMSO-d6) 1.31 (6H, d, J = 6.0, 1-Hβ) , 1.35 (6H, d, J = 6.0, 3-Hβ), 3.79 (2H, t, J = 4.6, 
2-Hβ), 3.93 (2H, d, J = 5.8, 4-Hα), 4.21 (2H, t, J = 4.6, 2-Hα), 4.61 (1H, sept, J = 6.0, 1-Hα), 4.71 
(1H, sept, J = 6.0, 3-Hα), 6.71 (1H, d, J = 8.8, 1-H5), 7.37-7.39 (2H, m, 1-H2 + 1-H6), 7.52 (1H, dd, J 
= 8.3, 1.7, 2-H6), 7.58-7.60 (2H, m, 2-H2 + 3-H6), 7.63 (1H, d, J = 1.9, 3-H2), 8.08 (1H, d, J = 8.3, 
2-H5), 8.33 (1H, d, J = 8.3, 3-H5), 8.81 (1H, t, J = 5.8, 4-NH), 9.20 (1H, s, 2-NH), 9.28 (1H, s, 3-
NH); δC (125MHz, DMSO-d6) 21.8, 21.9, 41.2, 59.5, 70.4, 71.5, 71.5, 112.1, 112.6, 112.8, 112.9, 
119.9, 120.0, 120.5, 121.0, 121.6, 121.7, 129.2, 130.0, 131.2, 143.2, 143.3, 148,0, 164.2, 164.8, 165.8, 
171.4; ESI-HRMS found m/z 631.2378 [M+Na]
+
, C31H36N4NaO9 requires 631.2374. 
NH2-[O-iPr-(3-HABA)]-[3-Me-ABA]-[O-iPr-(3-HABA)]-Gly-CO2H 29 
δH (500 MHz, DMSO-d6) 1.3 (6H, d, J = 6.0, 1-Hβ), 1.36 (6H, d, J = 6.0, 3-Hβ), 2.32 (3H, s, 2-Hα), 
3.93 (2H, d, J = 5.8, 4-Hα), 4.58 (1H, sept, J = 6.0, 1-Hα), 4.72 (1H, sept, J = 6.0, 3-Hα), 6.70 (1H, d, 
J = 8.3, 1-H5), 7.44-7.45 (2H, m, 1-H2 + 1-H6), 7.52 (1H, d, J = 8, 3-H6), 7.58-7.59 (2H, m, 2-H2 + 
2-H6), 7.76 (1H, d, J = 7.5, 2-H5), 7.82 (1H, s, 3-H2), 8.10 (1H, d, J = 8, 3-H5), 8.81 (1H, t, 5.8, 4-
NH), 9.26 (1H, s, 3-NH), 9.52 (1H, s, 2-NH); δC (125MHz, DMSO-d6) 18.21, 21.8, 21.9, 22.0, 41.2, 
70.5, 71.4, 112.6, 113.5, 119.9, 121.1, 121.6, 122.0, 125.0, 125.6, 129.5, 130.0, 130.7, 131.2, 132.9, 
140.6, 143.0, 143.2, 148.0, 164.5, 165.1, 165.8, 171.4; ESI-HRMS found m/z 561.2358 [M-H]
-
, 
C30H33N4O7 requires 561.2355. 
NH2-[O-iPr-(3-HABA)]-[O-p-
t
Bu-Bn-(3-HABA)]-[O-iPr-(3-HABA)]-Gly-CO2H 30  
δH (500 MHz, DMSO-d6) 1.30 (9H, s, 2-Ar-C(CH3)), 1.38 (6H, m, 1-Hβ, 3-Hβ), 3.95 (2H, d, J = 6.0, 
4-Hα), 4.59 (1H, sept, J = 6.0, 1-Hα), 4.74 (1H, sept, J = 6.0, 3-Hα), 5.30 (2H, s, 2-Hα), 6.73 (1H, d, 
J = 8.0, 1-H5), 7.36 (1H, d, J = 8, 1-H6), 7.40-7.44 (3H, m, 1-H2 + 2-HAr3),  7.51 (2H, d, J = 8.0, 2-
HAr2), 7.55 (1H, d, J = 8.0, 2-H6), 7.61-7.63 (2H, m, 2-H2 + 3-H6), 7.76 (1H, s, 3-H2), 8.11 (1H, d, 
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J = 8.2, 2-H5), 8.21 (1H, d, J = 8.2, 3-H5), 8.85 (1H, t, J = 6.0, 4-NH), 9.14 (1H, s, 2-NH), 9.35 (1H, 
s, 3-NH); δC (125MHz, DMSO-d6) 27.1, 27.2, 36.3, 39.5, 46.5, 75.3, 75.7, 76.7, 116.8, 117.9, 118.1, 
118.3, 125.1, 125.4, 126.6, 126.6, 126.8, 127.1, 130.4, 132.6, 135.0, 135.3, 136.4, 136.8, 138.9, 148.7, 
153.3, 154.0, 155.7, 169.5, 169.8, 171.1, 176.6; ESI-HRMS found m/z 733.3189 [M+Na]
+
, 
C40H46N4NaO8 requires 733.3208. 
NH2-[O-iPr-(3-HABA)]-[O-CH2-CH2-indole-(3-HABA)]-[O-iPr-(3-HABA)]-Gly-CO2H 32  
LC-MS analysis of this reaction indicated reasonable coupling of the central indole monomer to give 
the target trimer, however it was not possible to purify and isolate this oligomer. ESI-MS found m/z 
708 [M+H]
+
. 
NH2-[O-iPr-(3-HABA)]-[O-CH2-COOH-(3-HABA)]-[O-iPr-(3-HABA)]-Gly-CO2H 33  
δH (500 MHz, DMSO-d6) 1.31 (6H, d, J = 6.0, 1-Hβ), 1.35 (6H, d, J = 6.0, 3-Hβ), 3.93 (2H, d, J = 5.8, 
4-Hα), 4.61 (1H, sept, J = 6.0, 1-Hα), 4.71 (1H, sept, J = 6.0, 3-Hα), 4.91 (2H, s, 2-Hα), 5.43 (2H, br. 
s, 1-NH2), 6.70 (1H, d, J = 8.5, 1-H5), 7.42-7.43 (2H, m, 1-H2 + 1-H6), 7.52 (1H, d, J = 8.0, 2-H6), 
7.58 (1H, s, 2-H2), 7.61-7.66 (2H, m, 3-H2 + 3-H6), 8.06 (1H, d, J = 8.5, 2-H5), 8.32 (1H, d, J = 8.1, 
3-H5), 8.80 (1H, t, J = 5.8, 4-NH), 9.28 (1H, s, 3-NH), 9.43 (1H, s, 2-NH); δC (125MHz, DMSO-d6) 
21.8, 21.9, 67.2, 70.4, 71.5, 112.6,  112.7, 112.8, 113.5, 119.8, 120.1, 120.7, 121.4, 121.4, 122.0, 
129.1, 130.1, 131.1, 132.5, 143.3, 143.5, 147.8, 148.1, 164.0, 164.5, 165.8, 170.7, 171.4; ESI-HRMS 
found m/z 645.2087 [M+Na]
+
, C31H34N4NaO10 requires 645.2167. 
NH2-[O-iPr-(3-HABA)]-[O-CH2-CH2-CH2-S-CH2-(3-HABA)]-[O-iPr-(3-HABA)]-Gly-CO2H 34  
δH (500 MHz, DMSO-d6) 1.31 (6H, d, J = 6.0, 1-Hβ), 1.35 (6H, d, J = 6.0, 3-Hβ), 2.05 (3H, s, 2-
SCH3), 2.10 (2H, m, 2-Hβ), 2.69 (2H, t, J = 7.1, 2-Hγ), 3.93 (2H, d, J = 5.8, 4-Hα), 4.24 (2H, t, J 
=5.5, 2-Hα), 4.60 (1H, sept, J = 6.0 , 1-Hα), 4.72 (1-H, sept, J = 6.0, 3-Hα), 6.71 (1H, d, J = 8.0, 1-
H5), 7.35-7.42 (2H, m, 1-H2, 1-H6), 7.52 (1H, d, J = 8.0, 2-H6), 7.56-7.60 (3H, m, 2-H2, 3-H2, 3-
H6), 8.09 (1H, d, J = 8.0, 2-H5), 8.20 (1H, d, J = 8.0, 3-H5), 8.81 (1H, t, J = 5.8, 4-NH),  9.06 (1H, s, 
2-NH), 9.30 (1H, s, NH); δC (125MHz, DMSO-d6) 14.7. 21.8, 21.9, 28.2, 30.0, 41.2, 67.2, 70.4, 71.5, 
110.7, 112.6, 112.8, 112.9, 119.9, 121.0, 121.1, 121.6, 121.7, 129.6, 130.0, 131.2, 131.3, 143.1, 143.3, 
148.1, 148.7, 164.2, 164.7, 165.8, 171.4; ESI-HRMS found m/z 675.2433 [M+Na]
+
, C33H40N4NaO8S 
requires 675.2459. 
NH2-[O-iPr-(3-HABA)]-[O-CH2-CONH2-(3-HABA)]-[O-iPr-(3-HABA)]-Gly-CO2H 35  
δH (500 MHz, DMSO-d6) 1.31 (6H, d, J = 6.0, 1-Hβ), 1.36 (6H, d, J = 6.0, 3-Hβ), 3.93 (2H, d, J = 5.6, 
4-Hα), 4.61-4.71 (4H, m, 1-Hα, 2-Hα + 3-Hα), 6.71 (1H, d, J = 8.8, 1-H5), 7.46-7.47 (2H, m, 1-H2 + 
1-H6), 7.52 (1H, d, J = 8.5, 2-H6), 7.58-7.63 (2H, m, 2-H2 + 3-H6), 7.86 (1H, s, 3-H2), 8.06 (1H, d, J 
= 8.5, 2-H5), 8.11 (1H, d, J = 8.5, 3-H5), 8.81 (1H, t, J = 5.6, 4-NH), 9.31 (1H, s, 3-NH), 9.73 (1H, s, 
2-NH); δC (125MHz, DMSO-d6) 21.8, 21.9, 41.2, 66.5, 68.2, 71.5, 112.7, 119.8, 121.0, 121.1, 122.0, 
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129.8, 130.1, 130.2, 131.0, 131.1, 132.1, 143.3, 148.2, 148.3, 164.1, 164.9, 165.8, 170.2, 171.5; ESI-
HRMS found 622.2517 m/z [M+H]
+
, C31H36N5O9 requires 622.2508. 
NH2-[O-iPr-(3-HABA)]-[O-CH2-CH2-NH2-(3-HABA)]-[O-iPr-(3-HABA)]-Gly-CO2H 36 
δH (500 MHz, DMSO-d6) 1.31 (6H, d, J = 6.0, 1-Hβ), 1.35 (6H, d, J = 6.0, 3-Hβ), 3.37 (2H, m, 2-Hβ), 
3.93 (2H, d, J = 5.8, 4-Hα), 4.38 (2H, t, J = 4.1, 2-Hα), 4.60 (1H, sept, J = 6.0, 1-Hα), 4.72 (1H, sept, 
J = 6.0, 3-Hα), 6.72 (1H, d, J = 8.1, 1-H5), 7.39-7.42 (2H, m, 1-H2 + 1-H6), 7.53 (1H, dd, J = 8.3, 
1.8, 2-H6), 7.59-7.63 (3H, m, 2-H2, 3-H2 + 3-H6), 8.06 (1H, d, J = 8.3, 2-H5), 8.29 (1H, d, J = 8.9, 3-
H5), 8.83 (1H, t, J = 5.8, 4-NH), 9.29 (1H, s, 2-NH), 9.32 (1H, s, 3-NH); δC (125MHz, DMSO-d6) 
20.7, 20.8, 63.9, 69.4, 70.3, 109.6, 111.6, 112.3, 118.8, 119.2, 119.9, 120.0, 120.9, 121.1, 128.3, 
129.0, 129.9, 130.2, 142.1, 142.1, 146.6, 147.1, 163.0, 164.3, 164.7, 170.25; ESI-HRMS found m/z 
608.2701 [M+H]
+
, C31H38N5O8 requires 608.2715. 
NH2-[O-iPr-(3-HABA)]-[O-CH2-CH2-CH2-CH2-CH2-NH2-(3-HABA)]-[O-iPr-(3-HABA)]-Gly-
CO2H 37 
δH (500 MHz, DMSO-d6) 1.31 (6H, d, J = 6.0, 1-Hβ), 1.35 (6H, d, J = 6.0, 3-Hβ), 1.51 (2H, m, 2-Hγ), 
1.60 (2H, m, 2-Hδ), 1.85 (2H, m, 2-Hβ), 2.78 (2H, m, 2-Hε), 3.93 (2H, d, J = 5.5, 4-Hα), 4.17 (2H, t, 
J = 6.5, 2-Hα), 4.60 (1H, sept, J = 6.0, 1-Hα), 4.72 (1H, sept, J = 6.0, 3-Hα), 5.42 (2H, br. s, 1-NH2), 
6.70 (1H, d, J = 8.0, 1-H5), 7.35 (1H, d, J = 8.0, 1-H6), 7.38 (1H, s, 1-H2), 7.53 (1H, d, J = 8.5, 3-
H6), 7.52-7.70 (3H, m, 2-H2, 2-H6 + 3-H2), 8.09 (1H, d, J = 8.0, 3-H5), 8.19 (1H, d, J = 8.5, 2-H5), 
8.81 (1H, t, J = 5.5, 4-NH), 9.01 (1H, s, 2-NH), 9.28 (1H, s, 3-NH); δC (125MHz, DMSO-d6) 21.8, 
21.9, 22.2, 26.5, 27.9, 38.7, 41.2, 68.0, 70.5, 71.4, 110.9, 112.6, 112.9, 113.2, 119.8, 119.9, 121.1, 
121.4, 121.7, 129.7, 130.0, 131.1, 131.3, 142.6, 143.5, 148.0, 148.8, 164.2, 164.6, 165.8, 171.4; ESI-
HRMS found m/z 648.3048 [M-H]
-
, C34H42N5O8 requires 648.3039. 
NH2-[O-iPr-(3-HABA)]-[O-iBu-(3-HABA)]-[O-iLeu-(3-HABA)]-Ile-CO2H 39  
δH (500 MHz, DMSO-d6) 0.88 (3H, t, J = 7.4, 4-Hδ), 0.93-0.97 (6H, m, 3-Hγ + 4-CHβ(CH3)), 1.04 
(6H, d, J = 6.6, 2-Hγ), 1.25-1.31 (10H, m, 1-Hβ + 3-CHα(CH3) + 4-Hγ'), 1.53 (1H, m, 4-Hγ), 1.63-
1.79 (2H, m, 3-Hβ + 3-Hβ'), 1.96 (1H, m, 4-Hβ), 2.15 (1H, 2-Hβ), 3.95 (2H, d, J = 6.6, Hα), 4.35 (1H, 
t, J = 7.7, 4-Hα), 4.53-4.64 (2H, m, 1-Hα + 3-Hα), 6.76 (1H, d, J = 8.1, 1-H5), 7.36 (1H, dd, J = 8.1, 
1.5, 1-H6), 7.39 (1H, d, J = 1.5, 1-H2), 7.56-7.61 (4H, m, 2-H2, 2-H6, 3-H2 + 3-H6), 8.09 (1H, d, J = 
8.1, 3-H5), 8.22 (1H, d, J = 8.1, 2-H5), 8.40 (1H, d, J = 7.7, 4-NH), 9.03 (1H, s, 2-NH), 9.30 (1H, s, 
3-NH); δC (125MHz, DMSO-d6) 9.3, 11.0, 15.7, 18.9, 19.0, 21.9, 25.2, 27.8, 28.5, 35.7, 57.2, 70.5, 
74.6, 76.0, 110.6, 112.7, 123.0, 113.5, 119.9, 120.2, 120.8, 121.4, 121.5, 121.8, 129.6, 130.3, 131.1, 
131.3, 142.2, 143.7, 148.1, 148.7, 158.1, 158.3, 164.2, 164.5, 166.1, 173.2; ESI-HRMS found m/z 
713.3508 [M+Na]
+
, C38H50N4NaO8 requires 713.3521.   
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NH2-[O-iPr-(3-HABA)]-[O-CH2-cPr-(3-HABA)]-[O-iBu-(3-HABA)]-[O-iBu-(3-HABA)]-Gly-
CO2H 41 
δH (500 MHz, DMSO-d6) 0.44 (2H, m, 2-Hγ), 0.62 (2H, m, 2-Hγ'), 1.06 (12H, m, 3-Hγ + 4-Hγ), 1.31 
(6H, d, J = 6.0, 1-Hβ), 1.34 (1H, m, 2-Hβ), 2.16 (2H, m, 3-Hβ + 4-Hβ), 3.91-3.93 (4H, m, 3-Hα + 4-
Hα), 4.04 (2H, d, J = 6.8, 2-Hα), 4.63 (1H, sept, J = 6.2, 1-Hα), 6.74 (1H, d, J = 8.3, 1-H5), 7.37-7.42 
(2H, m, 1-H2 + 1-H6), 7.54-7.68 (6H, m, 2-H2, 2-H6, 3-H2, 3-H6, 4-H2 + 4-H6), 8.05 (1H, d, J = 
8.3, 4-H5), 8.11 (1H, d, J = 8.1, 3-H5), 8.26 (1H, d, J  = 8.1, 2-H5), 8.86 (1H, t, J = 5.6, 5-NH), 9.05 
(1H, s, 2-NH), 9.44 (1H, s, 4-NH), 9.46 (1H, s, 3-NH); δC (125MHz, DMSO-d6) 2.9, 10.0, 19.06, 
19.10, 21.9, 25.1, 27.8, 27.9, 41.2, 67.0, 70.4, 73.2, 74.5, 74.6, 110.8, 110.9, 111.1, 112.7, 112.8, 
119.8, 119.9, 120.2, 120.4, 120.8, 121.4, 122.3, 129.3, 130.1, 130.4, 130.6, 130.7, 131.5, 143.2, 143.4, 
148.4, 149.7, 149.8, 164.2, 164.3, 164.5, 171.4; ESI-HRMS found m/z 846.3699 [M+H]
+
, 
C45H53N5NaO10 requires 846.3685. 
NH2-[O-iPr-(3-HABA)]-[O-CH2-cPr-(3-HABA)]-[O-CH2-cPr-(3-HABA)]-[O-iBu-(3-HABA)]-
Gly-CO2H 42  
δH (500 MHz, DMSO-d6) 0.42 (4H, m, 2-Hγ + 3-Hγ), 0.58 (4H, m, 2-Hγ' + 3-Hγ'), 1.31 (6H, d, J = 
6.0, 1-Hβ), 1.35 (6H, d, J = 6.0, 4-Hβ), 1.35 (2H, m, 2-Hβ + 3-Hβ), 3.93 (2H, d, J = 4.9, 5-Hα), 4.61 
(1H, sept, J = 6.0, 1-Hα), 4.72 (1H, sept, J = 6.0, 4-Hα), 6.72 (1H, d, J = 8.1, 1-H5), 7.36 (1H, dd, J = 
8.1, 1.8, 1-H6), 7.38 (1H, d, J = 1.8, 1-H2), 7.53 (1H, d, J = 8.3, H5), 7.53-7.61 (5H, m, 2-H2, 3-H2 + 
H5), 8.08 (1H, d, J = 8.5, 4-H5), 8.12 (1H, d, J = 8.3, 3-H5), 8.26 (1H, d, J = 8.3, 2-H5), 8.81 (1H, t, 
J = 4.9, 5-NH), 9.02 (1H, s, 2-NH), 9.32 (1H, s, 4-NH), 9.39  (1H, s, 3-NH); δC (125MHz, DMSO-d6) 
2.87, 2.91, 10.0, 21.8, 21.9, 41.2, 70.5, 71.4, 73.0, 73.2, 111.3, 111.6, 112.6, 112.7, 112.8, 119.9, 
120.2, 120.3, 120.9, 121.4, 121.8, 122.0, 129.3, 130.1, 130.5, 130.0, 131.1. 131.6, 143.3, 148.1, 148.4, 
149.5, 164.2, 164.3, 164.5, 165.8, 171.4; ESI-HRMS found m/z 830.3364 [M+Na]
+
, C44H49N5NaO10 
requires 830.3372. 
NH2-[O-iPr-(3-HABA)]-[O-iPr-(3-HABA)]-[O-iPr-(3-HABA)]-[O-iPr-(3-HABA)]-[O-iPr-(3-
HABA)]-[O-iPr-(3-HABA)]-Gly-CO2H 43 
δH (500 MHz, DMSO-d6) 1.34-1.42 (36H, m, 1-6Hβ), 3.95 (2H, d, J = 5.5, 4-Hα), 4.59-4.76 (6H, m, 
1-6Hα), 6.78 (1H, d, J = 8.0, 1-H5), 7.34-7.37 (2H, m, 1-H2 + 1-H6), 7.54-7.64 (10H, m, 2-H2, 2H-6, 
3-H2, 3-H6, 4-H2, 4-H6, 5-H2, 5-H6, 6-H2, 6-H6), 8.16 (1H, d, J = 8.5, H5), 8.24-8.27 (3H, m, H5), 
8.34 (1H, d, J = 8.5, H5), 8.59 (1H, m, 7-NH), 8.87 (1H, s, 2-NH), 9.16-9.22 (4H, m, 3-NH, 4-NH, 5-
NH, 6-NH); δC unable to obtain meaningful spectrum; ESI-HRMS found m/z 1160.4982 [M+Na]
+
, 
C62H71N7NaO14 requires 1160.4951; found m/z 1182.4777 [M+2Na-H]
+
, C62H70N7Na2O14 requires 
1182.4771. 
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 NH2-[O-pCl-Bn-(3-HABA)]-[O-2-CH2-Nap-(3-HABA)]-[O-iPr-(3-HABA)]-Gly-CO2H 45 
δH (300 MHz,DMSO-d6) 1.33 (6H, d, J = 6.2, 3-Hβ), 3.93 (2H, d, J = 5.8, 4-Hα), 4.70 (1H, sept, J = 
6.2, 3-Hα), 5.06 (2H, s, 1-Hα), 5.49 (2H, s, 2-Hα), 6.69 (1H, d, J = 8.3, 1-H5), 7.39-7.50 (5H, m, 1-
H2, 1-H6 + ArCH), 7.53 (1H, dd, J = 8.3, 1.7, 3-H6), 7.58 (1H, d, J = 1.7, 3-H2), 7.61 (1H, dd, J = 
8.3, 1.7, 2-H6), 7.70 (1H, dd, J = 8.5, 2.8, 2-ArCH), 7.77 (1H, d, J =  1.8, 2-H2), 7.84-7.87 (2H, m, 
ArCH), 7.92 (1H, d, J = 8.8, ArCH), 8.07-8.09 (2H, m, 3-H5 + ArCH), 8.20 (1H, d, J = 8.3, 2-H5), 
8.81 (1H, t, J = 5.8, 4-NH), 9.21 (1H, s, 2-NH), 9.30 (1H, s, NH); δC (125 MHz, DMSO-d6) 30.4, 
41.2, 68.6, 70.4, 71.4, 111.2, 111.8, 112.5, 119.9, 120.8, 121.4, 121.8, 124.9,  125.3, 125.9, 126.2, 
126.4, 127.6, 128.1, 128.3, 129.2, 129.8, 130.0, 131.1, 131.6, 132.3, 132.6, 132.8, 134.4, 136.0, 139.2, 
142.4, 144.1, 148.1, 148.8, 151.4, 164.2, 164.6, 165.8, 171.4; ESI-HRMS found m/z 809.2468 
[M+Na]
+
, C44H39ClN4NaO8 requires 809.2354. 
NH2-[O-Bn-(3-HABA)]-[O-mCF3-Bn-(3-HABA)]-[O-iPr-(3-HABA)]-Gly-CO2H 46 
δH (300 MHz,DMSO-d6) 1.34 (6H, d, J = 6.0, 3-Hβ), 3.93 (1H, d, J = 5.8, 4-Hα), 4.71 (1H, sept, J = 
6.0, 3-Hα), 5.14 (2H, s, Hα), 5.42 (2H, s, Hα), 6.77 (1H, d, J = 8.3, 1-H5), 7.32 (1H, m, 1-HAr4), 
7.37-7.41 (3H, m, 1-H6 + 1-HAr3), 7.48 (2H, d, J  = 7.3, 1-HAr2), 7.53 (2H, m, 3-H6 + 1-H2), 7.58 
(1H, d, J = 1.3, 3-H2), 7.60-7.63 (2H, m, 2-H6 + 2-HAr5), 7.67 (1H, m, 2-HAr4), 7.73 (1H, dd, J = 
8.3, 1.5, 2-H2), 7.85 (1H, d, J = 7.7, 2-HAr6), 8.00 (1H, s, 2-HAr2), 8.07 (1H, d, J = 8.3, 3-H5), 8.13 
(1H, d, J = 8.3, 2-H5), 8.81 (1H, t, J = 5.9, 4-NH), 9.31 (2H, m, 2-NH + 3-NH); δC (125 MHz, 
DMSO-d6) 21.8, 41.2, 69.3, 69.5, 71.5, 111.5, 111.7, 112.7, 113.5, 114.1, 116.4, 119.9, 120.2, 121.4, 
121.9, 122.2, 123.9, 125.3, 124.6, 127.4 (2), 127.8, 128.4 (2), 129.5 130.1, 131.2, 131.3, 131.4, 137.0, 
138.3, 142.8, 148.1, 149.0, 158.1, 158.4, 164.2, 164.5, 165.8, 171.4; ESI-HRMS found m/z 793.2438 
[M+Na]
+
, C41H37F3N4NaO8 requires 793.2456. 
NH2-[O-Bn-(3-HABA)]-[O-iBu-(3-HABA)]-[O-iBu-(3-HABA)]-Gly-CO2H 47 
δH (300 MHz,DMSO-d6) 1.02-1.04 (12H, m, 2-Hγ + 3-Hγ), 2.10-2.18 (2H, m, 2-Hβ + 3-Hβ), 3.90-
3.95 (6H, m, 2-Hα, 3-Hα + 4-Hα), 5.18 (2H, s, 1-Hα), 6.73 (1H, d, J = 8.1, 1-H5), 7.32-7.42 (4H, m, 
1-H6, 1-HAr3 + 1-HAr4), 7.48 (1H, d, J = 1.7, 1-H2), 7.51-7.60 (6H, m, 2-H2, 2-H6, 3-H2, 3-H6 +1-
HAr2),8.03 (1H, d, J = 8.1, 3-H5), 8.21 (1H, d, J = 8.3, 2-H5), 8.81 (1H, t, J = 5.9, 4-NH), 9.01 (1H, 
s, 2-NH), 9.37 (1H, s, 3-NH); δC (125 MHz, DMSO-d6) 19.08, 19.12, 19.4, 27.8, 27.8, 41.2, 69.5, 
74.6, 110.5, 110.8, 110.8, 111.1, 112.7, 119.8, 119.8, 120.1, 120.7, 120.9, 121.5, 122.1, 127.4 (2), 
127.8, 127.8, 128.4 (2), 129.6, 129.6, 130.1, 131.3, 137.1, 144.4, 148.6, 149.7, 164.2, 164.5, 165.8, 
171.4; ESI-HRMS found m/z 705.2897 [M+Na]
+
, C37H40N4NaO8 requires 705.2900. 
NH2-[O-CH2-COOH-(3-HABA)]-[O-iBu-(3-HABA)]-[O-iLeu-(3-HABA)]-Val-CO2H 48 
δH (300 MHz,DMSO-d6) 0.94-1.02 (15H, m, 2-Hγ, 3-Hγ + 4-Hγ), 1.30 (3H, d, J = 6.0, 3-CHα(CH3)), 
1.63-1.77 (2H, m, 3-Hβ + 3-Hβ'), 2.12 (1H, m, 2-Hβ), 2.18 (1H, m, 4-Hβ), 3.93 (2H, d, J = 6.6, 2-
Hα), 4.29 (1H, t, J = 7.6, 4-Hα), 4.57 (1H, m, 3-Hα), 4.66 (2H, s, 1-Hα), 7.01 (1H, d, J = 8.1, 1-H5), 
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7.52 (1H, s, 1-H2), 7.56-7.58 (5H, m, 1-H6, 2-H2, 2-H6, 3-H2 + 3-H6), 8.03 (1H, d, J = 8.3, 3-H5), 
8.07 (1H, d, J = 8.1, 2-H5), 8.40 (1H, d, J = 8.1, 4-NH), 9.33 (1H, s, 2-NH), 9.36 (1H, s, 3-NH), 11.00 
(1H, s, 1-Hα(CO2H); (125 MHz, DMSO-d6) 9.3, 18.9, 19.0, 19.4, 27.7, 28.5, 29.5, 58.4, 66.7, 74.6, 
76.1, 111.0, 113.0, 115.2, 115.6, 119.7, 120.2, 121.7, 122.0, 122.7, 128.9, 130.4, 130.5, 130.6, 130.9, 
131.1, 142.9, 148.2, 150.0, 163.9, 164.2, 164.9, 166.2, 173.2; ESI-HRMS was not obtainable. 
NH2-[O-CH2-COOH-(3-HABA)]-[O-2-Nap-(3-HABA)]-[O-iBu-(3-HABA)]-Val-CO2H 49 
δH (300 MHz,DMSO-d6) 0.97-1.00 (12H, m, 3-Hγ + 4-Hγ), 2.08 (1H, m, 3-Hβ), 2.19 (1H, m, 4-Hβ), 
3.9 (2H, d, J = 6.9, 3-Hα), 4.30 (1H, t, J = 7.5, 4-Hα), 4.65 (2H, s, 1-Hα), 5.47 (2H, s, 2-Hα), 6.99 
(1H, d, J = 7.9, 1-H5), 7.52-7.66 (8H, m, 1-H2, 1-H6, 2-H6, 3-H2, 3-H6 + 2-ArCH), 7.79 (1H, s, 2-
H2), 7.85 (1H, d, J = 7.1, 2-ArCH), 7.91-7.98 (3H, m, 3-H5 + 2-ArCH), 8.03 (1H, d, J = 8.1, 2-H5), 
8.07 (1H, s, 2-HAr2), 8.40 (1H, d, J = 8.1, 4-NH), 9.43 (1H, s, 3-NH), 9.57 (1H, s, 2-NH), 10.98 (1H, 
s, 1-Hα(CO2H); 125 MHz, DMSO-d6) 18.9, 19.1, 19.4, 27.7, 29.6, 58.4, 66.7, 70.2, 74.76, 111.4, 
112.0, 115.3, 115.6, 120.0, 120.1, 122.2, 122.3, 123.1, 125.1, 125.7, 126.1, 126.4, 127.6, 127.7, 128.1, 
128.9, 130.0, 130.6, 130.8, 130.9, 131.0, 132.6, 132.8, 134.4, 142.9, 149.8, 149.9, 164.0, 164.2, 164.9, 
166.2, 173.2; ESI-HRMS found m/z 776.3295 [M], C43H44N4O10 requires 776.3057. 
NH2-[O-Bn-(3-HABA)]-[O-2-CH2-Nap-(3-HABA)]-[O-iPr-(3-HABA)]-Asp-CO2H 50 
δH (300 MHz,DMSO-d6) 1.34 (6H, d, J = 6.0, 3-Hβ), 4.71 (1H, sept, J = 6.0, 3-Hα), 4.76 (1H, m, 4-
Hα), 5.13 (2H, s, 1-Hα), 5.32 (2H, s, 2-Hα), 5.50 (2H, br. s, 4-Hβ), 6.72 (1H, d, J = 8.1, 1-H5), 7.31-
7.60 (18H, m, 1-H2, 1-H6, 2-H6, 3-H2, 3-H6, 4-HβCO2H + ArCH), 7.68 (1H, s, 2-H2), 8.07 (1H, d, J 
= 8.3, 3-H5), 8.18 (1H, d, J = 8.3, 2-H5), 8.70 (1H, d, J = 7.90, 4-NH), 9.15 (1H, s, 2-NH), 9.29 (1H, 
s, 3-NH); δC (125 MHz, DMSO-d6) 21.8, 25.1, 35.9, 39.1, 67.0, 69.4, 69.5,71.5, 111.2, 111.7, 112.5, 
112.9, 120.0, 120.2, 120.8, 121.5, 121.8, 121.8, 127.5 (2) ,127.8, 128 .4 (2), 128.5 (2), 129.3 (2), 
129.8, 130.0, 131.2, 131.5, 132.6, 135.8, 137.0, 142.4, 142.9, 144.3, 148.1, 148.6, 164.2, 164.6, 165.4, 
170.7, 171.8, 172.6;ESI-HRMS found m/z 833.1894 [M+Na]
+
, C46H42N4NaO10 requires 833.2799. 
NH2-[O-Bn-(3-HABA)]-[O-2-CH2-Nap-(3-HABA)]-[O-iPr-(3-HABA)]-Lys-CO2H 51 
δH (300 MHz,DMSO-d6) 1.33 (6H, d, J = 6.0, 3-Hβ), 1.40-1.47 (4H, m, 4-Hδ + 4-Hε) 1.77-1.88 (4H, 
m, 4-Hβ + 4-Hγ), 4.38-4.42 (1H, m, 4-Hα), 4.71 (1H, sept, J = 6.0, 3-Hα), 5.08 (2H, s, 1-Hα), 5.50 
(2H, s, 2-Hα), 6.70 (1H, d, J = 8.1, 1-H5), 7.29–17.42 (5H, m, 1-H6 + ArCH), 7.47-7.50 (2H, m, 
ArCH), 7.56-7.72 (6H, m, 2-H6, 3-H6 + ArCH), 7.77 (1H, s, 3-H2), 7.84-7.87 (2H, m, ArCH), 7.92 
(1H, d, J = 8.5, ArCH), 8.07-8.08 (2H, m, 2-H2 + 3-H5), 8.21 (1H, d, J = 8.1, 2-H5), 8.56 (1H, d, J = 
7.9, 4-NH), 9.22 (1H, s, 2-NH), 9.32 (1H, s, 3-NH); δC (125 MHz, DMSO-d6) 21.8, 22.8, 25.1, 30.1, 
38.7, 52.3, 69.4, 70.4, 71.5, 111.1, 111.8, 112.5, 113.0, 120.1, 121.5, 121.7, 121.8, 125.3, 125.9, 
126.2, 126.4, 127.4 (2), 127.6, 127.7, 127.7, 128.1, 128.3 (2), 129.8, 130.2, 131.2, 131.6, 132.6, 
132.8, 134.4, 137.0, 142.4, 144.3, 148.1, 148.8, 157.7, 158.0, 164.2, 164.6, 165.8, 173.3; ESI-HRMS 
found m/z 824.3677 [M+H]
+
, C48H50N5O8 requires 824.3659. 
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6.4 Molecular Modelling (Chapter 2) 
Conformational search and Superposition with a gp41 extended helix 
A conformational search was performed on hexamer  43. The structure was minimised by employing 
a full Monte Carlo search in the software Macromodel® using the MMFFs (Merk Molecular Force 
Fields) method. Water was chosen as implicit solvent and free rotation around the amide bonds was 
allowed in order to increase the accuracy of the conformational search. The results revealed the lowest 
energy conformation was the extended structure and all six side chains lie on the same face; a 
conformation displaying an alternative arrangement of side-chains however, has a relative potential 
energy of +3.2 kJ mol
-1
 demonstrating a variety of rotamers are accessible. Using a crystal structure of 
gp41 (PDB ID: 1AIK) we took a series of superpositions from our hexamer using different 
combinations of side chains (eg side chains 1,2 + 3 or 5,4 + 3) and the extended helix using different 
combinations of residues (e.g. i, i + 3 and i + 7 or i, i + 4 and i + 8) and at varying positions on the 
helix (e.g. towards the N or C terminus). From the relatively small set we sampled in comparison to 
the available combinations, we achieved RMSD (Root Mean Square Deviation) values ranging from 
0.421-0.788 when superimposing 3 atom pairs consisting of the oxygen of the alkoxy group and the 
a carbon of the amino acids.  
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6.5 Biophysical Assessment of Proteomimetics (Chapter 3) 
Assay Procedures  
Protein Titration: The assay was carried out manually and plates prepared as follows (96 well plate); 
 Make a 4x concentration solution of protein; if concentration range desired is 337 µM – 760 
nM, then a 1.52 mM stock is made 
 Make a 2x concentration solution of tracer; if the final concentration desired is 54.5 nM, then 
a 109 nM stock is made 
 Add buffer (50 µL) to each well  
 Add the protein stock (50 µL) to the first well (6 rows) and mix 
 Take half of this solution (50 µL) and transfer to the second well 
 Mix and transfer half, repeating to the last well: the final 50 µL is discarded 
 Add tracer solution (50 µL) to each well (3 rows) 
 Add buffer solution (50 µL) to each well (3 rows) 
 The final volume in all wells should be 100 µL 
 Cover and allow the plate to incubate for a set amount of time 
Competition Assays: Competition assays, including peptide displacement assays, were all carried out 
using the same format and kept on a single plate to reduce intensity fluctuations which can 
arise when using different plates (observed in preliminary experiments). The assays were 
prepared as follows (96 well plate); 
 Make a 4.5x concentration solution of ligand  
 Make a 3x concentration solution of protein 
 Make a 3x concentration solution of tracer  
 Add buffer (50 µL) to each well 
 Add the ligand stock (100 µL) to the first well (6 rows) and mix 
 Take 2/3 of this solution (100 µL) and transfer to the next well 
 Mix and transfer 2/3 again, repeating to the last well: the final 100 µL is discarded 
 Add the tracer solution (50 µL) to each well (3 rows) 
 Add buffer solution (50 µL) to each well (3 rows) 
 The final volume should be 150 µL 
 Cover and allow the plate to incubate for a set amount of time 
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6.6 Monomer and Dimer Synthesis (Chapter 4)  
3-Isobutoxy-4-nitrobenzoic acid 56 
Procedure F; Methyl 3-isobutoxy-4-nitrobenzoate 16b (3.50 g, 13.8 mmol) in a 1:1 mixture of 
methanol : tetrahydrofuran (90 mL), 10% aqueous sodium hydroxide (21 mL). Following 
acidification the precipitate was filtered, dissolved in chloroform and dried with magnesium sulfate. 
The solution was filtered and the organic solvents removed under reduced pressure yielding a pale 
yellow solid which was crystallised (chloroform / methanol) to yield the title compound (3.15 g, 13.5 
mmol, 95%) as a yellow crystals; m.p. 199.8-202.1 C (chloroform / methanol); (Found C, 55.05; H, 
5.45; N, 5.80%. C11H13NO5 requires C, 55.23; H, 5.48; N, 5.86%); δH (300 MHz, DMSO-d6) 0.98 
(6H, d, J = 6.7, H-10), 2.03 (1H, sept, H-9), 4.01 (2H, d, J = 6.4, H-8), 7.63 (1H, dd, J = 8.3 + 1.3, H-
3), 7.74 (1H, d, J = 1.3, H-7), 7.96 (1H, d, J = 8.3, H-4); δC (75MHz, DMSO-d6) 19.0, 28.0, 75.5, 
115.6, 121.5, 125.3, 136.0, 142.5, 151.4, 166.12; υmax/cm
-1
 (solid state) = 3088-2531, 2342-1817, 
1693, 1310, 1015, 748;  ESI-HRMS found m/z 238.0721 [M-H]
-
, C11H12NO5 requires 238.0721; 
2,5-Dihydroxy-4-nitrobenzoic acid
167
 54 
To a stirred solution of 3-hydroxy-4-nitrobenzoic acid 62 (40.00 g, 218.4 mmol) in 2N aqueous 
sodium hydroxide solution (800 mL) was added dropwise a solution of potassium persulfate (59.00 g, 
218.4 mmol) in water (1200 mL) The resulting solution was stirred at RT for 14 days. The reaction 
mixture was strongly acidified via the addition of sulphuric acid (conc) and the resulting precipitate 
was removed by filtration. The aqueous solution was refluxed for 1 hour. After cooling to ambient 
temperature the resulting precipitate was collected via filtration to yield the title compound (16.11 g, 
80.9 mmol, 37%) as gold microcrystals; m.p. 245.1-246.2 C (water); (Found C, 42.05; H, 2.35; N, 
6.80%. C7H5NO6 requires C, 42.22; H, 2.53; N, 7.03%);  δH (300 MHz, DMSO-d6) 7.37 (1H, s, H5), 
7.49 (1H, s, H2); δC (75MHz, DMSO-d6) 112.5, 119.1, 119.7, 141.7, 143.1, 152.3, 170.11; υmax/cm
-1
 
(solid state) = 3533, 3400-2000, 169, 1598, 1442, 1244, 760, 627; ESI-HRMS found m/z 198.0049 
[M-H]
-
, C7H4NO6 requires 198.0044. 
Methyl 2,5-dihydroxy-4-nitrobenzoate 63 
To a stirred solution of 2,5-dihydroxy-4-nitrobenzoic acid 54 (5 g, 25.1mmol) in methanol (200 mL) 
was added slowly concentrated sulphuric acid  (2 mL) and the resulting solution was stirred at reflux 
overnight. The reation mixture was allowed to cool to ambient temperature and sodium bicarbonate 
was added until carbon dioxide evolution ceased. The mixture was added to water (250 mL) and 
extracted with ethyl acetate (3 x 100 mL) and the combined organic fractions washed further by brine 
(100 mL). The organic solvents were removed by reduced pressure and the resulting orange solid was 
crystallised by chloroform to yield the title compound (5.33g, 25.0 mmol, quant. yield) as orange 
crystals; m.p. 135.3-137.2 C (chloroform); (Found C, 45.15; H, 3.25; N, 6.45%. C8H7NO6 requires C, 
45.08; H, 3.31; N, 6.57%);δH (300 MHz,CDCl3) 4.02 (3H, s, CO2Me), 7.69 (1H, s, H2), 7.71 (1H, s, 
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H5), 9.75 (1H, s, O
6
H), 10.19 (1H, s, O
3
H); δC (75MHz, CDCl3) 53.7, 112.8, 120.8, 121.4, 137.5, 
146.7, 153.5, 168.9; υmax/cm
-1
 (solid state) = 3359,1695, 1440, 1220, 790; ESI-HRMS found m/z 
212.0207 [M-H], C8H6NO6 requires 212.0273. 
Methyl 2,5-diisobutoxy-4-nitrobenzoate 64 
Procedure A; Methyl 2,5-dihydroxy-4-nitrobenzoate 63 (4.00 g, 18.8 mmol) and potassium carbonate 
(13.0 g, 93.8 mmol) in dimethylformamide (200 mL), 1-bromo-2-methylpropane (6.5 mL, 56.3 
mmol). Following work-up, the title compound (4.41 g, 13.6 mmol, 72%) was yielded as a yellow oil; 
δH (500 MHz,CDCl3) 1.04-1.07 (12H, m, Hγ
3
 + Hγ6), 2.11-2.17 (2H, m, Hβ3 + Hβ6), 3.79 (2H, d, J = 
6.4, Hα), 3.85 (2H, d, J = 6.4, Hα), 3.94 (3H, s, CO2Me), 7.39 (1H, s, H2), 7.47 (1H, s, H5); δC 
(75MHz, CDCl3) 19.0, 19.1, 28.3, 28.3, 52.5, 76.2, 76.6, 110.3, 118.0, 125.3, 141.7, 145.7, 151.6, 
165.6; υmax/cm
-1
 (solid state) =  2960, 1739, 1529, 1392, 1217, 1024, 793; ESI-HRMS found m/z 
348.1417 [M+Na]
+
, C16H23NNaO6 requires 348.1418;  
2,5-Diisobutoxy-4-nitrobenzoic acid 55 
Procedure F; Methyl 2,5-diisobutoxy-4-nitrobenzoate 64 (2.16 g, 8.0 mmol) in a 1:1 mixture of 
methanol : tetrahydrofuran (50 mL), 10% aqueous sodium hydroxide (13 mL). Following workup 
solvent was removed under reduced pressure to yield the title compound (2.13 g, 6.84 mmol, 97%) as 
an amorphous yellow solid; δH (500 MHz, CDCl3) 1.05 (6H, d, J = 6.6, Hγ
3
), 1.12 (6H, d, J = 6.6, 
Hγ6), 2.14 (1H, m, Hβ3), 2.25 (1H, m, Hβ6), 3.91 (2H, d, J = 6.4, Hα), 4.04 (2H, d, J = 6.4, Hα), 7.50 
(1H, s, H5), 7.90 (1H, s, H2); δC (125MHz, CDCl3) 19.0, 19.1, 28.1, 28.2, 76.6, 77.6, 110.1, 119.5, 
121.9, 142.4, 146.9, 150.3, 163.7; υmax/cm
-1
 (solid state) = 3229, 2961, 1747, 1525, 1203, 1003, 803; 
ESI-HRMS found m/z 334.1267 [M+Na]
+
, C15H21NNaO6 requires 334.1261; 
Methyl 4-amino-2,5-diisobutoxybenzoate 57 
Procedure C; Methyl 2,5-diisobutoxy-4-nitrobenzoate 64 (2.24 g, 6.89 mmol), tin(II) chloride 
dihydrate (9.32 g, 41.33 mmol) in ethyl acetate (50 mL). Following workup solvent was removed 
under reduced pressure to yield the title compound (1.83 g, 6.2 mmol, 90%) as light brown greasy 
solid; δH (500 MHz, CDCl3) 1.03-1.06 (12H, m, Hγ
3
 + Hγ6), 2.07-215 (2H, m, Hβ3 + Hβ6), 3.71 (2H, 
d, J = 6.4, Hα), 3.76 (2H, d, J = 6.4, Hα), 3.85 (3H, s, CO2Me), 6.29 (1H, s, H5), 7.33 (1H, s, H2); δC 
(75MHz, CDCl3) 19.3, 19.4, 28.4, 28.5, 51.5, 75.2, 76.0, 100.0, 107.7, 114.8, 139.7, 142.2, 155.7, 
166.8; υmax/cm
-1
 (solid state) = 3492, 3368, 2957, 1704, 1621,1523, 1445, 1252, 1210, 1035, 780; ESI-
HRMS found m/z 318.1675 [M+Na]
+
, C16H25NNaO4 requires 318.1676; 
NH2-[O-iBu-(3-HABA)]-[O
3
-iBu-O
6
-iBu-(3-DHABA)]-CO2H 60 
To a solution containing 3-isobutoxy-4-nitrobenzoic acid 56 (250 mg, 1.12 mmol) in chloroform (10 
mL), was added ghosez’s reagent (145 μL, 1.08 mmol) and the resulting mixture was refluxed for 3 
hours. Methyl 4-amino-2,5-diisobutoxybenzoate 57 (331 mg, 1.12 mmol) was subsequently added and 
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heated at 50 °C overnight. The solvents were removed under reduced pressure and the resulting 
mixture submitted to flash chromatograpy (Biotage: DCM/Ethyl acetate gradient) before  taking 
intermediate 67 through to the next step without further isolation; Intermediate 68 was obtained from 
intermediate 67 by procedure C  following standard work up without purification/ isolation; 
Following Procedure F, NH2-[O-iBu-(3-HABA)]-[O
3
-iBu-O
6
-iBu-(3-DHABA)]-CO2H 60 was 
obtained and purified by biotage flash chromatography to isolate the title compound (estimated 
overall yield: 42%) as a beige amorphous solid; δH (500 MHz, DMSO-d6) 1.00-1.04 (18H, m, 1-Hγ, 2-
Hγ3 + 2-Hγ6), 2.01-215 (3H, m, 1-Hβ, 2-Hβ3 + 2-Hβ6), 3.75 (2H, d, J = 6.6, 2-Hα6), 3.79 (2H, d, J = 
6.6, 1-Hα), 3.84 (2H, d, J = 6.2, 2-Hα3), 5.49 (2H, br. s, NH2), 6.71 (1H, d, 1-H5), 7.30 (1H, d, J = 
1.7, 1-H2), 7.32-7.34 (2H, m, 1-H6 + 2-H2), 8.07 (1H, s, 2-H5), 8.93 (1H, s, 2-NH); δC (125MHz, 
CDCl3) 19.0, 19.1, 19.2, 27.8, 27.9, 27.9, 74.1, 75.0, 75.3, 106.3, 109.8, 112.4, 114.0, 114.4, 120.6, 
212.2, 132.5, 141.6, 142.3, 144.7, 152.9, 164.5, 166.6;υmax/cm
-1
 (solid state) = 3491, 3424, 3361, 
2958, 1711, 1593, 1515, 1435, 1261, 1026, 751, 623;  ESI-HRMS found m/z 473.2664 [M+H]
+
, 
C26H37N2O6 requires 473.2646; 
NH2-[O
3
-iBu-O
6
-iBu-(3-DHABA)]-[O-iBu-(3HABA)]-CO2H 61   
Acyl chloride formation Method A was used to isolate a stable acyl chloride from 2,5-diisobutoxy-4-
nitrobenzoic acid 55 (150 mg, 0.48 mmol). The acyl chloride is dissolved in chloroform (10 mL) and 
methyl 4-amino-3-isobutoxybenzoate 17b (107 mg, 0.48mmol) was subsequently added and the 
resulting mixture was heated at 50 °C overnight. The solvents were removed under reduced pressure 
and the resulting mixture submitted to flash chromatograpy (Biotage: DCM/Ethyl acetate gradient) 
before  taking intermediate 69 through to the next step without further isolation; Intermediate 70 was 
obtained from intermediate 69 by procedure C  following standard work up without purification/ 
isolation; Following Procedure F, NH2-[O
3
-iBu-O
6
-iBu-(3-DHABA)]-[O-iBu-(3HABA)]-CO2H 61 
was obtained and purified by biotage flash chromatography to isolate the title compound (estimated 
overall yield: 45%) as a beige amorphous solid which was crystallised from chloroform to give small 
rectangular crystals; δH (500 MHz, CDCl3) 1.01 (6H, d, J = 6.6, 1-Hγ
3
), 1.06-1.08 (12H, m, 1-Hγ6 + 2-
Hγ), 2.12-2.24 (3H, m, 1-Hβ3, 1-Hβ6 + 2-Hβ), 3.86 (2H, d, J = 6.4, 1-Hα3), 3.93-3.96 (4H, m, 1-Hα6 + 
2-Hα), 6.39 (1H, s, 1-H5), 7.66-7.68 (2H, m, 1-H2 + 2-H2), 7.84 (1H, d, J = 8.5, 2-H6), 8.76 (1H, d, J 
= 8.5, 2-H5), 10.43 (1H, s, 2-NH); δC (125MHz, CDCl3) 19.2, 19.2, 19.3, 27.8, 28.0, 28.3, 75.2, 75.6, 
75.6, 99.9, 111.5, 112.6, 114.1, 119.1, 124.2, 134.3, 141.0, 141.6, 147.5, 152.7, 164.4; υmax/cm
-1
 (solid 
state) = 3639, 3495, 3333, 2959, 1691, 1588, 1520, 1206, 1027, 768;  ESI-HRMS found m/z 473.2647 
[M+H]
+
, C26H37N2O6 requires 473.2646; 
NH2-[O-iBu-(3HABA)]-[O-iBu-(3HABA)]-CO2Me 72  
To a solution containing 3-isobutoxy-4-nitrobenzoic acid 56 (107 mg, 0.45 mmol) and methyl 4-
amino-3-isobutoxybenzoate 17b (100 mg, 0.45mmol) in chloroform (2 mL) was added thionyl 
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chloride (65 μL, 0.90 mmol) and the resulting mixture was heated under microwave irradiation at 50 
°C for 60 minutes. The solvents were removed under reduced pressure and the nitro/ester intermediate 
was taken through to the next step without purification/isolation. Procedure C followed by 
purification by biotage flash chromatography resulted in the title compound (yield over 2 steps: 54 
mg, 0.13 mmol, 30%) as a cream amorphous solid; δH (500 MHz, CDCl3) 1.07 (6H, d, J = 6.6, 1-Hγ), 
1.12 (6H, d, J = 6.6, 2-Hγ), 2.14-2.24 (2H, m, 1-Hβ + 2-Hβ), 3.86 (2H, d, J = 6.6, 1-Hα), 3.92 (3H, s, 
CO2Me), 3.94 (2H, d, J = 6.6, 2-Hα), 6.76 (1H, d, J = 8.1, 1-H5), 7.32 (1H, dd, J = 8.1, 1.9, 1-H6), 
7.42 (1H, d, J = 1.9, 1-H2), 7.56 (1H, d, J = 1.7, 2-H2), 7.74 (1H, dd, J = 8.5, 1.7, 2-H6), 8.64 (1H, d, 
J = 8.5, 2-H5), 8.74 (1H, s, 2-NH); δC (125MHz, CDCl3) 19.3, 19.4, 28.3, 28.4, 28.3, 52.0, 74.8, 75.1, 
110.4, 111.5, 113.6, 118.2, 120.0, 123.5, 124.3, 124.5, 132.8, 146.4, 146.9, 165.1, 166.9; υmax/cm
-1
 
(solid state) = 3461, 3333, 2959, 1721, 1541, 1271, 1203, 1020, 759, 586; ESI-HRMS found m/z 
415.2243 [M+H]
+
, C23H31N2O5 requires 415.2227; 
FmocNH-[O-iPr-(3HABA)]-[O-Bn-(3HABA)]-CO2Me 79 
To a solution containing 75 (100 mg, 0.24 mmol) and 77 (62 mg, 0.24 mmol) in chloroform (2 mL) 
was added thionly chloride (34 μL, 0.90 mmol) and the resulting mixture was heated under 
microwave irradiation at 50 °C for 60 minutes. The solvents were removed under reduced pressure 
and the crude material purified via Biotage® flash chromatography (Snap® cartridge: hexane-
dichloromethane-ethyl acetate ramp) to yield intermediate 79 (90.6 mg, 0.14 mmol, 60%) as an 
amorphous beige solid, identified by NMR and HRMS; δH (300 MHz, CDCl3) 1.39 (6H, d, J = 6.0, 1-
Hγ), 3.93 (3H, s, CO2Me), 4.35 (1H, t, J = 7.0, FHβ), 4.53 (1H, t, J = 7.0, FHα), 4.65 (1H, sept, J = 
6.0, 1-Hα), 5.23 (2H, s, 2-Hα), 7.26 (1H, m, 1-H6), 7.35 (2H, t, J = 7.5, FHAr4), 7.40-7.47 (9H, m, 
FHAr3, 1-H2, 1-H5, 2-HAr2, 2-HAr3 + 2-HAr4), 7.64 (2H, d, J = 7.3,  FHAr2), 7.73 (1H, d, J = 1.6, 
2-H2), 7.77-7.81 (3H, m, 2-H6 + FHAr5), 8.12 (1H, br. s, 1-NH) 8.67 (1H, d, J = 8.4, 2-H5),  8.80 
(1H, s, NH); ESI-HRMS found m/z 657.2567 [M+H]
+
, C40H37N2O7 requires 657.2595;  
NH2-[O-iBu-(3HABA)]-[O-Bn-(3HABA)]-CO2H 73 
Procedure F; Intermediate 79 (85 mg, 0.13 mmol) in a 1:1 mixture of methanol : tetrahydrofuran (3 
mL), 10% aqueous sodium hydroxide (1 mL). Work up yielded the title compound (38 mg, 0.09 
mmol, 70%) as a beige amorphous solid; δH (500 MHz, CDCl3) 1.33 (6H, d, J = 6.0, 1-Hβ), 4.54 (1H, 
sept, J = 6.0, 1-Hα), 5.24 (2H, s, 2-Hα), 6.67 (1H, d, J = 7.9, 1-H5), 7.20 (1H, d, J = 7.9, 1-H6), 7.36 
(1H, s, 1-H2), 7.40-7.50 (5H, m, 2-HAr2, 2-HAr3 + 2-HAr4), 7.76 (1H, s, 2-H2), 7.87 (1H, d, J = 8.3, 
2-H6), 8.71 (1H, d, J = 8.3, 2-H5), 8.76 (1H, s, 2-NH); δC (125MHz, CDCl3) 22.1, 70.8, 71.4, 112.2, 
112.5, 113.6, 118.5, 120.3, 123.4, 123.8, 125.0, 127.9, 128.6, 128.9, 133.8, 136.0, 141.5, 144.8, 146.7, 
165.1, 170.9;υmax/cm
-1
 (solid state) = 3431, 3344, 2975m 1682, 1516, 1206, 764; ESI-HRMS found 
m/z 421.1775 [M+H]
+
, C24H25N2O5 requires 421.1758; 
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FmocNH-[O-Bn-(3HABA)]-[O
3
-iBu-O
6
-iBu-(3-DHABA)]-CO2Me 80 
To a solution containing 76 (168 mg, 0.36 mmol) and 78 (104 mg, 0.36 mmol) in chloroform (2 mL) 
was added thionly chloride (53 μL, 0.72 mmol) and the resulting mixture was heated under 
microwave irradiation at 50 °C for 60 minutes. The solvents were removed under reduced pressure 
and the crude material purified via Biotage® flash chromatography (Snap® cartridge: hexane-
dichloromethane-ethyl acetate ramp) to yield intermediate 80 (165 mg, 0.22 mmol, 62%) as an 
amorphous beige solid, identified by NMR and HRMS; δH (500 MHz, CDCl3) 1.09 (6H, d, J = 6.6, 2-
Hγ), 1.11 (6H, d, J = 6.8, 2-Hγ), 2.14-2.21 (2H, m, 2-Hβ3 + 2-Hβ6), 3.87-3.89 (4H, m, 2-Hα3 + 2-
Hα6), 3.91 (3H, s, CO2Me), 4.32 (1H, t, J = 7.1, FHβ), 4.53 (2H, d, J = 7.1, FHα), 5.24 (2H, s, 1-Hα), 
7.33 (2H, t, J = 7.0, FHAr4), 7.41-7.46 (5H, m, FHAr3, 1-H5, 1-H6 + 1-Hα), 7.47-7.48 (4H, m, 1-
HAr2 + 2-HAr3), 7.53 (1H, s, 2-H2), 7.61 (2H, FHAr2), 7.70 (1H, d, J = 1.5, 1-H2), 7.80 (2H, d, J = 
7.8, FHAr5), 8.41 (1H, s, 2-H5), 8.85 (1H, s, 2-NH); ESI-MS found m/z 507.2 [M+H]
+
; 
NH2-[O-Bn-(3HABA)]-[O
3
-iBu-O
6
-iBu-(3-DHABA)]-CO2H 74 
Procedure F; Intermediate 80 (150 mg, 0.20 mmol) in a 1:1 mixture of methanol : tetrahydrofuran (4 
mL), 10% aqueous sodium hydroxide (1.5 mL). Work up yielded the title compound (57 mg, 0.11 
mmol, 57%) as a beige amorphous solid; δH (500 MHz, CDCl3) 1.09-1.10 (12H, m, 2-Hγ
3
 + 2-Hγ6), 
2.16-2.25 (2H, m, 2-Hβ3 + 2-Hβ6), 3.90 (2H, d, J = 6.4, 2-Hα3), 4.08 (2H, d, J = 6.4, 2-Hα6), 5.15 (2H, 
s, 1-Hα), 6.77 (1H, d, J = 8.1, 1-H5), 7.37 (1H, m, 1-HAr4), 7.42 (2H, m, 1-HAr3), 7.46 (2H, m, 1-
HAr2), 7.55 (1H, d, J = 1.9, 1-H2), 7.65 (1H, s, 2-H2), 8.54 (1H, s, 2-H5), 8.83 (1H, s, 2-NH); δC 
(125MHz, CDCl3) 19.2, 19.3, 28.2, 28.3, 70.6, 75.5, 103.7, 110.7, 111.0, 113.5, 113.9, 120.5, 123.3, 
127.4, 128.3, 128.7, 134.3, 136.4, 141.9, 146.0, 152.9, 165.3, 165.6; υmax/cm
-1
 (solid state) = 3438, 
3334, 2960, 1728, 1595, 1485, 1260, 1027, 733, 591 ESI-HRMS found m/z 507.2495 [M+H]
+
, 
C29H35N2O6 requires 507.2490 
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6.7 Molecular Modelling (Chapter 4) 
Molecular modelling was carried out using maestro as an interface for a number of applications 
developed by Schrödinger.  
Conformational search  
A low energy conformational search of dimers 60 and 61 was run in which the structures were 
minimised by employing a Monte Carlo search in Macromodel® using the MMFFs (Merk Molecular 
Force Fields) method sampling a total of 50,000 structures. Water was chosen as implicit solvent and 
free rotation around the amide bonds was allowed in order to increase the accuracy of the 
conformational search.  
Superposition with the ERα coactivator peptide 
To calculate the RMSD, three atom pairs were superimposed consisting of the alkoxy oxygen of the 
dimers and the α-carbon of the leucine residues, at the i, i + 3 and i + 4 positions, of the NCOA2 
peptide (PDB ID: 2QZO). The orientation of the dimer in relation to the coactivator was also altered 
thereby changing the direction of the dipole moment.   
Docking 
The LBD of ERα (PDB ID: 3ERD) was prepared for docking using the Prep Wiz function in 
maestro.
155 
 Once the protein was refined, Glide was then used to generate a grid for docking. As the 
structure is dimeric, only 1 constituent monomer was used within the docking grid (chain C). Epik 
was used to predict the ionisation states of each ligand and the energetic penalties associated with 
them. Having prepared the “ligands”, Glide (default settings in extra precision (XP) mode) was then 
used to dock the results into the prepared protein. The predicted binding scores and energies can be 
used as a guide to assess a ligand’s ability to bind to a specified region on the protein surface. 
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6.8 1H-1H NOESY Spectra (Chapter 4) 
NOESY spectra of 4.5 and 4.6 were acquired at 30 mM, 20 mM and 10 mM concentrations in CDCl3 
and at 30 mM in DMSO. 20 scans were taken over ~2.5 hours at ~299 K at 500 MHz.  Figure 6.1 
shows relevant NOEs are present in DMSO (similar to those in CHCl3: Fig. 4.6 and Fig. 4.7), 
however, several aromatic peaks are less well resolved in DMSO than CDCl3. 
 
 
 
 
 
 
 
 
 
 
Figure 6.1  NOESY (500 MHz, DMSO-d6) spectra of (a) dimer 60 at 30 mM and (b) dimer 61 at 30 
mM.  
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6.9 Single Crystal X-ray Crystallographic Studies (Chapter 4) 
Prismatic crystals were obtained by the slow evaporation of a solution of the compound in 
chloroform. A crystal of size 0.4 x 0.4 x 0.3 mm was used for data collection; θ range = 2.37θ 
26.13°, Crystals belong to Monoclinic; Space group C 2/c ; Formula = C26H36N2O6; Formula weight = 
472.57; a = 22.224(3) Å, b = 16.806(2) Å; c = 15.8146(19) Å, β = 113.877(6)°, Volume = 5401.2(12), 
Z = 8, D (calculated): 1. 162 g/cm
3
, μ = 0.082 mm-1, Reflections collected 19204; Independent 
reflections 5305; Observed reflections 4102 [I >2(I)]; R  value = 0.0445, wR2 = 0.1195. 
Measurements were carried out at 120 K on a Bruker-Nonius Apex X8 diffractometer equipped with 
an Apex II CCD detector and using graphite monochromated Mo-Kα radiation from a FR591 rotating 
anode generator. The structure was solved by direct methods using SHELXLS-97 and refined using 
SHELXL-97. The compound crystallises in the monoclinic space group C 2/c with one molecule in 
the asymmetric unit. All non-hydrogen atoms were refined anisotropically. Hydrogen atoms were 
placed in calculated positions and refined using a riding model. All Uiso(H) values were constrained 
to be 1.2 times (1.5 for methyl) Ueq of the parent atom.  
Figure 6.2 Single X-ray crystal structure data for dimer 61. 
Chapter 6: Experimental Section 
 
145 
 
6.10 H/D Exchange Studies (Chapter 4) 
This was carried out on dimers 60 and 61 and data was taken from a previously published 
study for 81
171
 (Valeria Azzarito). A 10% CD3OD/CDCl3 system was used to ensure pseudo 
first order kinetics. An initial NMR spectrum was acquired with 450 μL of an analyte 
solution at 11.11 mM in CDCl3 to which was added 50 μL of CD3OD giving a final 
concentration of 10 mM. To minimize variability, a constant baseline correction was applied 
and a distinct, non-exchanging signal was used as an internal integration reference. 
Integration ranges for exchanging protons are user-defined and self-consistent within each 
experiment. Rate constants (and corresponding half-lives) were determined from the slope of 
a non-linear least squares fit to the graph following Equation 6.1.  
      
At = A0e
-kt
 
Equation 6.1 
At = Integral of amide proton at time t; 
A0 = Integral of amide proton at time zero (can be fixed) 
K = reaction rate coefficient 
The half life of the H/D exchange was determined using Equation 6.2. 
t ½ = ln 2 
          k 
Equation 6.2 
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Appendix I 
Collecting and processing fluorescence data: 
To collect fluorescence data for any given interaction, assays were ran in triplicate 
(including 3 blank/control wells) and data was collected using an EnVision plate reader.  
S- and P- channels corrected by subtracting the average polarisation value of the 
corresponding control wells. Equation 1 is used to calculate the total intensity, which can 
then be inserted into Equation 2 to get the anisotropy value for each individual well.   
I = 2PG + S 
Equation 1 Calculation for the total intensity: 
r = (S-PG)/I 
Equation 2 Calculation for the observed anisotropy: 
 
I = Intensity, r = observed anisotropy, P = polarisation value for P- channel, S = 
polarisation value for S- channel. G = G factor,  
Protein Titration 
Average anisotropy values from the titration can be directly plotted and fitted using 
a logistic model in Origin 8.6. IC50 values may be extracted directly from this data, however, 
in order to obtain Kd, Equation 3 is needed to calculate the fraction of ligand bound (or 
bound tracer: Lb). The minimum and maximum anisotropies (rmin and rmax) are identified 
from the data of plotted average anisotropies and λ is calculated from the change in intensity 
of the fluorophore in its bound and unbound state. This can be influenced by the 
hydrophobic environment of the protein which may vary λ away from a unitary value when 
the fluorophore is not influenced by its environment (λ =1). The value of Lb is then inserted 
into Equation 4 (y = Lb) to determine the dissociation constant (k1). 
minmax
min
)(
)(
rrrr
rr
Lb




 
Equation 3 Calculation for fraction of ligand bound. 
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Equation 4 Rearrangement of the equation allows for the calculation of the dissociation 
constant. 
 
Lb = y = Fraction of ligand bound, r = anisotropy, λ  = Ibound/Iunbound (intensity variation), [FL] = 
concentration of fluorescent ligand, k1 = Kd , [x] = [Protein]. 
Competition Assay 
In previous studies, competition assays have been unsuccessful in extracting Ki 
values due to a complex equilibrium between the components of the assay (discussed in 
section 3.2.3.3). IC50 values could alternatively be calculated by plotting anisotropy values 
(y) against ligand concentration (x). The IC50 value (x0) is extracted directly from the curve 
using Equation 5. If λ is not equal to 1 in the original protein titration, it may be appropriate 
for an EC50 value to be calculated instead. This involves fitting λ from the protein titration 
into Equation 3, with r and rmin  anisotropy data fitted from the competition assay. EC50 
values can then be calculated by plotting fraction of ligand bound (y) against ligand 
concentration (x) and fitting to a logistic model using Origin 8.6. The EC50 values (x0) are 
extracted directly from the curve using Equation 5. 
)log(
minmax
min
0101
xx
rr
ry



  
Equation 5 Rearrangement of equation allows for the calculation of; IC50 = x0  when y = 
anisotropy and rmin and rmax are the minimum and maximum anisotropies EC50 = x0  when y = 
fraction of ligand bound and rmin and rmax are the minimum and maximum ligand bound: rmax = 
[FL] (when y = Lb)   
 
2
]}][[4])[][{(])[][{( 211 FLxFLxkFLxk
y


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Appendix II 
Assay implementation notes for p53/hDM2 and Mcl-1/NOXA B 
screen: 
hDM2 Titration λ 
In a previous protein titration experiment, λ was calculated to equal 1, however, new 
intensity data did not agree with this on first examination. In Figure 3.4b, one can see that 
the intensity is fairly constant at high [hDM2] but begins to fluctuate when at low [hDM2]. 
The average intensity was plotted against protein concentration and fitted to a logistic model 
to determine the intensity of fully bound and fully unbound tracer. λ was calculated to be 
1.79, however, confidence in the fitting was particularly low due to scattering of the data at 
lower concentrations. The data from a sample of compounds was processed and the IC50  (y = 
1) and EC50  (y = 1.79) values determined and variations in these values were negligible. It 
was decided to calculate IC50 values for future competition assays for the following reasons:  
 Fluctuations in intensity readings presented uncertainty in the calculated λ 
 When this λ value was used to calculate the EC50, changes from the IC50 
were negligible  
 Previous studies had found λ = 1 
(a) Protein titration curve of the p53/hDM2 interaction when λ = 1(Kd = 129.67 nM). (b) 
Average intensity fitted to a logistic model to calculate λ. 
Mcl-1/NOXA B titration λ 
As observed previously λ ≠ 1, therefore the intensity was plotted against [protein] 
and fitted to a logistic model and was calculated as λ = 2.20 
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(a) Average intensity fitted to a logistic model to calculate λ (λ = 2.20). (b) Protein titration 
curve of the Mcl-1/NOXA B interaction (Kd = 148.19 ±55.97 nM) fitted to a logistic model 
when λ = 2.20. 
Competition Assays p53/hDM2 
 Due to poor inhibition of oligomer 25 (p53/hDM2 screen) the bottom plateau was 
not reached, however, an IC50 value could be obtained after fixing the bottom 
plateau to -0.02 which was the average rmin value. 
 Comparison of data obtained from two competition assays for oligomer 25 against 
the p53/hDM2 interaction demonstrating a similar scattering pattern was 
reproducible and not due to plating error. 
Competition Assays Mcl-1/NOXA B 
 The fluorescence intensity changes during the protein titration. More specifically, 
the intensity increases with increasing [protein] indicating the environment of the 
protein affects the amount of fluorescence emitted by the fluorophore. This has been 
taken into account and EC50 values have been calculated by plotting fraction of 
ligand bound (inserting λ = 2.20) against [proteomimetic].   
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